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ABSTRACT OF THE DISSERTATION 
SPECIATION, METABOLISM, TOXICITY, AND PROTEIN-BINDING OF 
DIFFERENT ARSENIC SPECIES IN HUMAN CELLS 
by 
Szabina Stice 
Florida International University, 2014 
Miami, Florida 
Professor Yong Cai, Major Professor 
Despite of its known toxicity and potential to cause cancer, arsenic has been proven to be 
a very important tool for the treatment of various refractory neoplasms. One of the 
promising arsenic-containing chemotherapeutic agents in clinical trials is Darinaparsin 
(dimethylarsinous glutathione, DMAIII(GS)). In order to understand its toxicity and 
therapeutic efficacy, the metabolism of Darinaparsin in human cancer cells was 
evaluated. With the aim of detecting all potential intermediates and final products of the 
biotransformation of Darinaparsin and other arsenicals, an analytical method employing 
high performance liquid chromatography inductively coupled mass spectrometry (HPLC-
ICP-MS) was developed. This method was shown to be capable of separating and 
detecting fourteen human arsenic metabolites in one chromatographic run. The developed 
analytical technique was used to evaluate the metabolism of Darinaparsin in human 
cancer cells. The major metabolites of Darinaparsin were identified as dimethylarsinic 
acid (DMAV), DMAIII(GS), and dimethylarsinothioyl glutathione (DMMTAV(GS)). 
Moreover, the method was employed to study the conditions and mechanisms of 
formation of thiol-containing arsenic metabolites from DMAIII(GS) and DMAV as the 
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mechanisms of formation of these important As species were unknown. The arsenic 
sulfur compounds studied included but were not limited to the newly discovered human 
arsenic metabolite DMMTAV(GS) and the unusually highly toxic 
dimethylmonothioarsinic acid (DMMTAV). It was found that these species may form 
from hydrogen sulfide produced in enzymatic reactions or by utilizing the sulfur present 
in protein persulfides. Possible pathways of thiolated arsenical formation were proposed 
and supporting data for their existence provided. In addition to known mechanism of 
arsenic toxicity such as protein-binding and reactive oxygen formation, it was proposed 
that the utilization of thiols from protein persulfides during the formation of thiolated 
arsenicals may be an additional mechanism of toxicity. The toxicities of DMAV(GS), 
DMMTAV, and DMMTAV(GS) were evaluated in cancer cells, and the ability of these 
cells to take the compounds up were compared. When assessing the toxicity by exposing 
multiple myeloma cells to arsenicals externally, DMMTAV(GS) was much less toxic than 
DMAIII(GS) and DMMTAV, probably as a result of its very limited uptake (less than 10% 
and 16% of DMAIII(GS) and DMMTAV respectively).  
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CHAPTER 1 
Introduction 
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1.1 Arsenic in the Environment and its Effects on Human Health 
1.1.1 Abundance, Forms, and Distribution 
Arsenic (As) is a naturally occurring element that can be found in many forms 
such as elemental, inorganic, and organic in large quantities all over the world. It is 
mostly present in the trivalent or pentavalent forms when it combines with other elements 
of the periodic table. Arsenic is present in our oceans, meteorites, living organisms, and is 
also the 20th most abundant element in the crust of the Earth.1 Arsenic compounds have 
diverse structures, chemical compositions, toxicities, and a broad range of applications. It 
forms ores with sulfide and metals such as copper, lead, nickel, and cobalt, just to name a 
few. Weathering of rocks converts arsenic sulfide to arsenic trioxide, the main form 
arsenic that enters and contaminates our rivers and groundwater or pollutes the air we 
breathe.   
1.1.2 Use and Source 
It is or was used at some point in history in animal feed (as an additive to 
promote growth and prevent infections of animals), ceramics, glass, computers, 
semiconductors, herbicides, insecticides, pesticides, rodenticides, metallurgy, wood 
preservatives, dyes, and for many other applications.1, 2 Arsenic originating from these 
and other applications contribute to anthropogenic As pollution of the environment in 
addition to the naturally present As (naturogenic pollution). 
1.1.3 Human Exposure to Arsenic  
The major sources of arsenic for the general population are contaminated soil, 
water, and food.1, 2 It is found in appreciable concentrations in food (such as seafood and 
rice, a staple food crop and an efficient arsenic accumulator) as well as in drinking water 
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from certain sources resulting in chronic arsenic toxicity in humans throughout the 
world.3 It has also been used as a homicidal and a suicidal agent since ancient times. 
1.1.4 Toxicity and Health Effects 
Arsenic compounds are known to be very toxic and carcinogenic. People 
exposed to arsenic compounds develop a wide range of health problems ranging from 
gastrointestinal disturbance to the development of various types of life threatening 
neoplasms such as kidney, liver, skin, and lung cancer.1, 2, 4-6   Table 1.1 gives a detailed 
list of the health consequences associated with acute, subacute, and chronic arsenic 
exposure in humans, while Table 1.2 contains the names, abbreviations, and structures of 
selected arsenic metabolites relevant to my research in mammals with an emphasis on 
humans.  
Different arsenic compounds have different toxicities and the extent of 
toxicity is also animal species dependent. The order of toxicity, within the same species 
also depends on the type of cells involved. For example, on the basis of the estimated 
IC50 values, the increasing order of toxicity in human hepatocytes was DMAIII(GS) ≈ 
iAsIII << MMAIII, while in human keratinocytes it is iAsIII << DMAIII(GS) < MMAIII, and 
in human bronchial cells it is DMAIII(GS) < iAsIII ≈ MMAIII.7 Pentavalent arsenicals were 
found to possess relatively low toxicities in these cell types compared to the above 
trivalent species. Generally, trivalent arsenicals are much more toxic than their 
pentavalent counterparts.7, 8 In addition, trivalent arsenicals are taken up more efficiently 
by organs/tissues or cells than that of pentavalent arsenicals.7, 9  The reason for the much 
lower toxicity of pentavalent species compared to the trivalent compounds was partially 
attributed to the lower rate of accumulation of pentavalent species.7 Additionally, toxicity 
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of these species is dependent on the extent of their methylation. When comparing arsenite 
(AsIII) and monomethylarsonous acid (MMAIII), the monomethylated arsenical has higher 
affinity for sulfur ligands (such as thiols in proteins and enzymes) than the non-
methylated AsIII, thus exhibiting higher toxicity.7 
Interestingly, while in general trivalent arsenic compounds are more toxic 
than their pentavalent counterparts, dimethylmonothioarsinic acid (DMMTAV) has been 
shown to be unusually highly toxic for a pentavalent species.10-13 According to Watanabe 
and Hirano, the toxicity of DMMTAV is comparable to that of MMAIII, while Bartel et al. 
reported lesser (approximately ½) toxicity compared to MMAIII in human lung cells.14, 15 
While the toxicity of DMMTAV was found to be similar to the even more toxic 
dimethylarsinous acid (DMAIII) in epidermoid carcinoma cells, in human lung 
adenocarcinoma epithelium cells it was found to be less cytotoxic than dimethylarsino 
glutathione (DMAIII(GS)).13, 16 Compared to dimethylarsinic acid (DMAV), the 
corresponding non-thiolated pentavalent species, DMMTAV was found to be about 10-
fold more cytotoxic in HepG2 cells derived from human hepatocarcinoma and 
approximately 80 times more toxic in epidermoid cells.11, 13 Its toxicity can be attributed 
to the fact that DMMTAV is highly reactive with thiol compounds. This is unusual for a 
pentavalent arsenical.   
The glutathione complexes, DMAIII(GS) and monomethylarsinoglutathione 
(MMAIII(GS)2) may form in the body from DMAV and monomethylarsonic acid (MMAV) 
with the help of reduced glutathione. By reducing the pentavalent species into trivalent 
glutathione complexes, their cytolethality increases. They were shown to be toxic by 
dissociating into trivalent species and glutathione.17, 18 On the other hand, GSH 
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conjugation promotes the elimination of these species and flags them for removal from 
the cells, thus reducing intracellular arsenic concentrations. 
1.1.5 Mechanism of Arsenic Toxicity 
The varying toxicity of arsenic species is partly caused by the ability of these 
species to generate reactive oxygen species (ROS) initiating oxidative stress and by their 
differing ability to cause DNA methylation (both hypomethylation and hypermethylation 
via interaction with DNA methylating enzymes or by depleting SAM).19 Arsenic 
exposure produces superoxide (O2•-), singlet oxygen species, peroxy radical (ROO•), 
hydrogen peroxide (H2O2), dimethylarsinicperoxyl radicals [(CH3)2AsOO•), 
dimethylarsinic radical ((CH3)2As•) in addition to nitric oxide (NO•).20, 21 The manner in 
which arsenic-containing compounds generate ROS and cellular oxidative stress is quite 
complex.14 Arsenic can significantly oxidize cytoplasmic thioredoxin-1 (Trx-1) and 
mitochondrial thioredoxin-2 (Trx-2).22 Thioredoxins act as antioxidants by facilitating the 
reduction of proteins. The oxidation of thioredoxins by arsenic may lead to the generation 
of ROS.  
The difference in toxicity of different arsenic species and in general their 
toxicity along with  their biological actions can also be attributed to the fact that trivalent 
arsenicals can bind to the thiol (-SH) groups of proteins and enzymes resulting in the 
disruption of their functions.23 
While trivalent arsenicals can easily bind to thiol groups of biomolecules, thus 
disrupt their functions, pentavalent arsenical only do so to a much smaller extent. This 
observation can be partially explained with the help of the hard and soft acids and bases 
theory (HSAB). According to HSAB, the small species with high charge states (mainly 
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for acids) that are weakly polarizable are designated as hard and the large low charge 
states that are strongly polarizable are labelled as soft. Soft acids are said to react faster 
and form stronger bonds with soft bases, while hard acids react faster and form stronger 
bonds with hard bases. Thiolates are categorized as soft bases. While both As3+ and As5+ 
are categorized as acids, As3+ is much softer than As5+, thus As3+ has higher affinity for 
the thiol groups of proteins and enzymes than As5+. The different binding affinity of the 
diverse arsenic species to various biomolecules may be responsible for the higher 
concentration (accumulation) of toxic arsenic species in certain cell types. The binding 
can be through different number of binding sites depending on the arsenic species 
involved in the process.  
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Table 1.1 Possible clinical manifestations of arsenicals in humans1, 2, 4-6 
Signs and Symptoms of Acute Toxicity Subacute Toxicity Chronic Toxicity 
Gastrointestinal Nausea, vomiting, diarrhea, hepatitis, pancreatitis 
Anorexia, weight loss, nausea, 
vomiting, diarrhea 
Nausea, vomiting and diarrhea, 
hepatomegaly, diabetes mellitus 
Cardiovascular, 
cerebrovascular and 
other vascular 
Sinus tachycardia, 
orthostatic hypotension, 
myocardial dysfunction 
Ventricular tachycardia (torsades 
de pointes) 
Cerebrovascular disease, 
Raynaud phenomenone 
Neurological 
Acute encephalopathy, 
fainting, delirium, coma, 
seizure, nerve paralysis, 
nerve palsy 
Headache, confusion, decreased 
memory, personality change, 
irritability, numbness, pain on 
touching, paralysis mimicking 
Guillain-Barré Syndromec 
Encephalopathy, peripheral 
neuropathy 
Respiratory Pulmonary edema, ARDS
a, 
respiratory failure Cough, crackles 
Restrictive and/or obstructive 
lung disease 
Renal Acute renal failure Renal failure Cancer 
Dermatologic Exfoliative dermatitis Dermatologic lesions, contact dermatitis 
Dermatologic lesions, 
hyperpigmentation 
Hematological Hemolytic anemia Leukopeniad, anemia Aplastic anemia 
Muscular Rhabdomyolysisb   
Others including cancer  Mees’ lines 
Squamous and basal cell 
carcinomas, hepatic 
angiosarcoma, adenocarcinoma 
and oat cell carcinoma (lung 
cancers), bladder carcinoma  
eARDS stands for acute respiratory distress syndrome 
bRhabdomyolysis is the quick breakdown of muscular tissue and may lead to kidney failure 
cGuillain-Barré Syndrome is a disorder affecting the peripheral nervous system and is characterized with ascending paralysis. It can cause breathing 
problems and disrupt the autonomous nervous system. 
dLeukopenia is the decrease of white blood cells 
eRaynaud phenomenon is the discoloration of finger and occasionally other body parts
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Table 1.2 Arsenic species of interest in this study 
Most common 
Structure Occurrence in humans Names Abbreviations 
Arsenite, Arsenious acid AsIII 
 
Urine24-28 
Fingernail26 
Blood plasma29 
Arsino-glutathione As
III(GS)3 
ATG 
 
Not yet reported, 
only in mammals30, 
31 
Arsenate, Arsenic acid AsV 
Urine24-28 
Fingernail26 
Blood plasma26, 29 
Monomethylarsonous acid, 
Methylarsonous acid, 
Methylarsonite 
MMAIII 
MAsIII 
Urine24-28, 32 
Hepatocytes33 
 
Monomethylarsino-
glutathione, 
Monomethylarsonic 
diglutathione 
MMAIII(GS)2 
MADG  
Not yet reported, 
only in mammals30, 
31 
Monomethylarsonic acid, 
Methylarsonic acid 
MMAV 
MAsV 
Urine24-28 
Fingernail26 
Blood plasma26, 29 
Hepatocytes33 
Dimethylarsinous acid, 
Dimethylarsinite 
DMAIII 
DMAsIII 
Urine24-28, 32 
Fingernail26 
Hepatocytes33 
S-(Dimethylarsenic) 
Cysteine DMA
IIICys 
 
Not reported 
Dimethylarsinous 
glutathione, Dimethylarsinic 
glutathione, 
Dimethylarsino-glutathione,  
Darinaparsin, ZIO-101, DAR 
DMAIII(GS) 
DAR 
DMAG 
DMAsIIIGS  
Human multiple 
myeloma cells34 
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Table 1.2 Arsenic species of interest in this study (cont’d) 
Most common 
Structure Occurrence in humans Names Abbreviations 
Dimethylmonothioarsinous 
acid DMMTA
III Not reported 
Dimethylarsinic acid, 
Dimethylarsinate 
DMAV 
DMAsV 
Urine24-28 
Fingernail26 
Blood plasma26, 29 
Hepatocytes 33 
Dimethylmonothioarsinic 
acid, 
Dimethylarsinothioic acid, 
Thio-dimethylarsinate 
DMMTAV 
Thio-DMA 
DMASV 
Urine11 
Red blood cells35 
Dimethyldithioarsinic acid 
Dimethylarsinodithioic acid DMDTA
V 
Not yet reported, 
only in mammals12, 
36 
Dimethylarsinothioyl 
glutathione 
DMMTAV-GS 
DMATG 
DMASV-GS 
DMMTAV(GS) 
Human multiple 
myeloma cells34 
and lymphoma cells
Trimethylarsine oxide TMAs
VO 
TMAO  
Arsenobetaine AsB 
Urine, Red Blood 
Cells, Blood 
plasma26, 37, 38 
Arsenocholine AsC  
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Table 1.3 Binding affinities of trivalent arsenic species to hemoglobin 
Name of arsenic compound AsIII  MMAIII DMAIII 
Number of binding sites 3 2 1 
Ability to bind human hemoglobin39 lowest medium highest 
 
As mentioned above, arsenic compounds (including thioarsenicals) can inhibit 
important enzymes by binding to them. The affinity of binding depends on the arsenic 
species and the biomolecule involved. Important enzymes that are inhibited by arsenic 
include, but are not limited to glutathione reductase, glutathione peroxidase, thioredoxin 
reductase, thioredoxin peroxidase, lipoamide dehydrogenase, Arg-tRNA protein 
transferase, and pyruvate dehydrogenase.40-50 In addition, arsenic binds to protein 
disulfide isomerase, an enzyme catalyzing protein folding, and peroxiredoxin 1/enhancer 
protein, an antioxidant enzyme that plays a role in cell proliferation (hence it may have a 
role in cancer progression).23 Furthermore, certain arsenic species may disrupt the 
functions of DNA repair proteins and enzymes such as PARP (Poly ADP ribose 
polymerase) which binds arsenic and xeroderma pigmentosum protein A (a DNA repair 
enzyme).19, 39 Additionally, arsenic interacts with the mitochondrial transmembrane 
protein complex called the mitochondrial membrane transition pore complex resulting in 
the induction of apoptosis.51, 52 Arsenic also affects the cell cycle through the stabilization 
of microtubules.52-56 As a result of this stabilizing effect, the cell cycle may be halted 
during mitosis. 
In order for arsenic to directly inhibit an enzyme by binding to it, it either has 
to bind and thus block the active sites of proteins or has to bind to the protein in a manner 
that the binding will cause a conformational change in the protein that also affects the 
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binding site and therefore inhibiting the active site from binding other molecules.57 
Protein binding may also be a detoxification process in some species (for example in 
monkeys).58, 59 The bonding of As to thiols of enzymes may not always be responsible for 
the inhibition of those enzymes; instead, ROS can cause oxidative damage to proteins 
rendering them unable to perform their enzymatic functions.60 
1.1.6 Treatments of Arsenic Toxicity 
The treatment of chronic arsenic toxicity includes, but is not limited to 
removing the source of arsenic from the patients’ lives and the administration of 
chelation therapy with Dimercaprol (BAL), Succimer, or Dimaval (DMPS) all of which 
have vicinal dithiol moieties.2, 61  Also, newer alternative chelation agents are in 
development, along with the usage of combination therapy. Combination therapy 
employs structurally different chelating agents simultaneously, one of which is lipophilic 
and the other one is lipophobic, to more efficiently remove arsenic from different tissue 
compartments than single agent therapy and to reduce the toxicity of the chelating agent 
itself. The lipophilic chelating agent can remove the intracellular As, while the lipophobic 
chelating agent can remove the extracellular As.62 Supplementing antioxidants to 
chelation therapy was shown to be beneficial in increasing the mobilization of some toxic 
metals and lessen the effects of oxidative stress caused by the presence of these noxious 
compounds. As oxidative stress is one of the main contributing mechanisms of metal 
toxicity, thus it makes sense to try to co-administer antioxidants, such as N-acetylcysteine 
(NAC), lipoic acid (LA), melatonin, ascorbic acid (vitamin C), or gossypin with primary 
chelation therapy as they have shown great potential in improving clinical recoveries in 
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animals.62 Moreover, some of the potential antioxidants are capable of interfering with 
the absorption of arsenic, such as lipoic acid, thus reduce arsenic burden. 
1.2 Arsenic in Medicine 
1.2.1 Past  
Numerous arsenic compounds have been used for over two thousand years for 
medicinal purposes and some are still in use today (Table 1.4). In ancient China and India 
different arsenic compounds have been employed to treat all kinds of diseases.63, 64 
Hippocrates, the ancient Greek physician and the father of western medicine, used 
orpiment (As2S3) and realgar (arsenic sulfide: As4S4 or AsS) to treat ulcers although by 
now it has been confirmed that these arsenic compounds are human carcinogens.63-67 
During history, arsenic compounds were used to treat numerous diseases and conditions 
ranging from respiratory diseases to head lice to the plague.63, 64, 68 It was also observed 
that the spread of use of arsenic to control rat populations, an important vector of the 
plague, coincided with the decrease in the spread of this deadly disease.69 Fowler’s 
solution, which contains 1% potassium arsenite, was utilized as a treatment for malaria, 
trypanosomiasis, leukemia and asthma along with other diseases from the 1700’s to the 
mid 1900’s.2, 4, 64 Donovan’s solution (containing iodomercury and triiodoarsane) and 
Valagin’s solution (arsenic trichloride) were employed to treat a range of ills from 
rheumatism to tuberculosis along with others. 68, 70, 71 Salvarsan (Arsphenamine) and 
Neosalvarsan, both of which are organoarsenic compounds from the laboratory of the 
famous Paul Erlich, had been used in the 20th century to treat trypanosomiasis and 
syphilis until they got replaced by penicillin.2, 4, 68, 71, 72 The active ingredients of both of 
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these drugs are produgs and are activated in the body during metabolism. Early on, it was 
noticed that arsenic is effective to treat chronic myelogenous leukemia, a cancer of the 
white blood cells.63, 72 As a consequence of the toxicity, carcinogenicity and 
teratogenicity of these compounds they fell out of favor for a while. Side effects of 
certain arsenic compounds include but are not limited to cirrhosis of the liver and the 
development of different types of cancers.  
1.2.2 Present and Future 
Despite of their known toxicity and potential to cause cancer, several arsenic 
compounds have been recently rediscovered and put to use again in order to manage and 
treat different conditions that may not respond to other agents or stopped responding to 
them. In 2013, there were 129 clinical trials involving As registered with the Food and 
Drug Administration (FDA).51 Most trials involved Trisenox (arsenic trioxide, As2O3), 
Darinaparsin (Dimethylarsinous glutathione, DMAIII(GS)), and GSAO (4-(N-(S-
glutathionylacetyl)amino)phenylarsonous acid). Most trials investigated these and other 
arsenicals for the treatment of hematological cancers such as leukemias (75) and 
lymphomas (11) and solid tumors (25). Interestingly, one of the trials involved arsenic 
trioxide for the treatment of lupus, a systemic autoimmune disease, while the rest of the 
trials focused on chronic arsenic exposure due to anthropogenic and naturogenic sources. 
Table 1.4 Arsenic-containing medicines 
Name Chemical Composition and/or Structure 
Oripment As2S3 
Realgar (REA, arsenic sulfide) As4S4 or AsS 
Fowler’s solutiona KAsO2 
Donovan’s solutiona (arsenic triiodide) AsI3 
Valagin’s solution AsCl3 
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Table 1.4 Arsenic-containing medicines (cont’d) 
Name Chemical Composition and/or Structure 
Arsenoplatin-1 
 
Trisenox (ATO, arsenic trioxide) 
As2O3        
Darinaparsin (DAR, dimethylarsino 
glutathione, DMAIII(GS)) 
 
Salvarsan (Arsphenamine, Ehrlich 606)b 
Melarsoprol (Mel B, Arsobal, Melarsen 
Oxide-BAL) 
 
Neosalvarsan (Neoarsphenamine, 914) 
 
GSAO  
(4-(N-(S-
glutathionylacetyl)amino)phenylarsonous 
acid) 
 
PENEAO 
 
aActive arsenic-containing ingredient 
bOther structures have been proposed as well 
15 
 
1.2.2.1 Salvarsan and Melarsoprol 
Salvarsan (Arsphenamine, Ehrlich 606) was used to cure syphilis and 
trypanosomiasis (sleeping disease) a parasitic infection (Fig. 1.1).73 Melarsoprol (Mel B, 
Arsobal, Melarsen Oxide-BAL) is now in use to treat East African (first-line of therapy) 
and West African (second-line of therapy) trypanosomiasis, a type of parasitic 
infection.74 Melarsoprol (Fig. 1.2), a derivative of mersalyl oxide, exerts its antiparasitic 
effects by lowering the amount of the reducing agent trypanothione which subsequently 
leads to the lysis of the parasite.2, 61 It is extremely toxic, both to the parasite and the host, 
but is still in use as there is no better drug for the treatment of East African (Rhodesian) 
trypanosomiasis. Melarsoprol causes abdominal pain, vomiting, joint pain (arthralgia), 
and cerebral edema in addition to other signs and symptoms of toxicity that may result in 
the death of the patient.61 Recently it has been observed that the parasite may be 
developing resistance to the above therapeutic agent.                                                                                    
 
 
Figure 1.1 Possible structures of Salvarsan75 
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Figure 1.2 Melarsoprol 
 
1.2.2.2 Arsenic Trioxide 
Arsenic Trioxide (As2O3) (ATO, Trisenox, Fig. 1.3), an inorganic 
arsenic compound, was first reported to be effective against chronic myelogenous 
leukemia in 1878 and for a while it experienced popularity.63, 72 However its usage then 
sharply declined as a result of the high incidence of chronic arsenic toxicity in patients 
and was replaced by cytotoxic chemotherapy and radiation therapy. Recently, arsenic 
trioxide given in the IV form was rediscovered for the treatment of acute promyelotic 
leukemia (APL) for both newly diagnosed and relapsed APL.63 Most importantly, it was 
shown to be effective for refractory disease when the illness was already unresponsive to 
traditional therapy. Trisenox finally received approval from the U. S. FDA in 2000 to 
treat APL. Moreover, the oral formulation that has been developed was found to have 
very high bioavailability (up to 95% of an equivalent dose of intravenous ATO) and can 
be self-administered in outpatient settings.51, 76 
 The side-effects of the ATO treatment include fatigue, fluid retention, 
weight gain, arrhythmia etc., and may lead to the development of APL differentiation 
syndrome which can be fatal.61, 77, 78 Retinoic-acid-Acute Promyelocytic Leukemia (RA-
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APL) or simply APL differentiation syndrome is characterized by the presence of skin 
rash, fluid retention, weight gain, shortness of breath (dyspnea), fever, pulmonary 
infiltrates in addition other symptoms.61, 78 The drug is cardio and neuro-toxic.4, 5, 79, 80 
Compared to IV ATO therapy, oral ATO has slower absorption resulting in reduced peak 
arsenic plasma concentration, which was found to be associated with lower levels of 
cardiotoxicity.76, 81 
ATO induces apoptosis (cell death) and cell differentiation, inhibits 
proliferation and angiogenesis.2, 61, 63, 64 During treatment with ATO, highly reactive 
oxygen species (ROS) form that can damage cells and lead to cell death.  
 
Figure 1.3 Arsenic trioxide (as a solid) 
 
 
Recently, arsenic trioxide has been encapsulated inside nanoscale 
liposomes, called nanobins.51, 82-86 The nanobin formulation is stable in plasma and long-
circulating, and the lipid bilayer surrounding the arsenic attenuates cytotoxicity3-4-fold 
and allows for controlled release. Moreover, anticancer efficacy of ATO is increased in 
this formulation as the nanobins reduce the clearance rate of arsenic (over 300 fold) and 
significantly increase the exposure of the neoplasm to the drug.51 
1.2.2.3 Realgar 
Realgar (REA), an inorganic arsenical that was used to treat ulcers, 
convulsion, schistosomiasis (a parasitic disease), and inflammation, is currently being 
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reexamined for the treatment of hematological malignant diseases because of it is less 
toxic than arsenic trioxide (Fig. 1.4).63, 87 It is also in clinical trials for the treatment of 
certain solid tumors.  While it was shown to be effective against hematological malignant 
diseases, it is presently unclear if it will be suitable for the treatment of solid malignant 
tumors. It is cytotoxic towards the malignant cells and induces cell apoptosis, but was 
observed to exert only a very small effect on healthy human cells and as such it is better 
tolerated than ATO therapy.64, 87 Unfortunately, it has low solubility and bioavailability, 
but efforts are underway to overcome this obstacle with the development of realgar 
nanoparticles called nanorealgar.51, 64 
 
 
Figure 1.4 Realgar 
 
 
1.2.2.4 GSAO (4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid) and 
PENEAO (4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid)  
These two compounds are potential anti-cancer drugs in the cases 
where tumor metastasis relies heavily on neovascularization (they have a very high 
potential as an anti-angiogenic therapeutic agents).88-90 Both GSAO (Fig. 1.5) and 
PENAO (Fig. 1.6) are or will soon be (respectively) in trials in patients with solid tumors 
refractory (resistant) to standard therapy. As hematological cancers do not rely on new 
blood vessel formation for proliferation, it is only suitable for use against solid tumors. 
As phase I clinical trials have not been completed, their side effects and toxicities in 
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humans are largely unknown. Their mechanism of action is similar; they both react with 
cysteine residues of the mitochondrial membrane protein ANT (adenine nucleotide 
translocase) and thus inactivate the transporter and cause proliferation arrest and cancer 
cell death. 88, 90 The metabolism of GSAO is depicted in Figure 1.4.88, 90 During its 
biotransformation, first GCAO forms on the cell surface and then it enters the cell in this 
form via an organic ion transporter. Once inside the cells, it further metabolizes to CAO. 
It is actually CAO that will react with ANT thus is responsible for its pharmacological 
effects, meaning that GSAO is only a pro-drug. On the other hand, PENAO is a cysteine 
mimetic of CAO and not a pro-drug, meaning that PENAO itself is responsible for 
inhibiting ANT and not one of its metabolites. 4-(N-(S-penicillaminylacetyl)amino) 
phenylarsonous acid accumulates much faster in cells and is a stronger anti-proliferative 
agent. 
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Figure 1.5 Metabolism of GSAO  90 
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Figure 1.6 PENAO 
1.2.2.5 Darinaparsin 
Darinaparsin (S-Dimethylarsino-glutathione, ZIO 101, DAR, 
DMAIII(GS)) (Fig. 1.7), an organo-arsenic compound to be discussed here and under 
investigation in our lab, is currently in clinical trials for hematological cancers and 
refractory solid tumors. 79, 91 The drug targets the pathways needed for cell survival, 
induces mitochondrial damage, antiangiogenic (angiogenesis inhibitor) and causes 
apoptosis. It has a different mode of action from ATO and is also less toxic. While the 
modulation of glutathione (GSH) levels affects the cytotoxicity of ATO, it does not affect 
the cytotoxicity of DAR. Furthermore, Darinaparsin seems to be more effective than 
ATO despite of its lesser toxicity even at higher concentrations.79 It may also be used as 
an alternative for ATO-resistant hematological malignancies as cross-resistance between 
these two drugs does not necessarily develop.91 Arsenic trioxide and Darinaparsin are 
uptaken by different transport mechanisms, illicit somewhat differing protective 
responses, and they are metabolized by cells differently.79, 91, 92 Darinaparsin was initially 
administered in IV (intravenous) form (no first-pass metabolism), but it is currently being 
evaluated as an orally administered medication. Current results show activity but as with 
all orally taken medications, first-pass metabolism could potentially limit its 
bioavailability. Data available at present suggest adequate bioavailability.93  
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As mentioned previously, the uptake of DAR is different from ATO. 
While the presence of exogenous GSH was shown not to affect the uptake of arsenic 
trioxide, it did prevent Darinaparsin uptake by the cells. DMAIII(GS)  has been postulated 
to enter the cells in the form of DMAIII (dimethylarsinous acid) at low concentrations of 
exogenous glutathione or in the absence of it. Newer research indicates that DMAIII(GS) 
may be processed by the enzyme γ-glutamyl transpeptidase (γ-GT) on the cell surface to 
S-(dimethylarsenic) cysteine (DMAIII(Cys)) prior to transport into the cells.94 This 
proposal is supported by the fact that the inhibition of γ-GT significantly inhibits the 
uptake and decreases the toxicity of DMAIII(GS), but not has no effect on the uptake and 
toxicity of DMAIII(Cys). Thiol-containing compounds such as glutathione and cysteine 
can decrease or inhibit the intracellular accumulation of both DMAIII(GS) and 
DMAIII(Cys) to the same extent by probably modulating the import of these two arsenical 
into the cell.94 DMAIII(Cys) was shown to be uptaken by multiple cystine/cysteine 
importers, while no transporter has been yet identified that could transport DMAIII(GS) as 
is. 
The metabolites found inside DMAIII(GS) treated cells include 
DMAIII(GS)  (which may re-form by the reaction of DMAIII or DMAIII(Cys) with 
intracellular GSH), DMAV, and DMMTAV(GS). To understand the mechanism of action 
and the overall potency of this chemotherapeutic agent along with the toxicities of 
Darinaparsin and its metabolites, it is necessary to determine with certainty what form of 
Darinaparsin enters cells, how it is metabolized, and evaluate the toxicity of all of its 
metabolites.  
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Figure 1.7 Darinaparsin (S-Dimethylarsino-glutathione) 
 
1.2.2.6 Design of New As-containing Anticancer Agents 
Platinum-based antineoplastic drugs (platins) are chemotherapeutic 
agents used to treat cancer. They are coordination complexes of platinum. While they are 
very effective to treat various cancers, platins exhibit neurotoxicity. Platinum (cisplatin) 
and arsenic trioxide has been recently combined into one molecular compound called 
arsenoplatin-1 (Fig. 1.8) in the hopes of developing a therapeutic agent that is more 
suitable to treat refractory malignancies.95 Arsenoplatin-1was found to be more cytotoxic 
in certain cancer lines than cisplatin. Moreover, in cisplatin resistant cells it was two 
times more cytotoxic than cisplatin itself and the development of cross resistance 
between the two drugs has not been observed.51 The development and the in vitro 
investigation of arsenoplatin compounds is an on ongoing project. 
 
Figure 1.8 Arsenoplatin-1 
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1.3 Arsenic Biotransformation  
The metabolism of these arsenic-containing medicinal preparations and 
environmental pollutants plays a key role in determining the potency and toxicity of these 
compounds. Once inside a living organism, arsenic compounds get distributed and 
metabolized in a process that is highly animal, plant, and chemical species dependent.96, 
97 
1.3.1 Arsenic Uptake 
Trivalent arsenicals are taken up more efficiently by organs/tissues or cells 
than pentavalent arsenicals.7, 9  The reason for the much lower toxicity of pentavalent 
species compared to the trivalent compounds was partially attributed to the lower rate of 
accumulation of these species.7 Uptake of inorganic arsenite (iAsIII) in cells is facilitated 
by membrane transporter proteins, in particular aquaglyceroporin-9 (AQP-9) while 
inorganic arsenate (iAsV) is thought to enter the cells with the help of phosphate 
transporters.14, 98-100 Aquaglyceroporin-9 is most highly expressed in acute promyelotic 
leukemia (APL) cells, correlating to higher arsenic uptake and sensitivity to arsenic 
treatment in this malignant cell type.101 As mentioned above, newer research indicates 
that DMAIII(GS) may be processed by γ-GT on the cell surface to DMAIII(Cys) prior to 
transport into the cells.94 
1.3.2 Arsenic Distribution, Metabolism, and Transport 
The distribution of the different metabolites depends on many factors, such as 
the arsenic species administered, the plant or animal species involved, the type of cells 
within the same organism, the availability of reducing agents such as glutathione (GSH) 
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and other thiol (–SH) containing biomolecules, the presence of arsenic methylating 
enzymes, and the pH of the matrix.9, 102 
During the detoxification of iAsIII, the compound is biomethylated to mono- 
and dimethylated (in some cases trimethylated) arsenicals of varying toxicity. Some of 
these metabolites will be less while others will be more toxic than iAsIII. Pentavalent 
methylated arsenicals are less toxic than inorganic iAsIII. However this is generally not 
the case for the trivalent methylated species which are highly cytotoxic and genotoxic.7 
Hence, the methylation of arsenic is a bioactivation pathway rather than a mode of 
detoxification. The toxic trivalent methylated species are easily oxidized to the less 
cytotoxic pentavalent species at low glutathione (and other reducing agent) 
concentrations. 
According to the early postulated scheme of metabolism, called the 
reductive/oxidative methylation pathway, during the detoxification of  iAsV (Fig. 1.9), it 
is first reduced to the more toxic iAsIII, and then methylated and oxidized to MMAV 
simultaneously.98, 103 Then MMAV gets reduced to MMAIII and during oxidative 
methylation it is transformed into DMAV, which is then reduced to DMAIII. In certain 
species, but not in humans, during oxidative methylation DMAV then can be converted 
into trimethylarsine oxide (TMAOV). Numerous evidence pointed to the flaws of this 
early proposed oxidation methylation pathway of arsenic biotransformation and 
suggested this pathway to be unreasonable and that it should be reconsidered.98  
On the basis of observations, it was proposed that the pentavalent methylated 
species, MMAV and DMAV form from the oxidation of MMAIII and DMAIII, and not the 
other way around. Moreover, the involvement of As-glutathione complexes in the 
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biotransformation of arsenic was finally recognized as a necessary component. S-
adenosylmethionine (SAM) was found to act as the methyl donor in the reaction and Cyt 
19 (As3MT, arsenic methyltransferase) was recognized as the catalyst. Glutathione and 
possibly other thiols were suggested to act as reducing agents.98, 104 According to this 
pathway, proposed by Hayakawa (Fig. 1.10), instead of the oxidative methylation of 
iAsIII and MMAIII to MMAV and DMAV respectively, the oxidative methylation is via 
arsenic triglutathione (As(GS)3), monomethylarsenic diglutathione (MMA(GS)2), and 
dimethylarsenic glutathione (DMAIII(GS)) to MMAV and DMAV.  
Kala et al. suggested that the formation of these arsenic-GSH complexes may 
play an important role in the transportation of arsenic and its methylated derivatives. 105 
They estimated that 60-70% of the urinary As metabolite may be present as GSH-
conjugate in mice, but it is catabolized by the enzyme γ-glutamyl transpeptidase and 80-
90% of the total arsenic excreted in the bile is also GSH conjugated.31, 105 Arsenic-
glutathione conjugates were observed to be the transported forms and account for the 
majority of excreted arsenic.100 As the addition of GSH to a molecule during metabolism 
is said to provide a molecular ‘flag’ that promotes the removal of the xenobiotic from 
cells, this is not surprising.106 However, others theorize that the trivalent species are 
mostly protein-bound and are not present as GSH-conjugates, and possess higher 
affinities to bind to proteins than to glutathione.1, 107-109   
A third possible pathway was proposed by Naranmandura (Fig.1.11), who 
theorizes that as arsenic compounds have a higher affinity for the thiol groups of proteins 
than glutathione, an such during methylation the trivalent arsenicals are attached to the 
thiols of proteins and are not glutathione conjugated.98 In addition to the above mentioned 
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arsenic metabolites, thiolated species may also form during the biotransformation of 
arsenic. The most often seen thiolated arsenical is dimethylmonothioarsinic acid 
(DMMTAV), which was reported to form from DMAIII in thiol-rich rat liver cells in 
addition to the less frequently observed dimethyldithioarsinic acid (DMDTAV).110 Suzuki 
proposed that these species must form from DMAIII and cannot form from DMAV, the 
reduction of DMAV to DMAIII is required for the reaction to take place.110 The proposed 
pathway of thiolated arsenical formation by Suzuki is depicted in Figure 1.12. 
 
                                       
 
                                                
                                                                                                                                                 
 
         
 
 
 
Figure 1.9 An early postulated scheme of metabolism (Challenger pathway) 
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Figure 1.10 New metabolic pathway of arsenic proposed by Hayakawa 
 
 
 
Figure 1.11 Proposed biotransformation pathway of iAsV by Naranmandura 
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Figure 1.12 Proposed formation of thiolated arsenicals in rat hepatocytes by Suzuki 
 
Naranmandura et al. also proposed a possible pathway for the formation of 
thiolated arsenicals (Fig. 1.13) but in rat red blood cells (RBC).111 According to this 
scheme, the formation of DMMTAV is via the formation of DMMTAIII from DMAIII. He 
also did not suggest that DMMTAV can directly form from DMAV, nor could he prove 
that the intermediate is DMMTAIII. Additionally, he suggested that DMDTAV may 
partially form utilizing HS- liberated from the enzymatic hydrolysis of DMMTAV. The 
enzyme responsible for the hydrolysis was not identified. It is important to note here, that 
the exact form of sulfur (S2-, HS-, or H2S) or the source of it (from enzymatic reactions 
that produce H2S or from the sulfane sulfur of biomolecules or from other sources) have 
not yet been identified.  
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Figure 1.13 Transformation of DMAIII in rat RBCs proposed by Naranmandura et al. 
 
In our lab the metabolism of Darinaparsin (DMAIII(GS)) was studied. It was 
found that DMAIII(GS) metabolizes to DMAV, dimethylarsinothioyl glutathione 
(DMMTAV(GS)), and DMAIII(GS).34 Dimethylarsenothioyl glutathione has not been 
identified in humans ever before. The only reported presence of this metabolite of 
unknown toxicity was in cabbage prior to this finding.112  
1.3.3 Retention and elimination 
Currently no studies exist for organic As retention in humans. Arsenic 
retention in the body can best be monitored via the analysis of hair, fingernails, and 
toenails. 113 After the extensive metabolism of arsenic in the liver and other cells, 
arsenicals are transported out of the cells. Different transporters are responsible for the 
cellular efflux of these species and some of the transporters responsible for a few of the 
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arsenic metabolites, such as DMAIII(GS) and DMMTAV(GS), are still not known.14, 100 A 
summary of these cellular efflux pathways are depicted in Figure 1.14. For the transport 
of As(GS)3 and MMA(GS)2 transporters MRP1 and MRP2 are responsible. These two 
transporters belong to the of ATP-binding cassette (ABC) transporters, namely to ABCC 
subfamily and are responsible for the efflux of these two arsenical from the liver into the 
bile (MRP2) and the blood (MRP1).14, 100 Additionally, multidrug resistant P-
glycoproteins (PGPs) that are also ATP-binding cassette transporters are also responsible 
for the efflux of glutathione conjugated arsenicals into the extracellular space.99 AsIII, 
MMAIII, MMAV, and DMAV are effluxed using the membrane protein family aquaporin 
isozymes 9 (AQP9) that facilitate the movement of solutes down their concentration 
gradient.99, 100 Moreover, glucose transporters, especially GLUT2, facilitate the transport 
of AsIII and MMAIII across the cellular membrane.99 Once exported from hepatocytes to 
the bile, these compounds are excreted into the intestines. Some of these may end up in 
the feces and eliminated, or reabsorbed unchanged, while others either may get further 
metabolized by intestinal bacteria to MMMTAV, DMMTAV, and DMDTAV and then 
excreted or reabsorbed from the intestines into the body.10, 14, 114 Additionally, large 
amounts of arsenic metabolites are excreted into the urine. As mentioned before, it is 
estimated that in mice 60-70% of urinary arsenic metabolites are present as glutathione 
complexes originally, but get further metabolized by γ-glutamyl transpeptidase (GGT), 
the enzyme responsible for the catabolism of glutathione-conjugates.31 
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Figure 1.14 Arsenic cellular efflux pathways 
 
1.4 Arsenic Speciation in Biological Systems 
To understand the metabolism, toxicity, and the therapeutic efficacy of arsenicals, an 
appropriate analytical technique is needed that can conserve species identities during 
storage, extraction (sample preparation), separation, and detection to enable us to 
correctly identify and quantify all arsenic species present in biological systems.  
1.4.1 Sample Preparation and Extraction 
Trivalent arsenic metabolites AsIII, MMAIII, and DMAIII are unstable and 
highly prone to oxidation to their pentavalent counterparts, especially DMAIII.115, 116 
Moreover, glutathione conjugates (AsIII(GS)3, MMAIII(GS)2, DMAIII(GS), and 
DMMTAV(GS)) easily hydrolyze and are oxidized if the native reducing environment of 
the cells is not maintained (as in the cases of all reported methods).117 Consequently, if 
samples are not stored properly or if the reducing environment of the sample (most 
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importantly its glutathione concentration) is not maintained during sample preparation, 
the identities of species will be altered and a misleading metabolic speciation profile will 
be obtained resulting in incorrect assessment of toxicity and mechanism of action of 
therapeutic arsenical preparations. Additionally, species stability is pH dependent thus the 
pH of the sample should be maintained during sample preparation or disturbed 
minimally. Ultrasonic bath and probe (Sonic Dismembrator) along with vortexing were 
evaluated for extraction efficiency of arsenic from cancer cells.117 The ultrasonic probe 
was found to be the fastest and most efficient extraction method. Using the sonicator 
probe double deionized water (DDIW), 0.1% trifluoroacetic acid (TFA), and 
DDIW/methanol (50/50 v/v) mix were used as extraction solvent and their ability to 
maintain species identities over time were evaluated and compared to pepsin, trypsin, and 
protease. It was found that DDIW in combination with the sonicator probe yielded similar 
stability results with trypsin and pepsin, while the other extraction solvents were able to 
preserve species identities to a lesser extent.117 
1.4.2 Separation of Species 
Currently existing arsenic speciation techniques usually employ high 
performance liquid chromatography (HPLC) separation on reverse phase (RP) or ion 
exchange column for the analysis of biological samples. In reverse phase chromatography 
(RPC) separation is achieved employing a solid hydrophobic stationary phase and a polar 
liquid mobile phase. The hydrophobic molecules in the mobile phase have a higher 
affinity for the stationary phase thus they are retained longer. In ion-exchange 
chromatography the analytes are retained on the column on the basis of ionic interactions. 
The stationary phase has ionic functional groups that interact with the analyte ions of 
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opposite charge. Ion exchange chromatography is further divided into cation and anion 
exchange chromatography. In cation exchange chromatography positively charged ions 
are retained as the stationary phase possesses negatively charged functional groups. In 
anion exchange chromatography negatively charged ions are retained as the stationary 
phase displays positively charged functional groups. 
Unfortunately, currently available techniques have shortcomings and cannot 
meet the need of "full-spectrum" analysis of As metabolites. First, standard ion 
chromatography was found to destroy glutathione complexes of As in both our and 
others' labs, failing to detect As-GSH complexes.117, 118 As these glutathione complexes 
are thought to be necessary intermediates for arsenic methylation, their unequivocal 
identification is important to depict the pathways of arsenic metabolism. Second, many 
current As speciation methods are unable to detect sulfur-containing arsenicals such as 
DMMTAV, DMDTAV, and DMMTAV(GS), and in particular cannot simultaneously 
determine methylated species (trivalent and pentavalent) and sulfur-containing arsenicals. 
It is necessary to identify sulfur-containing arsenicals as these As species may play an 
important role in As metabolism, toxicity, and anticancer activity. Finally, current 
analytical methods usually are able to separate a limited number of arsenic species only 
and co-elution of species occurs during analysis. For example, many of the methods 
employing anion exchange columns could not distinguish MMAIII from MMAV and 
DMAIII from DMAV, providing incomplete and misleading arsenic speciation profile. As 
a result of the inadequacy of the currently available methods to accurately evaluate the 
metabolism of Darinaparsin and other arsenic arsenicals in biological samples, I 
developed an analytical method that addresses most of the shortcomings of currently 
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available speciation methods. The objective of that study was to develop an analytical 
method using that is capable of performing a "full-spectrum" analysis of As metabolites. 
The method was aimed to simultaneously determine the arsenic species of traditional 
interest (e.g. inorganic AsV and AsIII and organic DMAV and MMAV), the highly toxic 
trivalent methylated As recently reported (DMAIII and MMAIII), and the newly 
discovered sulfur-containing As metabolites (e.g., DMMTAIII, DMMTAV, DMDTAV, 
and DMMTAV(GS)) in addition to the glutathione and cysteine complexes (AsIII(GS)3, 
MMAIII(GS)2, DMAIII(GS)), and DMAIII(Cys). These results are presented in this 
dissertation. 
1.4.3 Detection Techniques 
The separation techniques mentioned above are usually coupled to an element 
specific detector such as inductively coupled plasma mass spectrometer (ICP-MS), 
atomic fluorescence spectrometer (AFS), or atomic absorption spectrometer (AAS) for 
the detection of species.119-123 Unfortunately, these detectors are only element specific 
and cannot reveal the true identity of the species or detect co-elution as the only 
information they are able to provide is the presence of arsenic. To monitor co-elution of 
species and identify arsenic compounds, electrospray ionization mass spectroscopy (ESI 
MS) is employed. Unfortunately, the technique has its own shortcomings. Some of the 
arsenic species either have very low ionization efficiently and such they are not detected 
or only detected at higher concentration levels. Moreover, a few of the trivalent species 
may oxidize during the electrospray to their pentavalent counterparts (especially DMAIII 
to DMAV) thus giving way to misidentification of species. Furthermore, when an 
unknown species is found on the HPLC-ICP-MS chromatograms, in order to identify it, 
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the exact same method must be run on an HPLC-ESI-MS/MS system to determine the 
structure of the unknown at the retention time determined on the ICP system. 
Unfortunately, the ICP and the ESI ionization techniques are very different. While ICP 
does not tolerate the presence of large amounts of organic solvents and plasma instability 
and consequently extinction occurs, the presence of large amounts of organic solvent in 
the mobile phase is required for adequate and efficient ionization in ESI. As a result, it is 
very difficult to develop a method that can be used both on the ESI and the ICP. During 
method development, I aimed to develop a separation technique that could be coupled 
with both ICP and ESI detection technique to achieve the unequivocal identification of all 
species. 
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CHAPTER 2 
Problem Statement, Objectives and Hypotheses 
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2.1 Problem Statement 
Arsenic compounds are extensively metabolized in the human body. Deciphering the 
exact mechanism of metabolism and identifying and quantifying all metabolites produced 
during the biotransformation of arsenicals contribute significantly to our understanding of 
their toxicities, and in the case of arsenic containing therapeutics their mechanism of 
antineoplastic action. To accomplish this, an analytical method capable of conserving all 
species identities during sample preparation, separation, and detection was needed. In 
addition, the separation technique had to able to resolve all species that may be present in 
order to accurately assess the quantities and the identities of all species. Presently 
available analytical techniques are not capable to conserve, resolve, and detect all 
possible human arsenic metabolites from biological samples. Consequently, the 
development of an analytical method overcoming the shortcomings of the currently 
available methods was necessary.  
Moreover, the lack of a good separation method also hindered the deciphering of the 
exact mechanisms of metabolism of Darinaparsin (a promising new chemotherapeutic 
agent), the mechanism of formations of the newly discovered human metabolite 
DMMTAV(GS), and the thiolated arsenicals DMMTAIII, DMMTAV, and DMDTAV. 
Additionally, the source of sulfur used for the formation of these species (DMMTAIII, 
DMMTAV, DMDTAV, and DMMTAV(GS)) (either generated by enzymatic reactions 
producing H2S or from sulfane sulfur containing biomolecules) has not yet been 
deciphered. Furthermore, the form of sulfur (S2-, HS-, and/or H2S) that is involved in the 
formation of the thiolated arsenicals has not been determined either.  
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One of the main obstacles to decipher the mechanism of formation of thiolated 
arsenic species was the unavailability of a method describing the synthesis of DMMTAIII, 
a potential precursor of DMMTAV synthesis from DMAIII and DMAIII(GS), in addition to 
the lack of a good analytical separation method to identify all species formed in the 
reaction of arsenicals and sulfur donors. 
While the toxicity and the ability of cells to take many arsenic compounds up have 
already been evaluated, the uptake and toxicity of the newly discovered arsenic 
metabolite DMMTAV(GS) have not yet been assessed. It is also not known, if the 
formation of DMMTAV(GS) during Darinaparsin metabolism is a detoxification process 
or it is still a highly toxic metabolite. Thus the assessment of toxicity and the cancer 
cells’ ability to take DMMTAV up needed to be evaluated. 
 
2.2 Objectives 
The present work emphasized on the analytical method development for speciation 
of a large number of possible and confirmed human arsenic metabolites from biological 
samples. Once the method was successfully developed, it was employed to determine the 
arsenicals formed in cancer cell lines upon exposure to Darinaparsin and to propose the 
mechanism of metabolism of Darinaparsin in above cells. Additionally, the method was 
applied to decipher the mechanism and conditions of formation of thiolated arsenicals 
DMMTAIII, DMMTAV, DMDTAV, and DMMTAV(GS) from both trivalent 
(DMAIII(GS)) and pentavalent (DMAV) arsenicals and the source and the form of sulfur 
utilized for the formation of the above species. It was also pertinent to evaluate the uptake 
and the toxicity of the newly discovered human metabolite DMMTAV(GS). 
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The following objectives were established: 
1.  Development of efficient and selective speciation method for the simultaneous 
separation and detection of the known and suspected human arsenic metabolites from 
biological samples that is suitable with both ICP-MS and ESI-MS as detectors. 
2. Application of the newly developed analytical method to decipher the mechanism 
of metabolism of Darinaparsin by incubating the cancer cells with Darinaparsin and then 
analyzing the samples to determine the intermediates and the final metabolites of the 
biotransformation of this chemotherapeutic agent.  
3. Application of newly developed method to decipher the mechanism of formation 
of thiolated arsenic metabolites DMMTAIII (and resolve its synthesis), DMMTAV, 
DMDTAV, and DMMTAV(GS) from both trivalent and pentavalent arsenicals, and to find 
the source and the form of sulfur utilized for their formation in biological systems. 
4. To evaluate the toxicity of DMMTAV(GS) and the ability of cells to take it up and 
to understand its role in the metabolism of Darinaparsin.  
 
2.3 Hypotheses 
The objectives were guided by the following hypotheses: 
1. Stabilities and the adequate separation of trivalent arsenicals, thiolated arsenicals, 
and arsenic glutathione complexes during speciation analysis are dependent on the 
experimental conditions employed for sample preparation and separation. 
2. The proper speciation technique, once developed, will enable me to detect all 
possible metabolites and intermediates of metabolism of Darinaparsin from 
biological samples and will aid in understanding the mechanism of formation of 
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the thiolated arsenicals including the newly discovered metabolite 
DMMTAV(GS).  
3. The formation of DMMTAV(GS) is a detoxification process thus it is less toxic 
than the parent compound DMAIII(GS). The ability of cells to take 
DMMTAV(GS) up as is (without prior hydrolysis to DMMTAV) may be limited, 
just like the uptake of DMAIII(GS) in the presence of stabilizing GSH in the 
extracellular space. Moreover, in cells, DMMTAV(GS) is probably mainly formed 
in enzymatic reactions under physiological conditions. 
4. It is most likely that the forms of sulfur utilized for thiolated arsenical formation 
are HS- and H2S as these two are the mayor forms of hydrogen sulfide present at 
physiological pH. The HS- and H2S may come from both enzymatically generated 
processes and/or from sulfane sulfur-containing biomolecules. 
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CHAPTER 3 
Dimethylarsinothioyl Glutathione as a Metabolite in Human Multiple Myeloma Cell 
Lines upon Exposure to Darinaparsin: Formation, Toxicity, and Cellular Uptake 
 
 
 
 
 
 
 
Part of this chapter was accepted for publication in the journal of Chemical Research in 
Toxicology. Adapted with permission from Yehiayan, L., Stice, S., Liu, G., Matulis, S., 
Boise, L., & Cai, Y. (2014). Dimethylarsinothioyl glutathione as a metabolite in human 
multiple myeloma cell lines upon exposure to Darinaparsin. Chemical Research in 
Toxicology. Copyright (2014) American Chemical Society.
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3.1  Graphical Abstract 
 
 
3.2 Abstract 
Dimethylarsinothioyl glutathione (DMMTAV(GS)) was first identified as a 
metabolite in the cellular extracts of dimethylarsinous glutathione (Darinaparsin, 
DMAIII(GS)) treated human multiple myeloma and lymphoma cell lines in our 
laboratory. Formation studies in DMAIII(GS) spiked cells revealed the dependence of 
DMMTAV(GS) formation on the depletion of DMAIII(GS), while presence of 5 mM 
glutathione (GSH) prevented its formation.34 Dimethylarsinothioyl glutathione was 
observed to form under acidic and neutral pH conditions (pH 3.0-7.4). Liquid 
chromatography electrospray ionization mass spectrometry (LC-ESI-MS) in the MS and 
tandem MS modes (MS2 and MS3) revealed molecular ion peaks at m/z = 443.9, 466.0, 
corresponding to [DMMTAV(GS) + H]+ and [DMMTAV(GS) + Na]+, 314.8 for the loss 
of glutamic acid, 231.1 resulting from the loss of glycine and –C2H7AsS, 176.9 
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corresponding to cysteine and glycine adduct (loss of  glutamic acid and -C2H7AsS), and 
137.1 for [C2H6AsS]+ respectively. Both co-elution and increase in the peak area were 
observed upon spiking the cell extracts with a standard of DMMTAV(GS). Heat 
deactivation of the enzymes in the cells prevented the formation of DMMTAV(GS) 
arousing the possibility of its enzymatic formation.34 As some of the pentavalent thiolated 
arsenic metabolites are just as or almost as toxic as their trivalent non-thiol counterparts 
(dimethylmonothioarsinic acid (DMMTAV) and dimethylarsinous acid (DMAIII)) the 
toxicity of DMMTAV(GS), thus its role in detoxification of DMAIII(GS), and the ability 
of multiple myeloma cell lines to take it up were evaluated in addition to DMMTAV and 
DMAIII(GS). Dimethylarsinothioyl glutathione was found to be much less toxic than 
DMAIII(GS) and DMMTAV, probably as a result of its very limited uptake (less than 10% 
and 16% of DMAIII(GS) and DMMTAV respectively). 
 
3.3 Introduction 
Arsenic (As) is a worldwide contaminant with widespread human health effects. 
Aside from carcinogenesis, As is known to cause pulmonary, neurological, 
cardiovascular and hematological disorders, keratosis, hyperpigmentation and black foot 
disease.1, 124 Paradoxically, As has been used for medicinal purposes since ancient 
Greece.63 Darinaparsin (dimethylarsinous glutathione, DMAIII(GS)) is a novel organic 
arsenical that shows promising anticancer activity (structures and names of As species of 
interest are shown in Table 3.1).125-127 A series of in vitro and in vivo studies in toxicity 
and potency suggest Darinaparsin employs a mechanism of action that is different from 
that of arsenic trioxide (ATO). Darinaparsin seems to be more effective than ATO despite 
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of its lower toxicity even at higher concentrations. It may also be used as an alternative 
for ATO-resistant hematological malignancies as cross-resistance between these two 
drugs does not appear to develop.91, 127-129 While Darinaparsin shows clinical promise, the 
underlying mechanisms by which it metabolizes and exerts its apoptotic effects have yet 
to be fully understood.  
Since arsenic toxicity is species dependent, it is essential to obtain speciation 
information at the cellular and molecular level to identify active arsenic metabolites 
responsible for its toxicity or therapeutic efficacy. Arsenic taken up by cells can be 
metabolized into various species via different processes. Glutathione conjugates of 
arsenite (AsIII), monomethylarsonous acid (MMAIII) and dimethylarsinous acid (DMAIII) 
have been reported as As metabolites in mammals and they are more toxic than their 
pentavalent counterparts as a result of their high affinity to sulfhydryl groups on 
biomolecules.8, 17, 18, 104, 130, 131 Recently, it was shown that in fact S-adenosylmethionine 
(SAM), the enzyme responsible for the methylation of arsenite, prefers the 
glutathionylated arsenicals (arsino-glutathione (As(GS)3) and monomethylarsino-
glutathione (MMA(GS)2)) as substrates for methylation compared to AsIII and MMAIII.132 
Arsino-glutathione and monomethylarsino-glutathione have been identified in rat bile and 
urine following intravenous injection, while DMAIII(GS) was not.30, 31  
Latest studies reported the existence of toxic sulfur-containing pentavalent As 
species. Dimethylmonothioarsinic acid (DMMTAV), a thiolated pentavalent sulfur-
containing derivative of dimethylarsinic acid (DMAV), has been shown to be toxic toward 
human epidermoid carcinoma A431 and bladder carcinoma EJ1 cells.13, 133 This As 
species and dimethyldithioarsinic acid (DMDTAV) have been identified in urine, liver 
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and kidney homogenates, plasma and red blood cells.11, 35, 36, 110 The identification of 
these new thiolated species has provided new information on the metabolic pathways of 
DMAIII and DMAIII(GS). Suzuki et al. have proposed that after the decomposition of 
DMAIII(GS) to DMAIII in the absence of excess glutathione (GSH), 
dimethylmonothioarsinous acid (DMMTAIII) is formed through nucleophilic attack by a 
sulfide ion. Dimethylmonothioarsinous acid is further oxidized to DMMTAV, which has 
the potential for further thiolation to DMDTAV.110, 111 Dimethylmonothioarsinic acid has 
also been identified to be bound to rat hemoglobin, suggesting the possibility for 
pentavalent As interaction with sulfhydryls on proteins and peptides.35 Furthermore, Raab 
et al. have identified dimethylarsinothioyl glutathione complex (DMMTAV(GS)), a 
pentavalent thioarsenical bound to GSH, in Brassica oleracea extracts after subjecting 
the roots to DMAV for 24 hours.112 Hirano et al. reported the presence of an unknown As 
species in the culture media containing rat endothelial cells and human leukemia cells 
exposed to DMAIII(GS), however, they were unable to identify the species.131 
During previous studies to decipher the metabolism of DMAIII(GS) in human cancer 
cells in our laboratory, an unidentified arsenic metabolite was observed in addition to 
DMAIII(GS), DMAIII, and DMAV.117 The elucidation of chemical structure of this new 
arsenic metabolite present in the extracts of multiple myeloma cell lines incubated with 
DMAIII(GS) was performed. The molecular weight and structure information of this new 
metabolite was gained using liquid chromatography electrospray mass spectrometry (LC-
ESI-MS) performed in the tandem MS mode. The new arsenic metabolite was identified 
as DMMTAV(GS), dimethylarsinothioyl glutathione.34 The identity of DMMTAV(GS) 
was further confirmed by spiking the cell extract with the synthesized standard of 
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DMMTAV(GS). Experiments were performed to determine the range of pH at which this 
compound forms.  I proposed the possible pathways that may be involved in the 
formation of DMMTAV(GS) in the tested cells. As some of the pentavalent thiolated 
arsenic metabolites are just as or almost as toxic as their trivalent non-thiol counterparts 
(dimethylmonothioarsinic acid (DMMTAV) and dimethylarsinous acid (DMAIII)) the 
toxicity of DMMTAV(GS), thus its role in detoxification of DMAIII(GS), and the ability 
of multiple myeloma cell lines to take DMMTAV(GS) up were evaluated in addition to 
DMMTAV and DMAIII(GS). Dimethylarsinothioyl glutathione was found to be much less 
toxic than DMAIII(GS) and DMMTAV, probably as a result of its very limited uptake 
(less than 10% and 16% of DMAIII(GS) and DMMTAV respectively). 
 
3.4 Experimental Procedures 
Caution: The arsenic species included in this study are toxic and are potential human 
carcinogens; therefore, they should be handled with great care. 
3.4.1 Reagents and Standards 
All reagents used were of analytical grade or better. Argon (Ar) purged double 
deionized water (DDIW) was used throughout the experiments. Acetonitrile and pepsin 
were purchased from Thermo Fisher Scientific, USA. Reduced L-glutathione (GSH) was 
purchased from Sigma-Aldrich, USA. Sodium chloride (NaCl), sodium phosphate, 
dibasic (Na2HPO4.7H2O), potassium chloride (KCl), potassium dihydrogen phosphate 
(KH2PO4) used to prepare phosphate buffer saline (PBS) and phosphate buffer, 
ammonium hydroxide (NH4OH), potassium hydroxide (KOH), and nitric acid (HNO3) 
used for pH adjustments were also purchased from Thermo Fisher Scientific, USA. 
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Table 3.1 Names, abbreviations, and structures of compounds of interest 
Most common Structure Names Abbreviations 
Arsenate, Arsenic acid AsV 
Dimethyldithioarsinic acid 
Dimethylarsinodithioic acid DMDTA
V 
Arsenite, Arsenious acid AsIII 
Monomethylarsonic acid, 
Methylarsonic acid 
MMAV 
MAsV 
Monomethylarsonous acid, 
Methylarsonous acid, 
Methylarsonite 
MMAIII 
MAsIII 
Dimethylmonothioarsinic acid, 
Dimethylarsinothioic acid, 
Thio-dimethylarsinate 
DMMTAV 
Thio-DMA 
DMASV 
Dimethylarsinic acid, 
Dimethylarsinate 
DMAV 
DMAsV 
Arsino-glutathione As
III(GS)3 
ATG 
Dimethylarsinothioyl glutathione 
DMMTAV-GS 
DMATG  
DMASV-GS 
DMMTAV(GS) 
Monomethylarsino-glutathione, 
Monomethylarsonic diglutathione 
MMAIII(GS)2 
MADG 
Dimethylarsinous acid, 
Dimethylarsinite 
DMAIII 
DMAsIII 
Dimethylarsinous glutathione, 
Darinaparsin, Dimethylarsinic, 
glutathione, DAR, 
Dimethylarsino-glutathione, 
DMAIII(GS) 
DAR, DMAG 
DMAsIIIGS  
 
As CH3
SG
GS
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Formic acid and acetic acid used to prepare formate and acetate buffers were 
purchased from Acros Organics and Thermo Fisher Scientific, USA, respectively. 
DMAIII was synthesized in our lab following procedures previously reported.134 
DMAIII(GS) was obtained from Ziopharm Oncology, Boston, MA. 
3.4.1 Syntheses of DMMTAV and DMMTAV(GS) 
The syntheses of DMMTAV and DMMTAV(GS) were performed following 
previously reported methods.110, 112 Briefly, for DMMTAV synthesis, DMAV, Na2S and 
H2SO4 were mixed in mole ratios of 1:1.6:1.6 in water for 24 hours. For DMMTAV(GS) 
synthesis, GSH was added in excess (3 times of the molar concentration of DMAV) to the 
standard mixture of DMMTAV. No attempts were made to isolate the products, however, 
their formation was monitored on ESI-MS by monitoring m/z 155 and m/z 444 for 
[DMMTAV+H]+ and [DMMTAV(GS)+H]+, respectively. 
3.4.3 Instrumentation and Chromatographic Conditions 
A Perkin Elmer Series 200 HPLC system was coupled to a Perkin Elmer 
DRC-e ICP-MS to monitor As and S. A Thermo Finnigan Surveyor HPLC system 
equipped with a peltier-controlled autosampler and column compartment was used with 
an LCQ Deca XP MAX (Thermo Finnigan, USA) electrospray mass spectrometer to gain 
molecular weight information. Separation was achieved on a Waters Spherisorb C8 
column (150 x 4.6 mm in dimension and 5 micron particle size) following a previously 
published method134. Briefly, the mobile phase consisted of 0.1% formic acid and 
acetonitrile in linear gradient mode at a flow rate of 1 mL min-1. The sample injection 
volume was 50 μL with ICP-MS and 25 μL with ESI-MS as detectors. The column 
effluent was split into 2 parts, one going to the detector and the other going to waste.  
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 The ICP-MS was equipped with a cyclonic spray chamber and a Meinhard nebulizer 
and was employed both in standard and DRC modes. In standard mode, m/z 75 for As 
and m/z 77 for ArCl interference were monitored. Data were collected and processed 
using Chromera software version 1.2 (Perkin Elmer, USA). 
 The ESI-MS was used in the positive ionization mode and the total ion chromatogram 
(TIC) was acquired for m/z = 100 - 1050 with results being reported in the single ion 
mode (SIM). The instrument was also operated in tandem MS mode. Data were collected 
and treated using Xcaliar software (Thermo, USA). The instrument was optimized using 
the flow injection mode with a 5 μg mL-1 standard of caffeine. Instrumental parameters 
employed during analysis are listed in Table 3.2. 
Table 3.2 ICP-MS and ESI-MS parameters employed 
ICP-MS (DRC) Value 
Rf power (W) 1350 
Plasma gas flow rate (L/min.) 15.00 
Auxiliary gas flow rate (L/min.) 1.20 
Nebulizer gas flow rate (L/min.) 0.96-1.04 
Oxygen gas flow rate (L/min.) 1 
Lens voltage (V) 8 
Acquisition time (min.) 15 
Dwell time (ms) 600 
RPQ 0.45 
ESI-MS  
ISpray Voltage (kV) 5 
Sheath gas (arb) 30 
Capillary Voltage (V) 25 
Temperature (°C) 260 
Tube lens offset (V) 10 
Acquisition time (min.) 15 
Normalized collision energy 25 
Activation Q 0.25 
Isolation width 1 
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3.4.4 Cell Lines 
8226/S multiple myeloma and DAUDI lymphoma cell lines were purchased 
from the American Type Culture Collection (ATCC, Manassas, VA), while KMS11 
myeloma cell line was provided by Dr. P. Leif Bergsagel (Mayo Clinic, Scottsdale, AZ). 
The MM1S myeloma cell line was provided by Dr. Steven Rosen (Northwestern 
University). The cells were maintained at 37°C in a humidified atmosphere with 5% CO2 
on RPMI-1640 media, supplemented with 100 U mL-1 of penicillin, 100 μg mL-1 of 
streptomycin, 10% heat inactivated fetal bovine serum and 2 mM L-glutamine (all culture 
reagents from Cellgro, MediaTech, Herndon, VA). 
The cells were cultured at a concentration of 2.5 x 105 cells mL-1 and then 
harvested by centrifugation at 1000 rpm for 5 minutes, washed with PBS once, spun 
down again, then the pellets were frozen in liquid nitrogen and stored at -20 °C for 
analysis and incubation experiments. Each cell pellet contained 5.0 x 106 cell counts. 
3.4.5 Incubation Experiments 
The following incubation experiments with DMAIII(GS) were conducted at 
room temperature after the cell pellets thawed: 1) To confirm the formation and identity 
of the unknown arsenical in multiple myeloma (MM) cell lines and examine if 
DMMTAV(GS) can also form in lymphoma cell lines, MM and lymphoma cells were 
incubated with 0.26 mM DMAIII(GS) in double deionized water for 10 minutes and then 
analyzed for speciation on the HPLC-ICP-MS and HPLC-ESI-MS3; 2) To determine the 
range of pH where this metabolite can form (either enzymatically or non-enzymatically), 
DMAIII(GS) was prepared in pH 3.0 (formate), 3.5 (formate), 5.0 (acetate) and 7.4 
(phosphate) buffers and added into the cells. Immediately after the addition of 
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DMAIII(GS), the cells were broken up with a membrane sonicator and let stand for 10 
minutes prior to analysis. 
3.4.6 Extraction Procedure and As Speciation Analysis 
For As speciation analysis, cells were extracted following a procedure 
reported previously.115 To break up cell walls and to extract As, a sonic dismembrator 
(Fisher Scientific, Model 100) operated at power level 2 was employed. To the cells 
placed in 2 mL centrifuge tubes and dipped in ice, 1.5 mL of DDIW was added prior to 
sonication. Following sonication, the samples were filtered through a 0.2 micron sterile 
nylon syringe filter (Whatman, USA) before HPLC-ICP-MS and HPLC-ESI-MS 
analysis.  Samples were prepared and analyzed in duplicate. 
3.4.7 Uptake and Toxicity Experiments of DMMTAV(GS) 
Separate experiments were conducted to preliminarily evaluate the toxicity of 
DMMTAV(GS) and its uptake by cell viability measurements and cell total As analysis 
respectively. The chemically synthesized DMMTAV(GS) was prepared at 0, 1, 3, 5, 10, 
and 20 µM concentrations and the MM cells were exposed to these solutions for 24 hours 
before viability test and total As analysis. For the purpose of comparison, DMAIII(GS) 
and DMMTAV were also used in these experiments at the same concentration levels. Cell 
viability was measured by Annexin V-FITC and PI staining. Data were acquired on a BD 
FACS Canto II flow cytometer (Becton Dickinson, San Jose, CA) and analyzed using BD 
FACS Diva software (Becton Dickinson). The cells were then washed with PBS, pelleted 
for total As analysis, and kept frozen until analysis. Prior to speciation and total As 
measurement, the frozen samples were defrosted, lysed, and homogenized by using a 
sonic dismembrator after adding 500 µL of double deionized water. Following 
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homogenization, the sample was digested with 500 µL of concentrated nitric acid for 2 
hours followed by 250 µL of 30% hydrogen peroxide for another two hours, diluted, and 
analyzed on ICP-MS for total intracellular As. 
 
3.5 Results 
3.5.1 Formation of the newly observed DMMTAV(GS) 
I conformed DMMTAV(GS), DMAIII(GS), DMAIII, and DMAV to be the 
products of DMAIII(GS) metabolism in multiple myeloma cell lines (Fig 3.1). 
Additionally, the same metabolites were observed for the first time in lymphoma cells 
treated with DMAIII(GS) on the HPLC-ICP-MS speciation chromatograms. The majority 
of DMAIII(GS) that was spiked into the culture media (used as control) was oxidized to 
DMAV. 
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Figure 3.1 HPLC-ICP-MS chromatograms of cell line and culture media both spiked with 
DMAIII(GS). AsV was used as internal standard (IS). 
DMAV
DMMTAV(GS)
DMAIII 
DMAIII(GS)
IS 
53 
 
3.5.2 Confirmation of Identity of DMMTAV(GS) 
Using LC-MS in the electrospray mode I confirmed the structure of the 
unknown arsenical. Figure 3.2 A and B show the chromatograms acquired in total ion 
monitoring mode and processed to the responses of peaks at m/z 444 and 412, 
respectively. The mass spectra (Fig. 3.2 C and D) corresponding to peaks DMMTAV(GS) 
and DMAIII(GS) in Fig. 3.2 B revealed molecular ions at m/z = 444 and m/z = 412. The 
ion at m/z = 412 was the protonated form of DMAIII(GS) that was spiked to the cellular 
matrix. The ion at m/z = 444 was from DMMTAV(GS), a dimethylated pentavalent 
arsenical conjugated with glutathione. The unequivocal identification of this molecular 
ion was accomplished with the assistance of the results by Raab et al. who identified 
DMMTAV(GS) in Brassica oleracea extracts after subjecting the roots to DMAV for 24 
hours.112 The LC-MS analysis in the tandem mass mode performed for DMAIII(GS) and 
DMMTAV(GS) spiked cell samples (Fig. 3.3) revealed fragments at m/z = 314.8, 231.1, 
176.9 and 137.1. Peak at m/z = 314.8 corresponds to the loss of glutamic acid, 231.1 
results from the combined loss of glycine and the loss of –C2H7AsS, and m/z 176.9 
corresponds to an adduct of cysteine and glycine. The presence of glutamic acid, glycine 
and cysteine in the MS2 and MS3 fragments confirmed the presence of GSH. Peak at m/z 
= 137.1 observed in the MS2 spectra matches with DMMTAV with the loss of –OH from 
the molecule ([(CH3)2AsS]+). On the basis of these spectral information, it was concluded 
that the S on the cysteine group of GSH was bound to DMMTAV by replacing the -OH in 
the molecule. The lack of DMMTAV molecular ion peak at m/z= 155 could be a 
consequence of the fast transformation of DMMTAV to DMMTAV(GS) or the limited 
sensitivity of the mass spectrometer. 
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Figure 3.2 Typical ESI-MS chromatograms for (A) DMMTAV(GS) and (B) DMAIII(GS) 
in cell samples spiked with DMAIII(GS). The chromatograms were acquired in total ion 
monitoring mode and processed to show peaks at 444 and 412 m/z, respectively. 
Molecular ion peaks corresponding to (C) DMMTAV(GS) and (D) DMAIII(GS) are 
shown. 
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Figure 3.3 MS2 and MS3 spectra for m/z = 444 and m/z = 314.5, respectively to confirm 
the structure of the new As metabolite (DMMTAV(GS)).  
 
3.5.3 pH Dependence of DMMTAV(GS) Formation  
During incubation experiments under different pH values, the appearance of 
DMMTAV(GS) was monitored and confirmed with HPLC-ICP-MS and HPLC-ESI-
MS/MS, indicating that this metabolite could be formed in the tested pH range of 3.0 to 
7.4.  
3.5.4 Uptake and Toxicity Studies 
Uptake studies showed that DMMTAV(GS) is not efficiently taken up by the 
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cells. Compared to DMAIII(GS) treated at the same concentration level, the total amount 
of intracellular arsenic of the DMMTAV(GS) treated cells was only 9.5% of that of 
Darinaparsin. Dimethylmonothioarsinous acid (DMMTAV), the precursor of 
DMMTAV(GS), was more efficiently taken up than DMMTAV(GS), but its intracellular 
concentration was only 58.4% of that of Darinaparsin.  
Cell viability studies revealed that of the three compounds examined, Darinaparsin 
was the most toxic to multiple myeloma cells, followed by DMMTAV being less toxic 
than Darinaparsin, and DMMTAV(GS) being least toxic. Figure 3.4 below displays the % 
apoptosis dose curves for DMAIII(GS), DMMTAV(GS), and DMMTAV. 
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Figure 3.4 Comparison of toxicities of DMAIII(GS), DMMTAV, and DMMTAV(GS) in 
multiple myeloma cell lines 
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3.6 Discussion 
The presence of the newly observed human metabolite DMMTAV(GS) was 
confirmed in multiple myeloma cell lines and seen for the first time in lymphoma cell 
lines. Dimethylarsinothioyl glutathione appeared only on the chromatogram obtained in 
the presence of cell lines but not in culture media, indicating that the formation of this 
arsenical was resulting from the presence of both cellular material and DMAIII(GS), 
while culture media played no role in its formation. It should be noted that for the HPLC-
ESI-MS experiments I incubated cells at 0.26 mM DMAIII(GS) concentration level to 
ensure adequate sensitivity on the HPLC-ESI-MS. The cells probably cannot tolerate this 
As concentrations for an extended time period (as shown in the cell viability tests). 
However, most of the changes in As speciation profile (relative species distribution) 
occurred within 15 minutes. The rapid increasing and levelling off of DMMTAV(GS) 
concentrations at the beginning of the incubation experiments, when the cells were likely 
alive, suggest that its formation is still related to cellular metabolic processes. 
The LC-MS and tandem MS in the electrospray mode were performed to confirm the 
structure of DMMTAV(GS). On the basis of the m/z = 444 and the fragmentation pattern, 
species identity of the newly observed dimethylarsinothioyl glutathione 
(DMMTAV(GS)), a dimethylated pentavalent arsenical conjugated with glutathione, was 
reconfirmed. The identification of this molecular ion was accomplished with the 
assistance of the results by Raab et al. who identified DMMTAV(GS) in Brassica 
oleracea extracts after subjecting the roots to DMAV for 24 hours.112 To further confirm 
the identity of the new metabolite, fragmentation pattern was analyzed. Peak at m/z = 
314.8 corresponds to the loss of glutamic acid from the molecule of DMMTAV(GS), 
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231.1 results from the combined loss of glycine and the loss of –C2H7AsS, and m/z 176.9 
corresponds to an adduct of cysteine and glycine. The presence of glutamic acid, glycine 
and cysteine in the MS2 and MS3 fragments confirmed the presence of GSH. Peak at m/z 
= 137.1 observed in the MS2 spectra matches with DMMTAV with the loss of –OH from 
the molecule ([(CH3)2AsS]+). On the basis of these spectral information, it was concluded 
that the S on the cysteine group of glutathione was bound to DMMTAV by replacing the -
OH in the molecule. No m/z = 155 corresponding to the protonated molecular ion peak 
for DMMTAV was observed. The lack of this peak could be resulting from the fast 
transformation of DMMTAV to DMMTAV(GS) or from the limited sensitivity of the 
mass spectrometer. Additional support for the identification of DMMTAV(GS) came 
from the overlap in retention times of the unknown peak with the synthesized 
DMMTAV(GS) standard when it was spiked to the samples.34  
Formation experiments demonstrated that DMMTAV(GS) could be formed and 
detected at the pH range of 3.0-7.4. At physiological pH, the formation of 
DMMTAV(GS) was probably as a result of enzymatic processes, as prior experiments 
using heat deactivated cells indicated that the formation of DMMTAV(GS) under 
physiological conditions (pH 7.4) is probably enzymatically catalyzed, as evidenced by 
the absence of the unknown metabolite in heat deactivated cells.34 At other pH values, the 
formation of the metabolite could be attributed to non-enzymatic chemical processes, in 
particular for lower pHs (e.g., pH 3) where the enzymes were not active. Previous studies 
have shown that DMMTAV(GS) can be readily formed through chemical reactions under 
acidic conditions in the absence of cellular material.112, 135  
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Identification of DMMTAV(GS) in human multiple myeloma and lymphoma cell 
lines upon exposure to DMAIII(GS) in this study reveals that the thiolated As species 
could be important metabolites of DMAIII(GS) and influence the efficacy and toxicity of 
therapeutic arsenicals. As previous studies have identified DMDTAV, DMMTAV, and 
DMMTAV(GS) in biological systems exposed to other As species, it appears that 
thiolated arsenicals could play an important role in the metabolic transformation of As 
and its toxicity in general. In summarizing our current and previous, and others’ work,34, 
91, 115, 117 a conceptual model is proposed to illustrate the possible pathways for the 
formation of DMMTAV(GS) (Fig. 3.5). 
Darinaparsin (DMAIII(GS)) is a trivalent dimethylarsenic conjugated to GSH. 
Trivalent arsenicals, particularly dimethylated forms, whether or not conjugated with 
GSH, are highly unstable, subject to rapid oxidation, decomposition, and metabolic 
transformation.34, 115, 117 Inside DMAIII(GS)-treated cells, DMAIII, DMAIII(GS), DMAV, 
and DMMTAV(GS) could be detected. As shown in figure 3.5, the formation of 
DMMTAV(GS) could be resulting from the nucleophilic attack of sulfide on DMAV 
(pathway 1 in Fig. 3.5) after which DMMTAV is formed and then conjugated with GSH 
to form DMMTAV(GS). Another possible pathway of DMMTAV(GS) formation could be 
through dimethylmonothioarsinous acid (DMMTAIII), which could be formed through 
nucleophilic attack of sulfide on DMAIII or DMAIII(GS) (pathway 2 in Fig. 3.5), as 
proposed by Suzuki and co-workers.35, 110, 111 Dimethylmonothioarsinous acid could be 
then transformed oxidatively into DMMTAV, but the question about how DMMTAIII is 
transformed into DMMTAV is still unanswered. It is possible that the transformation of 
DMMTAIII to DMMTAV involves a series of reactions including DMAIII attack on 
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DMMTAIII dimer, nucleophilic attack of sulfide, and disproportionation as shown in 
figure 3.5, but further studies are needed to elucidate these pathways. 
Once DMMTAV is formed, transformation of DMMTAV to DMMTAV(GS) could 
readily occur, as evidenced by the experimental results of Raab et al., Suzuki et al., and 
our previous studies.34, 112, 135 The transformation of DMMTAV to DMMTAV(GS) was 
also supported by an ab initio calculation employing methanethiol (CH3SH) as a model 
compound.135 The reaction leading to the formation of the conjugate DMMTAV(SCH3) 
was exothermic (ΔH = -4.85 kcal/mol), indicating the formation of DMMTAV(GS) could 
be a favourable pathway in the presence of DMMTAV and GSH. Dimethylarsinothioyl 
glutathione  formation did not occur in the trials with heat-deactivated cell lines.34 The 
involvement of cells in the formation of DMMTAV(GS) suggests that the pathways of 
DMMTAV(GS) formation illustrated in figure 3.5 could be catalysed enzymatically (at 
least for some steps). As DMMTAV(GS) can be readily formed as shown in previous 
theoretical calculations and in experiments by mixing DMMTAV and GSH in water or 
under acidic conditions, one might infer that the last step, conjugation of DMMTAV with 
GSH, is non-enzymatic.112, 135 However, the theoretical calculations cannot fully consider 
the pH effect. Also, limited study shows that the formation of DMMTAV(GS) is pH 
dependent, and does not occur above pH 7.135 Therefore, at physiological pH, it is still 
possible that the conjugation of GSH to DMMTAV is enzymatic.  
Uptake studies revealed the limited cellular uptake of DMMTAV(GS) in multiple 
myeloma cell lines; only less than 10% and 16% of the uptakes of DMAIII(GS) and 
DMMTAV, respectively. A previous study in our lab revealed that DMAIII(GS) cannot 
enter the cells in the presence of 5 mM GSH in the extracellular space, while in the 
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absence of GSH DMAIII(GS) is taken up very efficiently.34 Initially it was proposed that 
the reason for this is that the hydrolysis of DMAIII(GS) to DMAIII may be required prior 
to uptake and the cells may not be able to take DMAIII(GS) up efficiently in the 
conjugated form.34 Recently it was proposed that DMAIII(GS) may be metabolized to S-
(dimethylarsenic)cysteine (DMAIII(Cys)) on the cell surface with the help of γ-glutamyl-
transpeptidase (γ-GT) and cysteinylglycine dipeptidase prior to uptake by 
cystine/cysteine transporters.94 It was theorized that in the presence of excess 
extracellular GSH, the GSH could compete for cystine transporters, thus reducing the 
uptake of DMAIII(GS) in the form of DMAIII(Cys). Additionally, excess GSH could 
compete with DMAIII(GS) for catabolism by γ-GT and cysteinylglycine dipeptidase and 
decrease the transformation of DMAIII(GS) into the transportable form of DMAIII(Cys) 
thus further reducing the uptake of DMAIII(GS).  
On the basis of the above information, I suspect there may be multiple reasons for the 
very low uptake of DMMTAV(GS). On the one hand, it may be necessary for 
DMMTAV(GS) to first hydrolyze into the transportable form of DMMTAV and GSH 
before entering the cells. As DMMTAV(GS) was synthesized in the presence of excess 
GSH in solution (no pure solid standard is available or methods for its synthesis 
reported), its hydrolysis to DMMTAV could occur only to a limited degree, hence the low 
uptake of the compound. On the other hand, it is possible that DMMTAV(GS) could also 
be potentially catabolized by γ-GT and cysteinylglycine dipeptidase to DMMTAV(Cys) 
and transported by the same cystine/cysteine transporters but the excess GSH may 
compete with DMMTAV(Cys) for catabolism by γ-GT and cysteinylglycine dipeptidase 
for uptake by these transporters hence decreasing the uptake of DMMTAV(Cys) in the 
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presence of excess GSH. Moreover, it is also plausible that DMMTAV(GS) is efficiently 
uptaken as is, but at the same time it is also quickly effluxed out of the cells, resulting in 
the low total As levels observed with DMMTAV(GS) treated cells. 
Cell viability test showed that DMMTAV(GS) was the least toxic species among 
DMAIII(GS), DMMTAV(GS), and DMMTAV. The main reason for its low toxicity can be 
attributed to the inability of the cells to take DMMTAV(GS) up in the presence of excess 
GSH. I evaluated the toxicity of this compound by exposing the cells to DMMTAV(GS) 
externally, hence the observed low toxicity resulting from very limited uptake, which 
might not be able to reflect the actual toxicity of this compound. However, during the 
metabolism of DMAIII(GS), this species forms inside the cells along with other 
metabolites, and could exhibit a higher toxicity.  
In summary, this study confirms the presence of DMMTAV(GS) in multiple 
myeloma cell lines and presents the first observation of this metabolite in human 
lymphoma cell line treated with DMAIII(GS). It is important to note that DMMTAV(GS) 
can be rapidly formed and is relatively stable under physiological conditions in the 
presence of cells. The identification of this glutathione bound pentavalent As species in 
human cells in this study and previous studies in our lab for the first time in humans has 
important implications on the interactions between As taken up by organisms and thiol-
rich biomolecules, and the role S compounds play in As metabolism.112 The presumption 
that trivalent arsenicals can bind to thiols in biological systems, whereas pentavalent 
arsenicals cannot form thiol conjugates needs to be revisited.31, 39 This finding is 
particularly important in studying the medicinal and toxicological effects of As since the 
identified species is a metabolite of DMAIII(GS), a drug in study for chemotherapy.91 
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CHAPTER 4 
Simultaneous Determination of Multiple Human Arsenic Metabolites Employing High 
Performance Liquid Chromatograph Inductively Coupled Plasma Mass Spectrometer 
 
 
 
 
 
 
 
 
 
 
Part of this chapter has been submitted to the journal of Analytical and Bioanalytical 
Chemistry for publication.
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4.1   Graphical Abstract 
 
 
4.2 Abstract 
During the metabolism of different arsenic-containing compounds in humans, a 
variety of metabolites are produced with significantly varying toxicities. Currently 
available analytical methods can only detect a limited number of human metabolites in 
biological samples during one run owing it to their diverse characteristics. In addition, 
with most detection techniques co-elution of species is unnoticeable leading to inaccurate 
metabolic profiles and assessment of toxicity. I developed a high performance liquid 
chromatography inductively coupled mass spectrometry (HPLC-ICP-MS) method that 
can identify thirteen common arsenic metabolites potentially present in humans in one 
chromatographic run to ensure that no co-elution of these species occur. The 13 species 
separated by the method are arsenite (AsIII), arsino-glutathione (AsIII(GS)3), arsenate 
(AsV), monomethylarsonous acid (MMAIII), monomethylarsino-glutathione 
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(MMAIII(GS)2), monomethylarsonic acid (MMAV), dimethylarsinous acid (DMAIII (from 
DMAIIII)), S-(dimethylarsinic)cysteine (DMAIII(Cys)), dimethylarsino-glutathione 
(DMAIII(GS)), dimethylarsinic acid (DMAV), dimethylmonothioarsinic acid (DMMTAV), 
dimethyldithioarsinic acid (DMDTAV), and dimethylarsinothioyl glutathione 
(DMMTAV(GS)). I applied this method to the analysis of cancer cells that were treated 
with Darinaparsin (dimethylarsino-glutathione, DMAIII(GS)), a novel chemotherapeutic 
agent for refractory malignancies, and compared the metabolic profile obtained with 
results using a previously developed method. 
  
4.3 Introduction 
Arsenic (As), through naturally occurring from the Earth's crust to groundwater and 
anthropogenic activities such as nonferrous metal mining and smelting, coal combustion, 
and pesticide application, has resulted in the contamination of water, soil, and food 
around the world.1, 2, 69, 136. The chronic toxicity of As exposure through drinking water 
and food (e.g., rice) poses serious health risks to millions of people.3, 137-140 Toxic effects 
of As include diabetes, anemia, diarrhea, and more importantly, the development of 
different types of cancers such as carcinomas of the skin, lung, bladder, kidney, and liver. 
141-143 
Despite of its known toxicity and potential to cause cancer, arsenic has been 
historically used for medicinal purposes to treat such diseases as ulcers, head lice, and 
plague.63, 72, 144, 145 Although the current use of medical As has been limited as a 
consequence of its high toxicity and carcinogenicity, some arsenic compounds have been 
recently rediscovered for the treatment of certain cancers.63, 72, 146 For example, arsenic 
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trioxide (As2O3, ATO, Trisenox) was revived for the treatment of both newly diagnosed 
and relapsed acute promyelotic leukemia (APL).72, 147 S-Dimethylarsino-glutathione 
(DMAIII(GS), Darinaparsin, DAR) has been in clinical trials for hematological cancers 
and refractory solid tumors.79, 91, 126, 148 
Both the toxicity and anticancer activity of As are partially determined by the 
metabolism of As in human body. Arsenic metabolism is rather complicated, as the 
metabolic profile depends on the arsenic species introduced, the route of administration, 
and the type of cells involved in As elimination. A wide variety of As species, including 
methylated arsenicals such as DMAV, MMAV, DMAIII, MMAIII, and As-glutathione 
(GSH) conjugates, have been observed during As metabolism (see Table 4.1 for the 
names, structures, and abbreviations of all thirteen arsenicals included in this study). In 
particular, a new type of arsenicals, sulfur-containing As compounds including 
DMMTAV, DMDTAV, and DMMTAV(GS), have been recently detected in humans 
and/or mammals.11, 12, 34-36 Although efforts have been made to reveal the pathways of As 
metabolism, much remains unclear about how some of these As species are formed and 
what role these arsenicals play in the toxicity and therapeutic efficacy of As.98, 104 
In order to understand the metabolic pathways of As, the mode of action of As 
toxicity, and the mechanisms underlying As chemotherapy, we must have an analytical 
method that is capable of unequivocally identifying these arsenicals formed during the 
metabolism of environmental As exposure or therapeutic As administration. Speciation 
analysis of arsenic metabolites is important, because each arsenic species possesses 
varying toxicities. For example, MMAIII and DMAIII were shown to be more genotoxic 
than iAsIII and more potent inhibitors of enzymes while thio-DMAV is more cytotoxic 
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than DMAV. 8, 11, 18, 96 Generally trivalent arsenicals are much more toxic than pentavalent 
ones. In addition, trivalent arsenicals are taken up more efficiently by cells than 
pentavalent ones.  
Currently existing arsenic speciation techniques usually employ high performance 
liquid chromatography (HPLC) separation on reverse phase or ion exchange column, 
coupled to an element specific detector such as inductively coupled plasma mass 
spectrometer (ICP-MS), atomic fluorescence spectrometer (AFS), or atomic absorption 
spectrometer (AAS).119-123 Unfortunately, currently available techniques have 
shortcomings and cannot meet the need of "full-spectrum" analysis of As metabolites. 
First, standard ion chromatography was found to destroy glutathione complexes of As in 
both our and others' labs, failing to detect As-GSH complexes.117, 118 As these glutathione 
complexes are thought to be necessary intermediates for arsenic methylation, their 
unequivocal identification is important to depict the pathways of arsenic metabolism. 
Second, many current As speciation methods are unable to detect sulfur-containing 
arsenicals such as DMMTAV, DMDTAV, and DMMTAV(GS), and in particular cannot 
simultaneously determine methylated species (trivalent and pentavalent) and sulfur-
containing arsenicals. It is necessary to identify sulfur-containing arsenicals as these As 
species may play an important role in As metabolism, toxicity, and anticancer activity. 
Finally, current analytical methods usually are able to separate a limited number of 
arsenic species and co-elution of species occurs during analysis. For example, many of 
the methods employing anion exchange columns could not distinguish MMAIII from 
MMAV and DMAIII from DMAV, providing incomplete information on the profile of As 
metabolism. 
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Table 4.1 Thirteen arsenic species identified and separated by the developed method 
Most common Structure Occurrence in humans 
pKa 
14 Names Abbreviations 
Arsenate, Arsenic acid AsV 
Urine24-28 
Fingernail26 
Blood plasma 26, 29 
2.3 
6.7 
11.6 
Dimethyldithioarsinic acid 
Dimethylarsinodithioic acid DMDTA
V In mammals 12, 36  
Arsenite, Arsenious acid AsIII 
Urine24-28 
Fingernail26 
Blood plasma 29 
9.2 
Monomethylarsonic acid, 
Methylarsonic acid 
MMAV 
MAsV 
Urine24-28 
Fingernail26 
Blood plasma 26, 29 
Hepatocytes 33 
3.6 
8.2 
Monomethylarsonous acid, 
Methylarsonous acid, 
Methylarsonite 
MMAIII 
MAsIII 
Urine24-28, 32 
Hepatocytes 33 
 
 
Dimethylmonothioarsinic acid, 
Dimethylarsinothioic acid, 
Thio-dimethylarsinate 
DMMTAV 
Thio-DMA 
DMASV 
Urine11 
Red blood cells35  
Dimethylarsinic acid, 
Dimethylarsinate 
DMAV 
DMAsV 
Urine24-28 
Fingernail26 
Blood plasma26, 29 
Hepatocytes 33 
6.3 
Arsino-glutathione As
III(GS)3 
ATG In mammals 
30, 31  
Dimethylarsinothioyl glutathione 
DMMTAV-GS 
DMATG 
DMASV-GS 
DMMTAV(GS)  
Human multiple 
myeloma cells34 
and lymphoma 
cells (this work) 
 
Monomethylarsino-glutathione, 
Monomethylarsonic diglutathione 
MMAIII(GS)2 
MADG In mammals
30, 31  
S-(Dimethylarsenic) Cysteine DMAIIICys   
Dimethylarsinous acid, 
Dimethylarsinite 
DMAIII 
DMAsIII 
Urine24-28, 32 
Fingernail26 
Hepatocytes 33 
 
Dimethylarsinous glutathione, 
Dimethylarsinic glutathione, 
Dimethylarsino-glutathione,  
Darinaparsin, ZIO-101, DAR 
DMAIII(GS) 
DAR 
DMAG 
DMAsIIIGS  
Human multiple 
myeloma cells34 
and lymphoma 
cells (this work) 
 
As CH3
SG
GS
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The objective of this study was to develop an analytical method using HPLC-ICP-MS 
that is capable of performing a "full-spectrum" analysis of As metabolites. The method 
was aimed to simultaneously determine the arsenic species of traditional interest (e.g. 
inorganic AsV and AsIII and organic DMAV and MMAV), the highly toxic trivalent 
methylated As recently reported (DMAIII and MMAIII), and the newly discovered sulfur-
containing As metabolites (e.g., DMMTAV, DMDTAV, and DMMTAV(GS)). Thirteen 
(13) possible human arsenic metabolites, which represent most of the As species reported 
so far during As metabolism, were included in this study. A variety of chemical and 
instrumental parameters were optimized for the method, with a focus on the key 
parameters influencing separation and detection of these arsenicals, such as mobile phase 
(composition and gradient program) and nebulizer gas (composition and flow rate). The 
developed method was applied to the analysis of human cancer cells that were incubated 
with Darinaparsin for the determination of arsenic speciation profile during the 
metabolism of this anticancer drug. 
 
4.4 Materials and Methods 
4.4.1 Reagents  
Argon (Ar) purged double deionized water (DDIW) (18.2 MΩ Barnstead 
Nanopure Diamond) was used throughout the experiments. Acetonitrile and methanol 
were purchased from Thermo Fisher Scientific. Ammonium hydroxide (NH4OH), sodium 
hydroxide (NaOH), potassium hydroxide (KOH), phosphoric acid (H3PO4), hydrochloric 
acid (HCl), and nitric acid (HNO3) used for pH adjustments were also purchased from 
Thermo Fisher Scientific. Isopropyl alcohol was obtained from Fluka. Glycine, L-
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glutathione reduced, and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich, 
USA. Trifluoroacetic acid and anhydrous citric acid were bought from Acros Organics. 
Formic acid and acetic acid used to prepare formate and acetate buffers were purchased 
from Acros Organics and Thermo Fisher Scientific, USA, respectively. Sulfur dioxide 
gas used for the synthesis of MMAIIII2 and DMAIIII was acquired from Specialty Gasses 
of America. Sodium metaarsenite (98%), sodium arsenate (99%), and cacodylic acid 
(98%) were from Aldrich. Monosodium acid methane arsonate sesquihydrate was 
obtained from Chem Service, PA, USA. Solid DMAIII(GS), obtained from Ziopharm 
Oncology, USA, was prepared in solution in our lab along with other arsenic standards 
used. All reagents used were of analytical grade or better. 
4.4.2 Arsenical Standards Synthesized in House  
As a consequence of the lack of availability, the following arsenical standards 
were synthesized in the laboratory: MMAIIII2, DMAIIII, DMAIII(Cys), AsIII(GS)3, 
MMAIII(GS)2, DMAIII(GS), DMMTAV, DMDTAV, and DMMTAV(GS). The synthesis of 
these arsenicals was on the basis of the previously reported procedures with some 
modifications if necessary, and the identity and purity (if it was possible to purify the 
arsenicals using currently available procedures) of the synthesized As standards were 
verified with NMR, HPLC-ESI-MS, and/or HPLC-ICP-MS.  
MMAIIII2 was synthesized following reported methods with minor 
modifications.149 Briefly, 0.01 mol of MMAV was added to a solution of 0.02 mol of KI 
in 10.0 mL of double deionized water (DDIW). Concentrated HCl (3.0 mL) was added to 
the reaction mixture in small portions over a period of 15 minutes and the reaction 
mixture was stirred under a stream of sulfur dioxide gas for a period of 3 hours. The 
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yellow precipitate was collected, washed with ice cold water and dried over phosphorous 
pentoxide. The product was extracted with anhydrous diethylether. Evaporation of the 
extract gave MMAIIII2 as a yellow powder. The product was stored in argon purged glass 
vials at -11°C. H-NMR was employed to confirm the formation of the desired product. 
After reduction of MMAV, the chemical shift changed from 1.68 ppm to 1.24 ppm. This 
value is in very good agreement with the previously reported values in the literature (1.24 
and 1.34 ppm) and confirms the formation of MMAIIII2.41, 107, 150 The purity of MMAIII 
was found to be near 100% using HPLC-ICP-MS. 
DMAIIII was synthesized following reported methods with minor 
modifications.110 Briefly, 0.016 mol of DMAV was added to a solution of 0.05 mol of KI 
in 10.0 mL DDIW water. The reaction mixture was placed in an ice-bath and 
subsequently saturated with sulfur dioxide and then 10.0 mL of 6M HCl was slowly 
added over a period of 1 hour. The yellow oil product, DMAIIII, was isolated, dried over 
calcium chloride and distilled at reduced pressure. The receiving flask was submerged in 
ice. The product was stored in argon purged glass vials at -11°C. HNMR was employed 
to confirm the formation of the desired product. After reduction of DMAV, the chemical 
shift changed from 1.50 ppm to 1.26 ppm. This value is in perfect agreement with the 
previously reported chemical shift value in the literature (1.26 ppm) and confirms the 
formation of DMAIIII.151 
DMAIII(Cys) was synthesized by reducing DMAV with L-cysteine according 
to previously reported methods with slight modifications (prepared at room temperature 
and no heating was employed).107 Formation of DMAIII(Cys) was confirmed by 
monitoring the retention time shift from DMAV towards to that of DMAIIII.  
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AsIII(GS)3 was prepared by mixing AsV with GSH in the molar ratio of 1:9 
and in some cases by reacting AsIII with GSH in the ratio of 1:6. Formation and purity of 
the compound was confirmed by HPLC-ICP-MS. If the purity was not found to be 100% 
on the HPLC-ICP-MS, three additional mol equivalents of GSH was added to the 
solution. The HPLC-ESI-MS was employed in the positive mode for the unequivocal 
identification of the product. The m/z value of synthesized compound was found to be 
994 [M+H]+, confirming the formation of AsIII(GS)3. 
MMAIII(GS)2 was prepared by mixing MMAV with GSH in the molar ratio of 
1:6. Formation and purity of the compound was confirmed by HPLC-ICP-MS. If the 
purity was not found to be 100% on the HPLC-ICP-MS, the molar ratio of MMAV to 
GSH was increased to 1:8. The HPLC-ESI-MS was employed in the positive mode for 
the unequivocal identification of the product. The m/z value of synthesized compound 
was found to be 703 [M+H]+ confirming the formation of MMAIII(GS)2. 
DMAIII(GS) was prepared by mixing DMAV with GSH in the molar ratio of 
1:9 under acidic conditions. Formation of the compound was confirmed by HPLC-ICP-
MS by comparing its retention time with solid standard received from Ziopharm 
Oncology, Boston, MA. Additionally, the HPLC-ESI-MS was employed in the positive 
mode for the unequivocal identification of the product. The m/z value of synthesized 
compound was found to be 412 [M+H]+, confirming the formation of DMAIII(GS). 
DMMTAV was prepared by reacting DMAV with sodium sulfide (Na2S) and 
sulfuric acid (H2SO4) in DDIW according to previously reported method with slight 
modification.10 Unlike the reference, I did not purify DMMTAV by extracting it into 
diethyl ether at the end. The mol ratio of As:Na2S:H2SO4 was 1:1.6:1.6. DMMTAV was 
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aliquoted and stored in argon purged glass vials at -11°C. Formation of DMMTAV was 
confirmed with the help of HPLC-ESI-MS in the positive mode. A peak with an m/z 
value of 155 was obtained confirming species identity. 
DMDTAV was prepared by stepwise addition of concentrated H2SO4 to an 
aqueous solution of DMAV and Na2S at the final molar ratio of DMAV:Na2S:H2SO4 was 
1:7.5:7.5. The reaction solution was allowed to stand for 1 day.107  
DMMTAV(GS) was prepared by adding GSH to DMMTAV in the molar ratio 
of 9:1 respectfully. Formation and purity of the compound was confirmed by HPLC-ICP-
MS. If needed, more GSH was added to the solution. The HPLC-ESI-MS was employed 
in the positive mode for the unequivocal identification of the product. The m/z value of 
synthesized compound was found to be 444 [M+H]+ confirming the formation of 
DMMTAV(GS).  
4.4.3 Instrumentation  
Proton NMR spectra for the confirmation of MMAIIII2 and DMAIIII synthesis 
was performed at 25 °C on a Bruker 400 FT NMR spectrometer operating at a proton 
frequency of 400 MHz. Samples were dissolved in D2O, except for the oily DMAIIII 
which was dissolved in a mixture of D2O and D3C-OD to increase its solubility. The 
samples were transferred to the NMR tubes and capped with rubber septa immediately. 
NMR spectra were collected within half an hour of sample preparation. Chemical shift 
values were referenced to the residual HDO signal at 4.70 ppm.  
A Thermo Finnigan Surveyor HPLC system equipped with an autosampler 
and column compartment was coupled with an LCQ Deca XP MAX (Thermo Finnigan, 
USA) MS. Data was collected and treated using Xcalibar software (Thermo, USA). The 
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instrumental parameters were optimized using the flow injection mode with a 5 μg mL-1 
caffeine standard. 
A Perkin Elmer Series 200 HPLC system equipped with a temperature 
controlled column compartment was coupled to a Perkin Elmer Elan DRC-e ICP-MS. 
The ICP-MS was equipped with a cyclonic spray chamber and a Meinhard nebulizer and 
was used in the standard mode. The ICP-MS signal at m/z 75 for 75As was monitored. 
Data was collected and processed using Elan v. 3.4 and Chromera v. 1.2 software (Perkin 
Elmer, USA).  
4.4.4 Optimization of HPLC and ICP-MS Parameters  
To develop an HPLC-ICP-MS method for speciation of various As 
metabolites, experiments were performed to optimize a variety of parameters, including 
HPLC column type and dimension, column temperature, mobile phase (composition, pH, 
and gradient program), and ICP-MS parameters such as nebulizer gas, RF power, analog 
stage, and lens voltages. It was observed that HPLC mobile phase and ICP-MS nebulizer 
gas were the two key factors influencing the separation and detection of the As 
compounds of interest. Therefore the experiments were focused on these two parameters 
to find the most optimal conditions for the separation and detection of all arsenic species 
of interest. 
The optimization of mobile phase included selection of aqueous buffer and 
organic solvent and the gradient elution program. Considering the pKa values of 
arsenicals, a number of buffers, including but not limited to trifluoroacetate (TFA, pKa = 
0.5), formate (pKa = 3.8), and acetate (pKa = 4.8), were tested. The commonly used 
organic solvents, such as acetonitrile, methanol, and isopropyl alcohol, were tested for 
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separation of the As species of interest. The gradient elution program was optimized by 
changing the v/v % of the selected organic component from 0-20%. 
Nebulizer gas was optimized for its composition and flow rate to investigate 
its effect on detection of the arsenic metabolites selected in this study. In order to address 
the issue of plasma instability and instrument contamination, which was caused by high 
v/v % of organic solvent used here (see Results and Discussion), oxygen was added 
through a T-connector to the nebulizer Ar gas. The flow rate of Ar for nebulization was 
further optimized to investigate its effect on separation of arsenic compounds and 
instrumental sensitivity, by varying the flow rate from 0.80 to 1.04 L/min. 
4.4.5 Linearity, Limit of Detection (LOD), and Limit of Quantitation (LOQ) 
Even at low v/v %, the organic portion of the mobile phase significantly 
changes the ionization characteristics in the plasma and thus the sensitivity of the method 
for the same species. Consequently, the linearity, LOQ and LOD of the method were 
demonstrated using two compounds, one (AsIII) eluting during very low (1%) acetonitrile 
(ACN) concentrations and one (AsIII(GS)3)  eluting during very high (> 15%) acetonitrile 
concentration. Linearity, LOQ, and LOD studies were performed under the optimized 
instrumental conditions. 
4.4.6 Application of Method for the Determination of Metabolites of DMAIII(GS) in 
Human Cells 
The developed method was used to analyze the metabolites of DMAIII(GS) in 
8226/S multiple myeloma cell line (ATCC, Manassas, VA). The cells were maintained at 
37 °C in a humidified atmosphere with 5% CO2 on RPMI-1640 media, supplemented 
with 100 U mL-1 of penicillin, 100 µg mL-1 of streptomycin, 10% heat inactivated fetal 
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bovine serum and 2 mM L-glutamine (all culture reagents from Cellgro, MediaTech, 
Herndon, VA). Following incubation the cells were harvested by centrifugation at 1000 
rpm for 5 minutes, washed with PBS once, spun down again, then the pellets were frozen 
in liquid nitrogen and stored at -11 °C. Each cell pellet contained 5.0 x 106 cell counts. 
For the As exposure experiment, the cell pellets were thawed, spiked with 0.26 mM 
DMAIII(GS) in double deionized water (DDIW) and left for 10 minutes. The cells were 
then broken up with a sonication probe, and the sample was filtered through a 0.2 µm 
NYLON syringe filter into an HPLC vial and analyzed. Unspiked cells used as control 
were prepared in the same way, but without spiking the cells with DMAIII(GS). 
 
4.5 Results and Discussion 
4.5.1 HPLC Column  
Since a number of As metabolites could exist in human cells and some of 
which (e.g., trivalent arsenicals) are redox sensitive, an efficient separation is required for 
their determination to maintain integrity of the analytes. I first compared three HPLC 
columns, namely ion exchange, C18, and C8, and found that C8 column was the most 
promising for further optimization to achieve better separation of a variety of arsenicals. I 
then performed further experiments to optimize the C8 column-based HPLC-ICP-MS 
method, focusing on mobile phase and nebulizer gas as I observed they are critical in the 
performance of the method. In addition, as I observed that lower temperatures help 
preserve the oxidation state of trivalent arsenic species and prevent the degradation of 
As-glutathione complexes, concurring with previous studies118, I conducted all the 
experiments with the column kept at 10 ºC. 
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4.5.2 Mobile Phase  
It was observed that a mixture of aqueous buffer and organic solvent was 
needed for the separation of the arsenic species of interest. For aqueous mobile phase, a 
number of buffers were evaluated, particularly such volatile buffers as trifluoroacetate 
(TFA, pKa = 0.5), formate (pKa = 3.8), and acetate (pKa = 4.8).152 The selection of these 
buffers was primarily on the basis of pH. Ideally, the pH of the mobile phase should be 
chosen to be at least two units away from the analyte pKa values in order to have all the 
analytes present in their neutral or fully ionized forms.152 Considering that the species to 
be separated have a wide range of pKa values (including unknown pKa for some species) 
and that many of these species are more stable at lower pH values, the final pH range 
studied was set from 1.5 to 4.6 on the basis of the available pKa values and stability 
experiments.118 In addition to pH, volatility was considered a factor for selection of 
aqueous mobile phase. This was because it would be ideal if the separation method could 
be used not only in HPLC-ICP-MS, but also in HPLC-ESI-MS. In this case, if an 
unknown peak appears or the identity of a peak is questionable solely on the basis of 
retention time, HPLC-ESI-MS can be used for the unequivocal identification of the 
species in question. A comparison of the above 3 mobile phases yielded that the best 
separation can be achieved using 0.05% TFA as the aqueous mobile phase (data not 
shown). 
For organic solvents in the mobile phase, acetonitrile, methanol, and isopropyl 
alcohol were considered. It was found that the ICP did not tolerate isopropyl alcohol well 
even at low concentrations, and isopropyl alcohol was not used after the initial trials. 
Methanol, though evaluated extensively to be used for separation, was not selected as our 
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research group previously observed the decreased stability of certain arsenic species in 
methanol.117 Acetonitrile was eventually selected as the organic part of the mobile phase, 
as it has higher eluotropic strength when used at the same volume percentage compared 
to methanol, achieving adequate separation within reasonable time. An additional benefit 
of acetonitrile addition to the mobile phase was the enhanced signal on ICP-MS detection 
(data not shown). This was not surprising, as it is known that the presence of organic 
solvents at 1-5 v/v% would cause signal enhancement of arsenic and other elements with 
higher ionization potentials as a result of the modification of equilibrium in the plasma.153 
This is the consequence of the modification of equilibrium in the plasma. The degree of 
ionization of carbon is significantly larger than that of Ar under standard conditions. As 
the C+ has an ionization energy (Ei) of 11.26 eV, the transfer of electrons to elements 
with lower Ei (such as 75As which has an Ei of 9.81 eV), thus their ionization improves 
considerably, hence the signal enhancement. 
After selection of aqueous and organic mobile phases, the gradient program was 
optimized by modifying the v/v % of the organic component, as the v/v % of organic 
solvent is the principal factor that governs the retention of analytes in reversed-phase LC 
separations. It was found that the v/v % needed to be gradually increased and a relative 
large amount of organic solvent (20% v/v) at the late stage of separation was necessary to 
achieve the most optimal separation of all species within reasonable time. Figure 4.1 
illustrates the separation of major arsenic compounds (excluding arsenic-glutathione 
complexes) under the optimized HPLC gradient program and other conditions (Tables 4.2 
A and B). The total run time was set to 30 min, although the retention time of the last 
peak was around 23.4 min. The extra run time (between 26 to 30 min) can be used for the 
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post column injection of a stable internal standard (e.g., AsV), if required, to correct for 
instrumental drifts occurring during the day. During the last ten minutes of the gradient 
program, the v/v % of acetonitrile was decreased to 5% from 20% in the previous step. 
This change of ACN v/v % not only had no significant effect on the retention time and 
the resolution of the peaks eluted during this period, but also provided a way to reduce 
the usage of organic solvent and to protect the stability of plasma. If the run was finished 
with 20% acetonitrile in the mobile phase at 0.5 mL/min without the decrease in ACN v/v 
%, the plasma would be frequently extinguished once the equilibration stage began when 
the mobile phase changed to 1% v/v acetonitrile at 1 mL/min. 
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Figure 4.1 Typical chromatogram for the separation and analysis of arsenic compounds 
containing no glutathione using HPLC-ICP-MS. The compounds separated are as 
follows: 1. AsV, 2. DMDTAV, 3. AsIII, 4. MMAV, 5. MMAIII, 6. DMMTAV, 7. DMAV, 
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12. DMAIII, * Baseline disturbance originating from high concentration of acetonitrile in 
the gradient program. 
 
Table 4.2 A Instrumental parameters after optimization 
IC
P 
pa
ra
m
et
er
s 
Parameter (unit) Typical values 
ICP-MS Nebulizer Ar Gas Flow (L/min) 0.84-0.90 
Nebulizer Oxygen Gas Flow (L/min) 0.2 
Auxiliary Gas Flow (L/min) 1 
Plasma Gas Flow (L/min) 15 
Lens voltage 9 
ICP RF Power (W) 1350 
Analog Stage Voltage -1525 
Pulse Stage Voltage 950 
Quadrupole Rod Offset Std (QRO) -2 
Cell Rod Offset Std (CRO) -7 
Discriminator Threshold 40 
Cell Path Voltage Std (CPV) -20 
H
PL
C
 p
ar
am
et
er
s Column Waters Spherisorb 5 µm C8, 4.0x250 mm 
Column temperature 10°C 
Mobile phase temperature Cooled in ice bath during analysis 
Sample temperature Room temperature 
Mobile phase (MP) MP A: 0.05% TFA  MP B: Acetonitrile 
 
Table 4.2 B Gradient elution program after optimization 
Step Step type Step time (min) 
Flow 
(mL/min) 0.05% TFA ACN % Curve 
0 Equilibration 6.0 1.0 99 1 N/A 
1 Run 5.5 0.4 99 1 0.0 
2 Run 3.5 0.5 87 13 1.0 
3 Run 11.0 0.5 80 20 0.0 
4 Run 10.0 0.5 95 5 0.0 
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4.5.3 Nebulizer gas  
From the optimization of mobile phase, it was seen that high acetonitrile 
composition (up to 20% v/v) was needed for the separation of arsenic species. The usage 
of high fraction of organic solvent in the mobile phase caused several problems. First, 
high fraction of ACN extinguished the plasma frequently during the run, interrupting 
sample analysis. Second, as a consequence of the high organic composition in the mobile 
phase, carbon built up quickly on the ICP sampling interface and torch, necessitating the 
frequent cleanup or replacement of the torch, the injector, and the cones. Finally, high 
ACN v/v % in mobile phase produced severe baseline disturbance during gradient elution 
and caused appearance of a ghost peak, interfering with detection of arsenic species. In 
order to solve these problems, I did further optimization on the method and found that 
nebulizer gas was the critical factor. I then optimized nebulizer gas, including 
composition and flow rate, to solve these problems. 
For nebulizer gas composition, I introduced a small amount of oxygen to the 
nebulizer gas flow, aiming to burn the carbon from organic solvent to avoid carbon 
deposition on ICP hardware. A T-connector was employed to add 0.2 L/min oxygen gas 
to the Ar nebulizer flow exiting from the ICP and going to the nebulizer. Prior to 
analysis, the flow rates of Ar and oxygen were separately measured and the flow of the 
two gasses added up was verified before the gases entered the nebulizer. The highest 
manufacturer recommended flow rate of 0.2 mL/min of O2 was used to achieve 
maximum protection for the instrument from carbon buildup. The approach was found to 
be successful and I managed to keep our equipment protected from carbon build up for a 
long time (e.g., months) and from the extinguishing the plasma. 
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Figure 4.2 Demonstration of signal enhancement as a consequence changes in nebulizer 
gas composition and flow rate for (A) MMAIII(GS)2 eluting during high (20%) v/v% 
acetonitrile and (B) AsV and AsIII eluting during low (1%) v/v% acetonitrile in the 
gradient program. 
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During the experiments of introducing oxygen into the nebulizer gas flow, it was 
observed that the intensity of the ICP-MS signal was enhanced when the nebulizer gas 
was composed of O2 and Ar than Ar alone, with the total flow rate being the same (Fig. 
4.2). For example, the signal for MMAIII(GS)2, which was eluted at high ACN v/v %, 
increased by a factor of about 7 when the nebulizer gas was composed of 0.2 L/min of O2 
and 0.84 L/min of Ar, compared to 1.04 L/min of Ar. Similarly, under the same 
experimental conditions, the signals for AsV and AsIII, which were eluted at low ACN v/v 
%, increased when the mixture of O2 Ar was used as nebulizer gas. This signal increase 
could be a consequence of the introduction of O2 and/or the difference in Ar flow rates 
(0.84 L/min when O2 was added versus 1.04 L/min with Ar only). From Fig. 4.2, it was 
also observed that the baseline disturbance from high ACN v/v % in the mobile phase 
was more severe at a lower flow of Ar (0.84 L/min), compared to a higher flow of Ar 
(1.04 L/min). It seems possible that a lower flow of Ar enhanced the instrumental signal 
and at the same time increased baseline disturbance. Further experiments were conducted 
to examine the effect of Ar flow rate on baseline disturbance and on instrumental signal. 
Blanks without As compounds were used to check the baseline disturbance 
during gradient elution under different flow rates of nebulizer Ar gas. It was found that 
the baseline disturbance producing the ghost peak can be substantially decreased by 
increasing slightly the Ar nebulizer flow (Fig. 4.3). Increasing the Ar flow from 0.80 to 
0.90 L/min could reduce the baseline disturbance to an acceptable level. It appears that 
O2 had no influence on baseline disturbance, as indicated by the similarity of baseline 
signals with or without O2 present in the nebulizer gas when Ar was 0.8 L/min. 
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Arsenic standards were run to assess the effect of Ar flow rate on instrumental 
signal. It was observed that increasing the nebulizer Ar gas flow decreased the sensitivity 
of the instrument for arsenic detection. Figure 4.4 A demonstrates an example of the 
negative effects of Ar flow increase on the response of the instrument, with DMAIII(Cys) 
being detected on ICP-MS. The instrumental intensity for DMAIII(Cys) decreased by a 
factor of 2 when the Ar flow increased from 0.80 to 0.90 L/min with O2 present in the 
nebulizer gas at 0.20 L/min. Again, the influence of Ar gas flow on baseline disturbance 
was observed, as 0.90 L/min of Ar produced significantly lower baseline disturbance, 
compared to 0.80 L/min of Ar. 
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Figure 4.3 Baseline disturbance vs nebulizer flow rate and composition for blank 
injection. 
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To exclude the possibility that the decreased instrumental response was the 
consequence of the overall increase of nebulizer gas flow (Ar + O2), experiments were 
conducted to examine the ICP-MS signal for DMAIII(Cys) at a fixed Ar flow rate with 
and without the addition of O2. It was observed that the ICP-MS signals were fairly 
similar when 0.2 L/min of O2 was added to 0.86 L/min of Ar (making up a total flow of 
1.06 L/min), compared to 0.86 L/min of Ar being used as nebulizer gas (Fig. 4.4 B). This 
result suggests that the increase in nebulizer gas flow as a consequence of O2 addition did 
not affect instrumental response. Additionally, others reported for some elements such as 
tellurium (Te) with similar behavior to As3+ in ICP-MS, the addition of O2 to the outer 
gas (nebulizer gas flow) had no effect on analyte sensitivity except when mixed in with 
the plasma gas.154 
From figure 4.4 B, it was also seen that the increase in nebulizer gas flow as a 
consequence of O2 addition did not affect baseline disturbance. These results confirmed 
that it is Ar flow rate that influences the instrumental response and baseline disturbance. 
Through the optimization of nebulizer gas, it was found that increasing Ar flow rate 
reduced baseline disturbance, but at the same time decreased instrumental response. 
Therefore, the nebulizer Ar flow rate (in addition to other instrumental parameters) 
should be carefully optimized prior to analysis, to achieve adequate sensitivity while 
minimizing the interference from baseline disturbance. The typical Ar flow rates used in 
our experiments were about 0.84-0.90 L/min (Table 4.2). As for O2, it was observed that 
O2 protected the instrument from carbon buildup and from plasma extinguishing, but did 
not affect signal intensity.  
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Figure 4.4 The effect of nebulizer gas on instrumental response demonstrated by (A) 
decreased sensitivity for DMAIII(Cys) detection with increasing Ar flow rate and (B) 
similar responses of DMAIII(Cys) at the same Ar flow rate regardless of the presence of 
oxygen. The effect of Ar flow rate on baseline disturbance is also observable in the 
figure. 
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3.5.4 Analysis of As-GSH complexes  
As-GSH complexes represent an important type of intermediates during As 
metabolism in human body, and thus the developed method was also intended for 
analysis of As-GSH complexes. For analysis of As-GSH complexes, the first 
consideration was about the standards. The As-GSH complexes standards were prepared 
by mixing As standard solutions (AsIII, MMAIII, DMAIII, and DMMTAV) with excess 
GSH, and thus the standards of As-GSH complexes, e.g., AsIII(GS)3, MMAIII(GS)2, 
DMAIII(GS), and DMMTAV(GS) were always present in excess GSH. The standard 
solution of As-GSH complexes could not be mixed with the non-GSH complexed As 
standards, because, once mixed, the non-GSH complexed arsenicals (free AsIII, MMAIII, 
DMAIII, and DMMTAV) would be complexed by GSH from the solution of As-GSH 
complexes. Therefore I prepared two sets of standards, one for As-GSH complexes and 
the other for non-GSH complexed arsenicals, and these two types of As standards need to 
be injected separately. For samples, when GSH and non-GSH complexed arsenicals are 
present in a sample, equilibrium will be established between the GSH complexes and 
their non-GSH counterparts depending on the reduced GSH concentration in the sample. 
When injected, the relative amounts of each arsenic species can be determined on the 
basis of the two sets of As standards. 
Figure 4.5 A shows a typical chromatogram with good separation for As-GSH 
complexes, AsIII(GS)3, DMMTAV(GS), MMAIII(GS)2, and DMAIII(GS), as well as thiol-
containing arsenicals, DMDTAV and DMMTAV. An overlay of the chromatograms for 
non-GSH complexes As standards and As-GSH complexes shows the separation of major 
As metabolites of interest (Fig. 4.5 B), suggesting that the developed method is indeed 
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able to detect both sulfur-containing and non-sulfur-containing arsenicals if they are both 
present in the sample. 
It should be pointed out that the DMAIII peak (#12 in the chromatogram, Fig. 
4.6) corresponded to the injection of DMAIIII synthesized in our laboratory, which could 
be hydrolyzed to DMAIII(OH) upon dilution in aqueous solutions. It was found that, 
when a high concentration of DMAIII(GS) (#13 in the chromatogram, Fig. 4.6) was 
injected, during the run it partially dissociated to DMAIII, as shown by the fronting peak 
of DMAIII(GS) in Figure 4.6. The decomposition of DMAIII(GS) to DMAIII during 
analysis, along with the lack of availability of pure DMAIII standard and DMAIII being 
extremely prone to oxidation during storage and sample preparation, make it nearly 
impossible to accurately determine the native DMAIII concentration in the sample. As the 
preparation of DMAIIII is rather difficult, DMAIII(Cys) and DMAIII(GS) have been used 
as standards for DMAIII in a number of studies, which further complicated the issue of 
DMAIII identification and detection. By using the developed method here, I observed that 
DMAIIII (probably should be labeled as DMAIII as this species usually refers to the non-
conjugated form), DMAIII(Cys), and DMAIII(GS) gave three completely different peaks, 
with a very broad peak for DMAIII and two sharp peaks for DMAIII(Cys) and DMAIII(GS) 
(Fig. 4.6). Therefore, DMAIII(GS), DMAIII(Cys), and DMAIII (non-conjugated form) 
should be treated as three different As species and caution should be exercised to avoid 
confusion. I further demonstrated that the developed method was able to separate all 
these three forms of the trivalent dimethylated arsenical (Fig. 4.6), if they are present as 
As metabolites in the sample. 
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Figure 4.5 Separation of arsenic metabolites demonstrated by (A) injection of glutathione 
complexes and S containing compounds and (B) overlay of the chromatograms for 
injection of sulfur-containing and non-sulfur-containing arsenicals. The compounds 
separated are as follows: 1. AsV, 2. DMDTAV, 3. AsIII, 4. MMAV, 5. MMAIII, 6. 
DMMTAV, 7. DMAV, 8. AsIII(GS)3, 9. DMMTAV(GS), 10. MMAIII(GS)2, 12. DMAIII, 
13. DMAIII(GS), * Baseline disturbance originating from high concentration acetonitrile 
gradient program. 
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Figure 4.6 Resolution of DMAIII, DMAIII(Cys), and DMAIII(GS) demonstrated by (A) 
generation of DMAIII during high concentration of DMAIII(GS) injection, (B) separation 
of DMAIII(Cys) (#11) and DMAIIII (#12), and (C) separation of DMAIII(Cys) from As-
GSH complexes. 
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3.5.5 Linearity, LOQ and LOD  
Linearity, LOQ, and LOD were determined using AsIII and AsIII(GS)3 under 
the optimized conditions, with a nebulizer flow consisting of 0.2 L/min O2 and 0.84 
L/min Ar giving a total flow of 1.04 L/min. Because AsIII and AsIII(GS)3 were two peaks 
eluted at low and relatively high acetonitrile v/v %, respectively, the results obtained for 
these two species are indicative of the method performance for all As species. The 
method was found to be linear between the tested range of 1.25 to 2500 ppb for both AsIII 
(Fig. 4.7) and AsIII(GS)3 (Fig. 4.8)  with r2 > 0.999. Limit of detections of AsIII and 
AsIII(GS)3 were experimentally determined to be 1.25 ppb with an average of signal to 
noise ratio (S/N) of 3 for three injections for both compounds. The limits of quantitation 
for AsIII and AsIII(GS)3 were experimentally found to be 2.5 ppb for each. Though the 
average S/N for three injections was only 6 for AsIII and 8 for AsIII(GS)3  (less than the 
customary 10), the percent relative standard deviation of the peak areas was only 4.2 for 
AsIII and 7.0 for AsIII(GS)3 at this concentration level, thus the LOQ concentration was 
set to be 2.5 ppb for both compounds. Though the linearity ranges and the detection 
limits were not determined for each compound, I expect similar results for other As 
species. Additionally, depending on the age and condition of the ICP-MS, the type of 
spray chamber used, the sampling interface, and other parameters, the sensitivity of the 
instrument varies, thus the LOD and LOQ may vary in different laboratories and should 
be determined in each laboratory. 
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Figure 4.7 Linearity graphs for AsIII 
 
 
Figure 4.8 Linearity graphs for AsIII(GS)3 
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4.5.6 Application of Method  
The analysis of the 8226/S multiple myeloma cells exposed to DMAIII(GS) 
using the developed method revealed the presence of several As species (Fig. 4.9). In 
addition to the parent DMAIII(GS), its dissociation product DMAIII and its oxidation 
product DMAV were detected. The thiol-containing arsenical DMMTAV was detected, 
and more importantly its GSH conjugate, DMMTAV(GS), was found to be the major 
species of DMAIII(GS) metabolism in the cells. These results suggest that thiol-
containing arsenicals may play an important role in the metabolism of DMAIII(GS) and 
these thiolated arsenicals could be eventually related to the anticancer activity of 
DMAIII(GS). The simultaneous determination of thiol-containing and non-thiol-
containing arsenicals (e.g., DMMTAV(GS), DMMTAV, and DMAIII) demonstrates the 
robustness of the developed method, as a combination of two HPLC-ICP-MS methods 
had to be used to run the same sample twice for the separation of the metabolites of 
interest in our previous studies. Even running both previous methods (on two different 
columns) could not separate all possible As intermediates during Darinaparsin 
metabolism, as the missing of DMMTAV in the previous studies indicates. It was also 
observed that the method developed had better resolution of As species separation. 
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Figure 4.9. Results of human cells analysis using the developed method after incubation 
with Darinaparsin. The compounds separated are as follows: 6. DMMTAV, 7. DMAV, 9. 
DMMTAV(GS), 12. DMAIII, 13. DMAIII(GS) 
 
4.5.7 Potentials and Problems 
The HPLC separation method developed in this study can be used for ICP-MS 
(as reported here) or ESI-MS detection, as the mobile phases used in the HPLC 
separation are compatible with ESI-MS. It is possible to use the separation method on 
ESI-MS for the identification of unknown arsenic species, with the flow rate of mobile 
phase being adjusted to 0.5 mL/min during equilibration and the equilibration time being 
extended as a result of the reduced flow rate. Fortunately, these changes during 
equilibration stage will not affect chromatographic separation of arsenic species. This 
dual suitability of the separation method for both ICP-MS and ESI-MS can help us in the 
unequivocal identification of arsenic species. It should be noted that not all arsenic 
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species could be easily detected on ESI-MS, as some arsenic species do not have high 
ionization efficiency and/or could get oxidized during the electrospray ionization stage. 
When identifying and quantifying arsenic metabolites, the unavailability of 
some species as stable high purity standards poses a significant problem. AsIII, AsV, 
MMAIII, MMAV, DMAV, AsIII(GS)3 (in solution), MMAIII(GS)2 (in solution), 
DMAIII(Cys) (in solution), DMAIII(GS),  can be purchased or synthesized as high purity 
standards, but DMDTAV, DMMTAV, DMAIII, and DMMTAV(GS) cannot, making the 
quantification of these species difficult. For example, DMAIII has the high capacity of 
being oxidized to DMAV without the presence of relatively high concentrations of GSH 
or when exposed to oxygen, so it is difficult to accurately quantify this species. However, 
it is also difficult to detect DMAIII in the presence of GSH, as in this case DMAIII is 
present in the form of DMAIII(GS) and not as free DMAIII. 
 
4.6 Conclusions 
An HPLC-ICP-MS method was developed and optimized in an attempt to analyze 
for the above mentioned thirteen confirmed and plausible human arsenic metabolites and 
intermediates of As metabolism in one chromatographic run. Results showed that while it 
is difficult to separate all these species as a consequence of their very different chemical 
properties, it is indeed achievable. The HPLC-ICP-MS technique described here is 
applicable to (or suitable for) the analysis of these arsenic metabolites from cells as 
demonstrated with the incubation experiments of human cancer cells with DMAIII(GS).  
While ICP-MS is supposed to be element specific, significant baseline disturbance 
was observed resulting from the high acetonitrile v/v% present in the gradient elution 
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program. Adjustment of Ar nebulizer flow rate could reduce the problem. Under 
optimum conditions the detection limits were experimentally shown to be 1.25 ppb and 
the quantitation limit 2.5 ppb. The method was found to be linear between the tested 
ranges of 1.25 to 2500 ppb. This method is also suitable for use on HPLC-ESI-MS for the 
identification of unknown arsenic metabolites. 
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CHAPTER 5 
Mechanistic Study on the Formation of Dimethylarsinothioyl Glutathione and Other 
Sulfur Containing Arsenic Metabolites 
 
 
 
 
 
 
 
 
 
Part of this chapter has been submitted to Chemical Research in Toxicology for 
publication.
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5.1 Graphical Abstract 
 
 
5.2 Abstract  
While in general arsenic (As) compounds are highly toxic carcinogens, they may 
also possess strong and unique antineoplastic properties. The toxicity and the potential 
beneficial therapeutic efficacy of arsenicals depend on the form of arsenical present and 
their metabolism. Arsenic-containing chemicals are extensively metabolized in mammals. 
During biotransformation metabolites with toxicity higher than the parent compound may 
form. While generally pentavalent arsenic xenobiotics are less toxic than trivalent ones, 
pentavalent thiolated arsenic metabolites may possess unusually high toxicity. Until now, 
the mechanism and the conditions of the formation of these noxious sulfur-containing 
arsenicals have not yet been fully deciphered. Moreover, the source of sulfur and the 
form of sulfur utilized in these reactions have been highly debated.  In the course of my 
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research I investigated the possible mechanisms and conditions of formation of these 
noxious species.  I found that under physiological conditions (pH and glutathione 
concentrations (GSH)) both dimethylmonothioarsinic acid (DMMTAV) and 
dimethyldithioarsinic acid (DMDTAV) easily form from dimethylarsinic acid (DMAV) 
and dimethylarsinous glutathione (DMAIII(GS), Darinaparsin), the chemotherapeutic 
agent under investigation in our lab. I have found that there are different pathways 
through which DMMTAV may form. The conditions of formation of the newly 
discovered human metabolite of DMAIII(GS) dimethylarsinothioyl glutathione 
(DMMTAV(GS)) were determined as well. It was observed that under physiological pH 
and GSH concentrations DMMTAV(GS) only forms to a very minimal extent non-
enzymatically. Attempts to find the enzyme that may catalyze its formation were carried 
out. Additionally, the form (H2S, HS-, or S2-) and the source of sulfur (H2S (3/4th present 
as HS- at pH 7.4) produced as a byproduct of metabolism or liberated from protein 
persulfides (R-S-S-H)) utilized for these reactions were studied.  
 
5.3 Introduction  
The metabolic pathways involved in the biotransformation of arsenic compounds are 
still highly debated though this knowledge is necessary to understand the mechanisms of 
arsenic toxicity and the therapeutic efficacy of As-containing medicinal preparations. The 
most common mammalian arsenic metabolites reported are arsenite (AsIII), arsenate 
(AsV), monomethylarsonous acid (MMAIII), monomethylarsonic acid (MMAV), 
dimethylarsinous acid (DMAIII), and dimethylarsinic acid (DMAV). Additionally, sulfur-
containing pentavalent arsenic metabolites such as monomethylmonothioarsonic acid 
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(MMMTAV), dimethylmonothioarsinic acid (DMMTAV), and dimethyldithioarsinic acid 
(DMDTAV) were also detected.10, 11, 14, 25, 35, 36, 114, 155 Interestingly, while in general 
trivalent arsenic compounds are more toxic than their pentavalent counterparts, 
DMMTAV has been shown to be unusually highly toxic for a pentavalent species.10-13, 98 
According to Watanabe, the toxicity of DMMTAV is comparable to that of MMAIII, 
whereas Bartel et al. reported lesser (approximately ½) toxicity compared to MMAIII in 
human lung cells.14, 15 While its toxicity was found to be similar to DMAIII, which is even 
more toxic than MMAIII, in epidermoid carcinoma cells, DMMTAV was found to be less 
cytotoxic than dimethylarsinous glutathione (DMAIII(GS)) in human lung 
adenocarcinoma epithelium cells.13, 16 Compared to DMAV, the corresponding non-
thiolated pentavalent species, DMMTAV was found to be about 10-fold more cytotoxic in 
HepG2 cells derived from human hepatocarcinoma and approximately 80 times more 
toxic in epidermoid cells.11, 13  
Dimethylmonothioarsinic acid (DMMTAV) is highly reactive with thiol compounds, 
which is very unusual for a pentavalent arsenical.  Up until now, the form and the source 
of sulfur utilized for the formation of DMMTAV and DMDTAV in human and animal 
cells remain unclear. One possible source of sulfide is hydrogen sulfide enzymatically 
generated in the body with the help of cystathionine beta synthase (CBS) and 
cystathionine gamma lyase (CSE) from the metabolism of cysteine and homocysteine 
along with other enzymatic processes.156-159 The true concentration level of H2S in cells is 
highly debated and varies over a 105-fold concentration range in different reports; 
therefore its importance for the production of DMMTAV and other sulfur-containing 
compounds cannot be accurately estimated.158, 159 In red blood cells it was proposed that 
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the source of sulfur may be sulfane sulfur.35, 107 Sulfane sulfur has the ability to reversibly 
attach to other sulfur atoms and it is attached to proteins as persulfide (R-S-S-H) or 
trisulfide.160 According to Mueller, it is protein persulfide groups rather than the noxious 
bisulfide that is the major source of sulfide for the biosynthesis of many biomolecules.161 
Moreover, it is estimated that the formation of persulfides in cells is prevalent; 
approximately 10-25% of many hepatic proteins are sulfhydrated under physiological 
conditions and sulfhydration appears to be a common physiologic posttranslational 
modification of proteins.162, 163 Consequently, it is very plausible that the sulfur may 
come from persulfides of biomolecules in the presence of reducing agents, such as GSH, 
that can liberate HS- from protein persulfides. 
Trivalent arsenic-glutathione complexes such as As(GS)3, MMA(GS)2, and 
DMA(GS) have also been reported to be the products of As biotransformation.34, 100 The 
existence of these complexes are not surprising knowing that trivalent arsenic species 
have high affinity for thiols and the thiol-containing GSH can be present in high 
concentrations, up to 10 mM, in the cells. Conjugation of GSH decreases sensitivity to 
these compounds and promotes their efflux from the cells.  According to estimates, a very 
high percentage of trivalent arsenic species are bound to glutathione inside the cells.31, 100 
Kala et al. estimated that 60-70% of As may be present as GSH-conjugate (As(GS)3 and 
MMA(GS)2) in the kidneys of mice, but it is catabolized by the enzyme γ-glutamyl 
transpeptidase in the microvilli of the proximal tubules of the kidney.31 Moreover, 80-
90% of the total arsenic excreted in the bile is also GSH conjugated.105 On the basis of 
observations, As-glutathione conjugates are the transported forms and account for the 
majority of excreted arsenic.100 This is not surprising as the addition of GSH to a 
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molecule during metabolism is said to provide a molecular ‘flag’ that promotes the 
removal of the xenobiotic from cells.106 However, others theorize that the trivalent 
species are mostly protein-bound and are not present as GSH-conjugates and possess 
higher affinities to bind to proteins than to glutathione.1, 107-109   
For the first time in human cancer cell lines, our laboratory have reported the 
presence of dimethylarsinothioyl glutathione (DMMTAV(GS)) as a metabolite of 
dimethylarsino glutathione (Darinaparsin, ZIO-101, DAR, DMAIII(GS)).34 This 
compound has only been seen in cabbage before.112 The toxicity of this compound, thus 
its role in the detoxification of DMAIII(GS), and the ability of multiple myeloma cell 
lines to take DMMTAV(GS) up was evaluated. DMMTAV(GS) was found to be much 
less toxic than DMAIII(GS) and DMMTAV, probably as a consequence of its very limited 
uptake (less than 10% and 16% of DMAIII(GS) and DMMTAV respectively).   
The precursor of DMMTAV(GS) is thought to be DMMTAV. Theoretical 
calculations indicate that the conjugation of DMMTAV with GSH is exothermal, though 
these calculations did not take the effect of pH into calculation and used methanethiol 
(CH3SH) instead of GSH to shorten calculation time.135 Previous formation studies 
conducted in our lab in human cancer cells showed the presence of this metabolite even 
at pH 7.4 and its stability upon extraction between pH 3 to 7.4.34 Heat deactivation of the 
enzymes prevented its formation indicating the possibility that at pH 7.4 (under 
physiological pH) it forms in an enzymatic reaction. According to Suzuki above pH 7, in 
the presence of glutathione, no DMMTAV(GS) forms from DMMTAV in the absence of 
cellular material.135 As our previous results showed the formation of substantial amounts 
of this metabolite within ten minutes in the presence of cells, it further indicates that it is 
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probably mostly produced in enzymatic reactions. It is also possible that DMMTAV(GS) 
forms in acidic organelles in intact cells. The enzyme suspected to help its formation is 
glutathione S-transferase (GST). GSTs form three superfamilies: the cytosolic, 
mitochondrial, and microsomal GSTs that are further divided into classes on the basis of 
their structures. Glutathione transferases have the ability to inactivate toxic compounds 
thus play important roles in the detoxification of noxious chemicals that are cytotoxic and 
genotoxic. Moreover, glutathione conjugation flags the molecule for removal. While the 
ability of GSTs to aid in the removal of toxic chemicals is beneficial to the organism, in 
cancer therapy in the tumor cells, it is a potential problem to the host. Tumors may 
overexpress GSTs and increase their ability to conjugate GST significantly resulting in 
acquired resistance to chemotherapeutic agents.164 On the other hand, while xenobiotics 
may initially be detoxified by conjugation with GSH with the help of GSTs, the initial 
toxic compound can be regenerated spontaneously. I examined if human microsomal and 
cytosolic GSTs may catalyze the formation of DMMTAV(GS), but did not look at 
mitochondrial GSTs or other enzymes or proteins at this time. Human cytosolic class pi 
GST, widely distributed in tissues, was tested individually to examine if it can catalyze 
the conjugation of GSH to DMMTAV.  
Moreover, I conducted experiments to determine the conditions of formation and the 
mechanism of formation of DMMTAV, DMDTAV, DMAIII, DMAIII(GS), and 
DMMTAV(GS) from DMAV and DMAIII(GS), the form (H2S, HS-, or S2-) and the source 
of sulfur involved in the generation of thioarsenicals (sulfane sulfur (protein persulfides 
in particular) or H2S produced during metabolism). Previous studies investigating H2S 
reactions with dimethylated arsenicals used directly bubbling gaseous H2S or addition of 
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sodium sulfide (or sodium hydrosulfide) as a means of producing H2S. These methods 
will produce H2S in a large, rapid bolus and thus it remains a question as to how well this 
simulates the physiological condition with regards to the kinetics and concentrations of 
H2S release. The resulting pH in the cases of sodium (hydro)sulfide and hydrogen sulfide 
cannot mimic physiological condition. In this study, I used a recently reported slow-
releasing H2S donor, GYY4137 (morpholin-4-ium 4 methoxphenyl (morpholino) 
phosphinodithionate) which has been shown to slowly release H2S both in vitro and in 
vivo to produce H2S creating a reaction environment milder and more closely relevant to 
physiological conditions.165 The reaction producing hydrogen sulfide from GYY4137 is 
depicted in Figure 5.1. In order to investigate the ability of arsenic to react with protein 
persulfides to form thiolated arsenicals, I employed glutathione persulfide (GSSH) as a 
simple model molecule for protein persulfides. 
 
 
 
Figure 5.1 Proposed reaction involved in the production of H2S from GYY4137 
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5.4 Experimental  
Caution: The arsenic species included in this study are toxic and are potential human 
carcinogens; therefore, they should be handled with great care. 
5.4.1 Reagents and Standards 
All reagents used were of analytical grade or better. Argon (Ar) purged double 
deionized water (DDIW) (18 MΩ Barnstead Nanopure Diamond) was used throughout 
the experiments. Acetonitrile a component of the mobile phase, potassium dihydrogen 
phosphate (KH2PO4) used to prepare potassium phosphate buffer (pH 6.5, 7.0 and 7.4), 
ammonium hydroxide (NH4OH), potassium hydroxide (KOH), and nitric acid (HNO3) 
used for pH adjustments were purchased from Thermo Fisher Scientific, USA. Sulfuric 
acid used for the synthesis of DMMTAV, along with tris(2-Carboxyethyl)-Phosphine 
Hydrochloride (TCEP-HCl), dithiothreitol (DTT), and morpholine were also acquired 
from Fisher Scientific, USA. 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 2-(N-morpholino)ethanesulfonic acid (MES), and ethylenediaminetetraacetic 
acid (EDTA) used for buffer preparation were all purchased from Sigma-Aldrich, USA 
along with  L-glutathione reduced (GSH), cysteine, Glutathione S-Transferase from 
human placenta (catalog # G8642), trifluoroacetic acid (TFA) used in aqueous mobile 
phase component, cacodylic acid (DMAV), 5,5’-dithiobis-2-nitrobenzoic acid (Ellman’s 
reagent, DTNB), 2,4-bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane 
(Lawesson’s reagent), anhydrous sodium sulfide, and sodium hydrosulfide hydrate. L-
glutathione oxidized (98%, GSSG) and formic acid (FA) used to prepare formate buffer 
(pH 3.0) were purchased from Acros Organics. Deuterium oxide (D2O) and methanol-D4 
used for NMR studies were acquired from Cambridge Isotope laboratories, Inc. 
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Darinaparsin (DMAIII(GS)) was obtained from Ziopharm Oncology, Boston, MA. 
Purified human pi GST was provided by Dr Barry Rosen’s lab, Florida International 
University, FL. The protein sequence of the 24 KDa enzyme was 
GQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVED 
LRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADY
NLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGK
Q HHHHHH. 
 
5.4.2 Synthesis and Identification of DMMTAV 
Dimethylmonothioarsinic acid (DMMTAV) was prepared by reacting DMAV 
with sodium sulfide (Na2S) and sulfuric acid (H2SO4) in DDIW according to previously 
reported method with slight modification.10 Unlike the reference, I did not purify 
DMMTAV by extracting it into diethyl ether at the end. The mol ratio of As:Na2S:H2SO4 
was 1:1.6:1.6. DMMTAV was aliquoted and stored in argon purged HPLC glass vials at -
11°C. Formation of DMMTAV was confirmed with the help of high performance liquid 
chromatography electrospray ionization mass spectrometry (HPLC-ESI-MS) in the 
positive mode. A peak with an m/z value of 155, corresponding to the protonated form of 
DMMTAV, was obtained confirming species identity. 
5.4.3 Synthesis, Identification, and Activity Assessment of GYY4137 (a Slow 
Hydrogen Sulfide (H2S) Releaser) 
Synthesis of GYY4137 (FW 376.47) was conducted at room temperature 
following reported procedures with modifications.165 Briefly, morpholine (20 mmol) in 
methylene chloride (CH2Cl2, 36 mL) was added dropwise to a CH2Cl2 solution (12 mL) 
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of 4 mmol 2,4-bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane 
(Lawesson’s reagent). The reaction is depicted in Figure 5.2. The mixture was then 
stirred for 2 hours at room temperature. The precipitate formed was filtered and washed 
several times with CH2Cl2, to obtain a white solid that was dried under vacuum.  
 
           
 
Figure 5.2 Reaction involved in the synthesis of GYY4137 
 
1H NMR, IR, and melting point determination were used to identify and 
characterize GYY4137 and were compared to those found in the literature. 161-164°C 
(performed in triplicate) were obtained during melting point determination that 
corresponded with the previously reported 160 to 164°C. Formerly, the IR data of 
GYY4137 found in the literature merely consisted of three wavenumber values and no 
assignment of these numbers to corresponding functional groups was carried out. I 
obtained the full IR spectrum and attempted to assign the wavenumbers to functional 
groups to confirm the formation of GYY4137. The IR spectrum is presented in Figure 5.3 
and IR data interpretation in Table 5.1. The data confirmed the successful synthesis of 
GYY4137. The H-NMR chemical shift values of GYY4137 found in the literature were 
reported in acetone-D6. When I first tried to obtain the NMR spectra I have noticed that 
GYY4137 had an extremely low solubility in this solvent and the resulting spectra were 
Lawesson’s reagent Morpholine GYY4137 
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very poor in quality. As a result, I used a solution of D2O: Acetone-D6 1:4 v/v mix to 
obtain the NMR characteristics of my compound. The sample was analyzed within five 
minutes of preparation to retard the formation of H2S and other degradation products. The 
chemical shift values were referenced to acetone-D6. The values obtained by us 
corresponded well to the chemical shift values reported in the literature and to those 
predicted by MestReNova software further confirming the identity of GYY4137. This 
data is presented in Table 5.2.  
 
 
 
Figure 5.3 IR spectra of GYY4137 
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Table 5.1 Infrared spectroscopy results for GYY4137 
Literature* Our 
IR** values (cm-1) 
film neat powder 
NR 3200-2600  (very broad) May indicate N-H stretch 
3019* 3030 Indicates sp3 C-H stretch 
NR 
2932 (very broad) Indicates sp3 C-H stretch 
2768 & 2440 May indicate S and/or P (?) 
1590 & 1568  
& 1496 
Aromatic C=C stretch is in the 1600 to 1475 
region and N-H bend above 1550 
1466 -CH2- bend 
1399 -CH3- bend 
1215* 1243 Aromatic C-O stretch (Phenyl-O-alkyl) 
NR 
1177 Not assigned 
1099 (strong) C-O and/or C-N stretch 
1024 Phenyl-O-alkyl 
867 (strong band) Para substituted aromatic ring 
756* 799 =C-H aromatics or N-H  (out-of-plane bend for both) 
NR 668 (strong) N-H oop 
NR: Not Reported 
*Peaks were not assigned to corresponding functional groups in the literature 
**Peaks assigned in our lab 
 
Table 5.2 1H NMR results of GYY4137 
1H NMR Literature δ Predicted by MestReNova 
Our results 
s, NH2  9.69 5.60 
m, 2H, aromatic CH 8.03 to 8.11 7.25 7.82 to 8.00 
m, 2H, aromatic CH 6.88 to 6.90 6.90 6.70 to 6.78 
m, 4H, CH 3.94 4.26  3.95 to 3.97 
   3.90 
s, CH3 3.82 3.80 3.78 
m, 4H, CH 3.50 to 3.53 3.50 3.40 to 3.43 
m, 4H, CH 3.36 to 3.40 3.07  
Dd 2.87 to 2.92   
m, 4H, CH 2.04 to 2.09   
NR: Not Reported 
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The ability of GYY4137 to release hydrogen sulfide and its time profile were 
determined after confirming the identity of the synthesized product. Ellman’s reagent 
(5,5’-dithiobis-2-nitrobenzoic acid or DTNB) was employed to asses H2S release from 
GYY4137. It has two electron-deficient phenyl groups linked by a disulfide bond. The 
disulfide readily undergoes a transsulfuration reaction or reduction by a sulfhydryl group 
and in the process may release a conjugate and intense yellow 5-thio-2-nitrobenzoate 
(TNB) with a strong absorption at 412 nm. The reaction is presented in Figure 5.4.  
 
                  
 
 
Figure 5.4 Reaction of Ellman’s reagent with thiols 
 
Reduced glutathione (GSH) and cysteine (Cys) were used to establish 
calibration curves in order to quantitate the amount of hydrogen sulfide released from 
GYY4137 over time. In the literature, sodium hydrosulfide hydrate (NaHS•xH2O) is 
usually employed to establish the calibration curve for H2S. The problem with this 
compound is that it contains an unknown amount of water, hygroscopic and over time 
absorbs more moisture and such requires a lengthy iodometric titration process to 
establish its HS- concentration before use. Thus I decided to employ GSH and Cys 
instead to construct the calibration curves used for quantitation. The UV absorbance of 
RSH
Ellman’s reagent Conjugate TNB
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the standards was measured at 412 nm, and the calibration curves were constructed. A 
solution of GYY4137 was prepared with a known theoretical concentration. The 
absorbance of the solution was measured over three hours and the amount of hydrogen 
sulfide quantified over time. The time profile of H2S release at pH 7.4 is depicted in 
Figure 5.5. Most of the H2S was found to be released in about 30 minutes, which result is 
in close agreement with those obtained by Li et al.165 The total time required to release all 
H2S took almost 3 hours. On the basis of the theoretical concentration of GYY4137 and 
the amount of hydrogen sulfide released from this solution it was determined that most of 
the GYY4137 expected to be released, were released. (On the basis of the Cys and GSH 
calibration curves, 98 and 91% of the theoretical amount of H2S were released 
respectively.) 
 
 
Figure 5.5 The accumulated cconcentration of H2S released over time at pH 7.4 
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5.4.4 Synthesis and identification of glutathione persulfide (GSSH) 
Glutathione persulfide was synthesized according to a previously reported 
method.166 Briefly, sodium sulfide and oxidized glutathione were mixed in a 1 to 1 mol 
ratio in 50 mM pH 7.4 HEPES buffer and placed in a 37°C water bath for 15 minutes. 
The solution was used immediately after the 15-minute incubation period. The formation 
of GSSH was confirmed using UV/Visible spectroscopy. Immediately after preparation, 
the UV spectrum of GSSH was acquired (Fig. 5.6).  
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Figure 5.6 UV spectra of GSSH and GSS- 
 
The UV spectra showed a maximum around 284 nm, which is in a good 
agreement with the results obtained by Francoleon et al. who reported a maximum around 
280 nm.166 In the next step, the pH of the solution was changed to 9 using sodium 
hydroxide to generate the conjugate base (GSS-) of GSSH resulting in a shift in 
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absorbance wavelength. The peak at 284 nm gradually decreased and a new peak around 
335 nm showed up. This value is also in good agreement with the previously reported 
value of 340 nm for GSS- and 335 nm for CysS- (conjugate base of cysteine 
persulfide).166, 167  
5.4.5 Instrumentation and Chromatographic Conditions 
A Perkin Elmer Series 200 HPLC system equipped with a temperature 
controlled column compartment was coupled to a Perkin Elmer Elan DRC-e ICP-MS 
(dynamic reaction cell inductively coupled mass spectrometer). The ICP-MS was 
equipped with a cyclonic spray chamber and a Meinhard nebulizer and was used in the 
standard mode. ICP-MS signal at m/z 75 for 75As was monitored. Instrument 
performance was checked daily against a tuning solution recommended by the 
manufacturer and if necessary nebulizer gas flow and composition adjustments were 
made manually for maximum sensitivity. List of instrument parameters for ICP-MS are 
listed in Table 5.3 and the HPLC gradient elution program is provided in Table 5.4. 
Waters Spherisorb 5 µm C8, 4.0 x 250 mm (Part No. PSS845281) column was employed 
for the separation of species and the column was kept at 10°C. Data was collected and 
processed using Elan v. 3.4 and Chromera v. 1.2 software (Perkin Elmer, USA).  
A Thermo Finnigan Surveyor HPLC system equipped with an autosampler 
and column compartment was coupled with an LCQ Deca XP MAX (Thermo Finnigan, 
USA) MS. Data was collected and treated using Xcalibar software (Thermo, USA). The 
instrumental parameters were optimized using the flow injection mode with a 5 μg mL-1 
caffeine standard. 
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Proton NMR spectrum was recorded at 25 °C on a Bruker 400 FT NMR 
spectrometer operating at a proton frequency of 400 MHz. Samples were dissolved in 
D2O: Acetone-D6 1:4 v/v mix. The samples were transferred to the NMR tubes and 
capped with rubber septa immediately. NMR spectra were collected within ten minutes 
of sample preparation. The chemical shift values were referenced to acetone-D6. 
Perkin Elmer Spectrum 100 Fourier Transform Infrared Spectrometer (FT-IR) 
with Perkin Elmer Spectrum software version 10.01.00 was employed to acquire infrared 
spectrums.  Varian Cary 100 Bio UV-Visible Spectrophotometer with Cary 300 software 
was used to collect UV data. 
Table 5.3 ICP-MS parameters employed 
Parameter (unit) Typical value 
Nebulizer Ar Gas Flow (L/min) 0.94-0.96 
Auxiliary Gas Flow (L/min) 1 
Plasma Gas Flow (L/min) 15 
Nebulizer Oxygen Gas Flow (L/min) 0.2 
Lens voltage 9 
ICP RF Power (W) 1350 
Analog Stage Voltage -1525 
Pulse Stage Voltage 950 
QRO1 -2 
CRO2 -7 
Discriminator Threshold 40 
CPV3 -20 
1QRO stands for Quadrupole Rod Offset Std 
2CRO stands for Cell Rod Offset Std 
3CPV stands for Cell Path Voltage Std 
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Table 5.4 HPLC gradient program 
Step Step type Step time (min) 
Flow 
(mL/min) 
0.05% 
TFA ACN % Curve 
0 Equilibration 7.0 1.0 99 1 N/A 
1 Run 5.5 0.4 99 1 0.0 
2 Run 3.5 0.5 87 13 1.0 
3 Run 11.0 0.5 80 20 0.0 
4 Run 10.0 0.5 95 5 0.0 
 
5.4.6 Experimental Procedures 
5.4.6.1 Determination of the Source and the Form of Sulfur Used for the 
Formation of Thiolated Arsenicals 
The slow hydrogen sulfide releaser (GYY4137) was used to react 
with DMAIII(GS) in addition to NaHS and Na2S at pH 7.4, 6.0, and 3.0 in 50 mM 
HEPES, MES, and formate buffers respectively in addition to double deionized water 
with no pH control at 1 to 5 As to S ratio and the formation of DMMTAV and DMDTAV 
were monitored over 24 hours. Furthermore, to determine the possibility of DMMTAV 
and DMDTAV formation from sulfane sulfur, DMAV was reacted with GSSH in the mol 
ratio of 1 to 2 respectively. The samples were stirred for 15 minutes and to half of the 
samples GSH was added in 1 to 1mol ratio of GSSH to GSH. The samples with no added 
GSH were used as controls. The final mol ratio of DMAV:GSSH:GSH was 1:2:2. Both 
the controls and the samples were monitored over time to observe if thiolated arsenicals 
can be produced from sulfane sulfur.  
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5.4.6.2 The Effect of pH, Sulfide and GSH Concentrations on the Formation 
of Thiolated Arsenical from DMAIII(GS) and DMAV; Mechanism of 
Formation of Thiolated Arsenicals 
I previously proposed that the formation of DMMTAV, and 
ultimately the formation of DMMTAV(GS) from DMAIII(GS) may go through either the 
formation of DMAV (DMAV pathway #1) and/or a dimer (dimerization pathway #2). The 
updated proposed pathways are depicted in Figure 5.7.  
 
Figure 5.7 Proposed mechanism of formation of thiolated arsenicals 
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For every sample, DMAV and DMAIII(GS) were separately prepared 
at the exact same As concentrations (to enable me to compare peak areas) for incubation 
with Na2S at mol ratios of As:S 1:1, 1:2, 1:5, and 1:80 in 50 mM pH 3.0 (formate), 6.0 
(MES), and 7.4 (phosphate) buffers to determine the effect of pH on the formation of 
thiolated arsenic metabolites and the effect of excess sulfide on species distribution. No 
GSH was added to these samples. To study the effect of GSH on the formation of 
thiolated and GSH-conjugated species (all species distribution) I incubated DMAIII(GS) 
with Na2S in the mol ratio of As:S 1:1, 1:2, and 1:5 at pH 7.4, 6.0, and 3.0 with 2.5 mM 
and 5.0 mM GSH present in the initial reaction medium in addition to samples containing 
no added GSH. In order to study the effect of GSH on the formation of DMMTAV(GS) 
directly from already synthesized DMMTAV, I also incubated DMAIII(GS) with Na2S in 
the mol ratio of As:S 1:2 at pH 7.4, 6.0, and 3.0 and let the samples stand for 90 minutes 
(to allow the formation of DMMTAV) and then added GSH to the reaction medium to 
yield final concentrations of 0, 2.5, and 5.0 mM GSH at each tested pH. The amount of 
DMMTAV(GS) that formed as a function of pH, sulfide and GSH concentration levels 
was determined. Moreover, these experiments were used to examine if thiolated 
arsenicals form via different pathways from trivalent (DMAIII(GS)) and pentavalent 
(DMAV) arsenicals 
5.4.6.3 Enzymatic Reactions for the Identification of Enzymes Responsible 
for the Catalysis of DMMTAV(GS) Formation from DMMTAV 
Human pi GST and also a mixture of human microsomal and 
cytosolic GSTs extracted from human placenta were tested to determine if they catalyze 
the formation of DMMTAV(GS) via the conjugation of GSH to DMMTAV.  The enzymes 
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were separately added to the mixture of DMAIII(GS) and Na2S (1:2 mol ratios 
respectively) and the formation of DMMTAV(GS) was monitored and compared to the 
controls that were prepared the same way, but without the addition of enzyme. The 
experiment with pi GST was performed at pH 7.4 in 50 mM HEPES buffer containing 
2.5 mM GSH and the experiment involving the mixture of cytosolic and microsomal 
GSTs was performed in 100 mM potassium phosphate buffer (pH 6.5) with 100 mM 
EDTA, as recommended by the manufacturer, and in 50 mM HEPES buffer at pH 7.4. 
Both buffers contained 2.5 mM GSH. All experiments were carried out at 37°C. 
5.4.6.4 Identification of Unknown Chromatographic Peaks 
During the course of experiments with DMAIII(GS) and Na2S, 
unknown peaks showed up in the chromatograms acquired on the HPLC-ICP-MS. I 
suspected that one of the peaks was dimethylmonothioarsinous acid (DMMTAIII) as I 
hypothesized that DMMTAV forms from DMAIII(GS) via DMMTAIII as depicted in 
Figure 5.7 (dimerization pathway). As the synthesis of this highly unstable and oxidation 
prone compound has not been published to my knowledge, I attempted to produce 
DMMTAIII by reacting DMAIII(GS) with Na2S in an completely oxygen free environment 
to try to stop the formation of dimers and other products (such as DMMTAV and 
DMDTAV) that are all formed by oxidation and retard the reaction at the formation of 
DMMTAIII. The samples were then analyzed on the HPLC-ICP-MS and the retention 
time of the produced compound was compared to the retention times of the unknown 
peaks to determine if the peak produced by DMMTAIII matches one of the unknown 
peaks. Then the sample was exposed to air and reanalyzed periodically to monitor the 
change in species distribution compared to the initial results. 
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5.5 Results 
5.5.1 Comparison of the Abilities of S2-, HS-, and H2S to Produce DMMTAV 
GYY4137, NaHS, and Na2S in 50 mM pH 7.4 HEPES, pH 6.0 MES, pH 3.0 
formate buffers, and in double deionized water were able to produce DMMTAV. Results 
for pH 7.4 and 6.0 are presented in Figures 5.8 A and B respectively. 
 
 
 
 
Figure 5.8 Reactions between DMAIII(GS) and GYY4137, NaHS, and Na2S at (A) pH 7.4 
and (B) pH 6.0. Full names of peaks, their abbreviation, structure, and peak numbers are 
displayed in Table 5.5. 
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Table 5.5 Names, abbreviations, structures and peak numbers 
Most common 
Structure Peak # 
Names Abbreviations 
Dimethylmonothioarsinous 
acid DMMTA
III 
 
• (?) 
Unknown peaks * and • 
Baseline disturbance resulting from the gradient program ᵜ 
Dimethyldithioarsinic acid 
Dimethylarsinodithioic acid DMDTA
V 
 
1 
Dimethylmonothioarsinic acid, 
Dimethylarsinothioic acid, 
Thio-dimethylarsinate 
DMMTAV 
Thio-DMA 
DMASV 
 
2 
Dimethylarsinic acid, 
Dimethylarsinate 
DMAV 
DMAsV 
 
3 
Dimethylarsinothioyl 
glutathione 
DMMTAV-GS 
DMATG 
DMASV-GS 
DMMTAV(GS)  
4 
Dimethylarsinous acid, 
Dimethylarsinite 
DMAIII 
DMAsIII 
 
5 
Dimethylarsinic glutathione, 
Dimethylarsinous glutathione, 
Dimethylarsino-glutathione, 
DAR, ZIO-101, Darinaparsin,  
DMAIII(GS) 
DAR, DMAG 
DMAsIIIGS  
6 
 
The results showed that from all starting compounds DMMTAV could be 
formed at every tested pH value. The formation of significant amounts of DMDTAV was 
also observed with the highest amount at pH 7.4 but almost no DMDTAV formed at pH 
3.0. Very small amount of DMMTAV(GS) formation was observed at pH 7.4, while with 
decreasing pH, its amount increased.  
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5.5.2 Evaluation of the Ability of Glutathione Persulfide (GSSH), a Model 
Compound of Protein Persulfides, to Produce DMMTAV at Physiological pH 
When DMAV was reacted with only GSSH (control) at pH 7.4, almost no 
DMMTAV formation was observed (Fig. 5.9). After the addition of GSH (to reduce the 
disulfide bond in GSSH to liberate –SH), the sample was reanalyzed periodically over a 
day. The initial chromatograms obtained 10 minutes after the addition of GSH showed 
the quick formation of DMMTAV in addition to DMDTAV and a very small amount of 
DMMTAV(GS) as shown in Figure 5.9. 
0 5 10 15 20 25 30
0
12500
25000
37500
50000
In
te
ns
ity
 (c
ps
)
Time (min)
 No GSH added   GSH added
 
Figure 5.9. Reaction between DMAV and GSSH at pH 7.4 in the presence and absence of 
added GSH. See Table 5.5 for peak identification. The control (black) only contained 
GSSH and DMAV, while to the sample (red) GSH was added 10 minutes after mixing 
GSSH and DMAV. 
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5.5.3 Formation of DMMTAV from DMAV 
DMAV was reacted with Na2S at pH 7.4, 6.0, and 3.0 in the mol ratios of As:S 
1:1, 1:2, 1:5, and 1:80 and the formation of DMMTAV was monitored over time. All 
samples were prepared at the same As concentration to enable me to compare peak areas. 
The results showed that at all tested pH values DMMTAV formed from DMAV. The 
highest amount of DMMTAV formed at pH 7.4, and the more sulfide was present, the 
faster it formed and in larger amounts. Interestingly, more DMMTAV was observed at pH 
3.0 than at 6.0. The pH dependence of DMMTAV formation is depicted in Figure 5.10. 
Additionally, the formation of DMDTAV was observed. DMDTAV had the highest ability 
to form at pH 7.4 and to lesser extent at pH 6.0. Almost no DMDTAV formed at pH 3.0. 
(For information on the pH dependence of DMDTAV formation from DMAIII(GS), refer 
to Figure 5.12.) 
 
Figure 5.10 Formation of DMMTAV from DMAV at pH 7.4, 6.0 and 3.0 at As:S mol ratio 
of 1:2 over time 
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5.5.4 Formation of Thiolated Arsenicals from DMAIII(GS)  
The results showed that while DMMTAV formed very easily from 
DMAIII(GS) at physiological pH, as the GSH concentration increased, the amount of 
DMMTAV decreased (Fig. 5.11). As far as the pH dependence of DMMTAV formation 
goes, at a specific GSH concentration, the highest amount formed at pH 7.4 and lesser 
amounts at 6.0 and 3.0. Interestingly, at all the tested GSH concentrations, slightly more 
DMMTAV was present at pH 3.0 than 6.0, same as when DMMTAV formed from DMAV. 
Not surprisingly, under the same conditions, as the concentration of sulfide increased, the 
peak distribution shifted to DMDTAV from DMMTAV. The formation of DMDTAV was 
strongly favored at pH 7.4, and its formation significantly dropped by pH 6.0, and 
minimal amounts formed at pH 3.0 (Fig. 5.12). At one specific pH, such as pH 7.4, the 
higher the GSH concentration, the more favored the formation of this dithiolated species 
is. In summary: 
i) At pH 7.4 and 6.0, the higher the concentration of GSH, the more favorable the 
formation of DMDTAV and less favorable the formation of DMMTAV 
ii) At pH 7.4 and 6.0, the higher the sulfide concentration, the more favorable the 
formation of DMDTAV and less favorable the formation of DMMTAV 
iii) The formation of both DMMTAV and DMDTAV is the most favorable at pH 7.4 
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Figure 5.11 Formation of DMMTAV from DMAIII(GS) at pH 7.4, 6.0, and 3.0 with As:S 
mol ratios of 1:2 at different GSH concentrations 
 
Figure 5.12 Formation of DMDTAV from DMAIII(GS) at pH 7.4, 6.0, and 3.0 with As:S 
mol ratios of 1:2 at different GSH concentrations 
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DMAIII(GS) levels quickly decreased under all tested conditions (Fig. 5.13). 
The lower the pH, the higher the stability of this species is. At one specific pH value, the 
higher the GSH concentration, the higher the stability of DMAIII(GS). The results 
indicated that while high GSH concentration is needed to conserve species identity, pH is 
also a very important factor in maintaining the identity of DMAIII(GS). 
 DMAIII, just like DMAIII(GS) was observed to be present in higher amounts 
at pH 3.0, than at higher pH (Fig. 5.14). Moreover, just like DMAIII(GS), at one specific 
pH, the higher the GSH concentration, the higher the amount of DMAIII. Basically, 
DMAIII mirrored the tendencies observed for DMAIII(GS) On an important note, I 
suspect, that most of the DMAIII present comes from the hydrolysis of DMAIII(GS) 
during HPLC separation, and is not present in the sample. (See Discussion for 
explanation.) 
 
Figure 5.13 Formation of DMAIII(GS) from DMAIII(GS) at pH 7.4, 6.0, and 3.0 with 
As:S mol ratios of 1:2 at different GSH concentrations 
0 5 10 15 20
0
15000
30000
45000
In
te
ns
ity
 (c
ps
)
Time (Hours)
 pH 7.4 5.0 mM GSH        pH 7.4 2.5 mM GSH    
 pH 6.0 2.5 mM GSH        pH 3.0 2.5 mM GSH 
 pH 7.4 No GSH added    pH 6.0 No GSH added 
 pH 3.0 No GSH added
126 
 
 
Figure 5.14 Formation of DMAIII from DMAIII(GS) at pH 7.4, 6.0, and 3.0 with As:S mol 
ratios of 1:2 at different GSH concentrations. (Most of the DMAIII present is suspected to 
originate from the hydrolysis of DMAIII(GS) to DMAIII during HPLC separation.) 
 
The formation of DMMTAV(GS), just like the formation of DMAIII(GS) was 
preferred at lower pH and at higher GSH concentrations at a specific pH. I observed the 
formation of DMMTAV(GS) at pH 7.4, although only to a very small extent (Fig. 5.15), 
in the presence of 2.5 and 5.0 mM GSH, but not in the absence of it. These results are not 
in agreement with those presented by Naranmandura and Suzuki who reported that 
DMMTAV(GS) only forms under pH 7. 111, 135  
Comparable amounts of DMMTAV were formed from DMAV and 
DMAIII(GS) at a specific pH (Fig. 5.16). The chromatograms obtained using DMAIII(GS) 
as the starting material showed two unidentified peaks, one eluting before DMDTAV, and 
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the other eluting after the DMAV peak (Fig. 5.17). These unidentified peaks did not show 
up in the chromatograms where DMAV was the starting compound. No DMAIII peaks 
were observed in the chromatograms using DMAV as the starting material.   
 
Figure 5.15 Formation of DMMTAV(GS) from DMAIII(GS) at pH 7.4, 6.0, and 3.0 with 
As:S mol ratios of 1:2 at different GSH concentrations 
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Figure 5.16 Comparison of formation of DMMTAV from DMAV and DMAIII(GS) at pH 
3.0, 6.0, and 7.4. The mol ratio of As:S was 1:2. (No GSH was added.) 
 
Figure 5.17 Overlay of chromatograms to show the presence of unknown peaks for 
chromatograms with DMAIII(GS) as a starting material and the absence of these peaks for 
experiments where the starting compound was DMAV. See Table 5.5 for peak 
identification. 
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5.5.5 Identification of Unknown Peaks  
The major peak produced by the reaction of DMAIII(GS) with Na2S in the 
absence of oxygen (assumed to be DMMTAIII) eluted in between the DMAV and the 
ghost peaks produced by the gradient elution program (Fig. 5.18 A). Once the sample 
was exposed to air, in less than 5 minutes increase in DMMTAV, DMDTAV, and DMAV 
peak areas was observed. To compensate for this, a very quick decrease in the peak area 
of the compound assumed to be DMMTAIII was observed. The DMMTAIII peak was very 
large and broad and originally eluted at a slightly longer retention time and partially co-
eluted with the ghost peak (Fig. 5.18 B). Once the sample was exposed to air, the peak 
gradually shifted to the retention time of the second unknown peak as the amounts of 
DMAV, DMMTAV and DMDTAV increased. Additionally, the other unknown peak that 
elutes right before DMDTAV, though much smaller than the later eluting unknown 
assumed to be DMMTAIII, was observed (Fig. 5.18 C). Changes in this peak were 
observed over time. Initially, this unknown and DMDTAV produced one broad peak that 
visibly consisted out of two peaks and did not separate well. As the sample was exposed 
to air, the peak areas of both increased and the presence of two peaks eluting close to 
each other became apparent. As additional time passed, the unknown peak area decreased 
and the counts for DMDTAV increased.  
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Figure 5.18. (A) Overlay of chromatograms to show changes in peak distribution when a 
sample produced under anaerobic conditions is gradually exposed to air. To prepare the 
sample DMAIII(GS) was reacted with Na2S in the absence of oxygen, immediately 
analyzed and then exposed to air and re-analyzed periodically. Chromatograms B) and C) 
show how the unknown peaks changed in size over time once exposed to air. See Table 
5.5 for peak identification. (1st time point: 5 minutes after exposure to air, 2nd time point: 
45 minutes after exposure to air.) 
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5.5.6 Enzymatic Reactions 
The amount of DMMTAV(GS) produced in control samples containing no 
enzymes were the same as in samples that contained human pi GST or the mixture of 
human microsomal and cytosolic GSTs extracted from human placenta.  
 
5.6 Discussion 
Currently it is not known what form or forms of sulfur (H2S, HS-, or S2-) are 
responsible for the formation of DMMTAV. The pKa1 of H2S is 7.02 and pKa2 is 12.0. As 
the pKa2 is large (the Ka is so small), as soon as Na2S is dissolved in water, it reacts with 
water to form HS- and –OH. The resulting solution is very basic. As depicted in Figure 
5.19, sulfide (S2-) does not exist in appreciable amounts below pH 10.  
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Figure 5.19 Distribution diagram for H2S 
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At pH 7.4 almost 3/4th of sulfide is present as HS- and the rest as H2S. As the pH 
drops, the fraction of H2S increases while the portion of HS- decreases. At pH 6.0, over 
90 % of the sulfur species is present as H2S and this percentage increases to 99.99% at 
pH 3.0. As I have observed the formation of DMMTAV from DMAV under pH conditions 
where H2S was the major species (pH 3.0) and where HS- was the major species (pH 7.4), 
it is reasonable that both of these species can react with arsenic to form thiolated 
arsenicals. Larger amounts have formed at pH 7.4, thus I theorize, that depending on the 
pH (and thus the form of sulfur present (HS- or H2S) DMMTAV may form from DMAV 
by different mechanisms. At higher pH, including the physiologically relevant pH of 7.4, 
where the major species is HS-, DMMTAV forms by nucleophilic attack of HS- on 
DMAV, and no prior reduction of DMAV to DMAIII is required to form DMMTAV (Fig. 
5.7). On the other hand, at lower pH values where almost 100% of sulfide is present in 
the form of H2S (known reducing agent) or at physiological pH in a reducing 
environment maintained by high intracellular GSH levels, the formation of DMMTAV 
from DMAV is through a different mechanism that may involve the prior reduction of 
DMAV to DMAIII or DMAIII(GS) enzymatically or non-enzymatically. While I did not 
observe DMAIII peaks on the chromatograms where DMAV was the starting material, it 
may have been the result of the fast transformation of DMAIII to DMMTAIII and 
ultimately to DMMTAV. Moreover, it is also possible that DMAV reacts with H2S to form 
DMMTAV without the prior reduction of DMAV to DMAIII (Fig. 5.7). Considering the 
faster transformation of DMAIII(GS) to thiolated arsenicals at physiological pH compared 
to lower pH, it seems that the major species responsible for the formation of the As-S 
compounds is HS-. It is unlikely that under physiological pH and reducing conditions S2- 
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plays a role in the formation of DMMTAV. Consequently, it is possible that DMMTAV 
may form from H2S generated in enzymatic processes in cells in the form of H2S or HS-. 
As a consequence of the highly debated concentration level of hydrogen sulfide in human 
cells, its contribution to the formation of thiolated arsenicals cannot be assessed at this 
point.  
It has also been proposed that the source of sulfur for the formation of DMMTAV 
may come from sulfane sulfur compounds. When DMAV was reacted with only the 
persulfide GSSH (control) at pH 7.4, almost no DMMTAV formation was observed but 
upon the addition of GSH after 10 minutes (to reduce the disulfide bond in GSSH to 
liberate –SH), quick formation of DMMTAV was observed. It is plausible, that during this 
reaction DMMTAV formed from DMAV via a reduction step to DMAIII or DMAIII(GS) 
resulting from the addition of GSH or via a non-reductive nucleophilic attach by HS- 
(liberated from GSSH with the help of GSH) on DMAV. The prior reduction of the 
DMAV to DMAIII or DMAIII(GS) after the addition of GSH is unlikely as the amount of 
GSH added was very small and the formation of DMAIII(GS) is very slow and takes place 
to a minimal extent in the absence of excess GSH at pH 7.4, while the formation of 
DMMTAV was very fast. Moreover, no DMAIII(GS) peak was observed though this 
compound is more stable than DMAIII and should have appeared on the chromatograms. 
Thus I suspect that the major reaction was a nucleophilic attack by HS-, liberated from 
GSSH with the help of GSH, on DMAV without the prior reduction of DMAV. The 
experiment involving GSSH, a model compound for protein persulfides, indicates that in 
the reducing environment of cells, it is indeed possible that the thiolated As species form 
from HS- released from protein or other persulfides with the help of GSH, Cys, or other 
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biomolecules capable of reducing disulfide bonds. According to a recent report, the 
formation of persulfides in cells is prevalent; approximately 10-25% of many hepatic 
proteins are sulfhydrated under physiological conditions.162 Depending on the 
intracellular level of GSH and other reductants, -SH can be liberated from persulfides and 
directly utilized for the formation of thiolated arsenicals. It is also a possibility that in the 
first step arsenic directly reacts with the terminal S atom of R-S-S- and forms a complex 
and then the disulfide gets reduced and two compounds, a thiolated arsenical and a 
reduced R-SH or R-S- forms.  As sulfuration (attachment of –SH to thiols of biomolecules 
forming persulfide popularly, but incorrectly referred to as sulfhydration) alters protein 
function (may hyperactivate or deactivate it), the loss of –SH to form thiolated arsenicals 
may significantly affect protein function and in turn, the survival of the cell. On an 
important note, it was shown that cystathionine beta synthase (CBS) and cystathionine 
gamma lyase (CSE), responsible for the generation of H2S in the presence of L-cysteine, 
are also partially responsible for donating the hydrogen sulfide needed for the generation 
of protein persulfides. In the liver of CSE-/- knockout mice (no working CSE present), it 
was shown that endogenous sulfhydration was abolished indicating that proteins are 
physiologically sulfhydrated through CSE activity.162 Thus it is reasonable that not only 
the direct destruction of these protein persulfides during thiolated arsenic metabolite 
formation may be responsible for the toxicity of arsenic (in addition to other known 
mechanisms), but by utilizing the H2S needed for the synthesis of these protein 
persulfides for thiolated arsenic species production, these important post translational 
protein modifications cannot take place, or to a smaller extent, and such their enzymatic 
capabilities diminishes contributing to As toxicity indirectly. 
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Formation studies revealed that while DMMTAV very easily formed from 
DMAIII(GS) at physiological pH, as the GSH concentration increased, the amount of 
DMMTAV decreased. The reason for this is that as the GSH concentration increased at 
pH 7.4, the DMDTAV concentration increased. As far as the pH dependence of 
DMMTAV formation is concerned, at a specific GSH concentration, the highest amount 
formed at pH 7.4 and lesser amounts at 6.0 and 3.0. Interestingly, at all the tested GSH 
concentrations, slightly more DMMTAV was present at pH 3.0 than 6.0. The reason for 
the unusually high DMMTAV concentration at pH 3.0 is that at this pH the formation of 
DMDTAV is not favored, and most of the thiolated species are in the form of DMMTAV. 
The reason for this probably lies in the fact that almost all sulfur is in the form of H2S at 
pH 3.0. As seen in Figure 5.7, under strongly acidic conditions, DMMTAV can form from 
DMAV with the help of H2S, but the formation of DMDTAV from DMMTAV requires the 
presence of HS- and cannot form from H2S. As expected, at the same pH, as the 
concentration of sulfide increased, the peak distribution shifted to DMDTAV from 
DMMTAV, except at pH 3.0 where the formation of DMDTAV was not favored.  
On the basis of prior stability testing in our lab, it was not surprising that DMAIII(GS) 
was found to be unstable at physiological pH, and quickly transformed to other species.34, 
115 The formation of DMAIII(GS) was preferred at lower pH and at higher GSH 
concentrations at a specific pH. DMAIII almost completely mirrored the tendency of 
DMAIII(GS) formation under different conditions, thus I suspect that probably most of 
the DMAIII observed originates from the hydrolysis of DMAIII(GS) on the LC column to 
DMAIII and GSH during HPLC separation. 
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The formation of DMMTAV(GS) was also preferred at lower pH and at higher GSH 
concentrations at a specific pH. Though only to a very small extent, I did observe the 
formation of DMMTAV(GS) at pH 7.4 in the presence of 2.5 and 5.0 mM GSH, but not 
in the absence of it. These results are in contrast with those reported by Suzuki and 
Naranmandura who found that DMMTAV(GS) forms only below pH 7.111, 135 It is 
possible that the method used by them was either not sensitive enough to detect 
DMMTAV(GS) at a very low concentration or it hydrolyzed on the column during 
separation. Additionally, care must be taken to maintain the native GSH concentration of 
cells during sample preparation prior to analysis to minimalize the hydrolysis of 
DMMTAV(GS) and other GSH conjugated species. In my experiments, the sample GSH 
concentrations were maintained at all tested (2.5 and 5.0 mM) GSH levels at all times. 
These results showed, that it may be possible that DMMTAV(GS) indeed forms to a very 
small extent at pH 7.4 in cells with high GSH concentration non-enzymatically. Our 
previous experiments in heat deactivated cells (Chapter 3) did not show the presence of 
this compound at pH 7.4. It is likely, that in the presence of cells, due to matrix effects, 
this small amount of DMMTAV(GS)  may not be detectable. 
The chromatograms obtained with DMAIII(GS) as the starting compound showed two 
unidentified peaks, one eluting before DMDTAV, and one eluting after the DMAV peak. 
These peaks did not show up in the chromatograms where DMAV was the starting 
compound. Moreover, no DMAIII peak was observed in the DMAV chromatograms. 
These results indicate that the formation of DMMTAV from DMAV and DMAIII(GS) are 
likely through different pathways and the reduction of DMAV to DMAIII and the 
oxidation of DMAIII(GS) to DMAV are not needed prior to the formation of DMMTAV. 
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As comparable amounts of DMMTAV formed from both DMAV and DMAIII(GS) at pH 
7.4 (Fig. 5.16), the formation of DMMTAV is possible under physiological pH via both 
the DMAV and the dimerization pathways (Fig. 5.7).  
In order to decipher the mechanism of DMMTAV formation from DMAIII(GS) via the 
dimerization pathway, I attempted to identify the unknown peaks observed in the 
chromatograms where the starting material was DMAIII(GS). According to the 
dimerization pathway, DMMTAIII is an important intermediate in this route, thus I 
attempted to determine if one of the unknown peaks is DMMTAIII. Unfortunately, no 
description of the synthesis of this very highly oxidation prone compound is available in 
the literature to my knowledge.  Experiments carried out to synthesize DMMTAIII 
yielded a peak with a retention time close to the second unknown peak. The 
chromatogram in Figure 5.18 clearly showed as the peak area of the DMAV (always 
eluting as a broad peak) increases, its retention time (RT) decreases (along with the RT of 
the unknown peak) and such exhibits a Langmuir type of behavior. This type of behavior 
of peaks presents when solute-stationary phase interactions are strong and solute-solute 
interactions are relatively weak, as arises in cases when the stationary phase has sites 
capable of hydrogen bonding with the compound producing the peak.168-171 This type of 
behavior of DMAV affects the retention time of the later eluting peaks including the peak 
assumed to be DMMTAIII. Consequently, DMMTAIII elutes earlier when DMAV is 
present in larger concentrations. At lower DMAV concentrations, the retention time of the 
DMMTAIII increases and the peak is pushed closer to the later eluting ghost peak 
produced by the gradient program. Moreover, at high DMMTAIII concentrations a broad 
peak is produced and makes it hard to separate it from the ghost peak. On the basis of 
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these results, though not unequivocally, I can make the assumption that the second 
unknown is probably the highly unstable and oxidation prone DMMTAIII. Though 
presently I have no evidence, I assume that the peak eluting before DMDTAV is produced 
by one of the dimers or a mix of these dimers. These dimers we expect to be far less 
stable than DMMTAIII, and such they present with much smaller peak areas resulting 
from their fast transformation into other species.  
Human microsomal and cytosolic GSTs did not seem to catalyze the formation of 
DMMTAV(GS). Further experiments are needed to find the biomolecule responsible for 
the enzymatic catalysis of this species in biological systems. As the results showed, it is 
also possible that to a small extent DMMTAV(GS) forms at pH 7.4 non-enzymatically, 
thus some of the DMMTAV(GS) seen in cells may have formed non-enzymatically, 
though considering the large amounts observed within a short period of time, its 
formation must be mainly enzymatically catalyzed in cells.  Moreover, it is possible that 
in intact cells DMMTAV(GS) forms in acidic organelles.  
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CHAPTER 6 
 
Stabilization of Arsenic Metabolites in Biological Samples: The Chapter of Negative 
Results 
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6.1 Introduction 
In order to correctly assess the toxicity of arsenic-containing compounds in 
biological samples, the true metabolic speciation profile of the arsenical must be 
obtained. Unfortunately, many of the human As metabolites are highly unstable and 
during storage, sample preparation, and analysis transform to other species possessing 
different toxicities than the original species present. Arsenite (AsIII), 
monomethylarsonous acid (MMAIII), and especially dimethylarsinous acid (DMAIII) are 
prone to oxidation to their much less toxic pentavalent counterparts arsenate (AsV), 
monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMAV). Arsino-glutathione 
(AsIII(GS)3), monomethylarsino-glutathione (MMAIII(GS)2), and dimethylarsino-
glutathione (DMAIII(GS)) can easily and quickly hydrolyze to their non-GSH conjugated 
trivalent counterparts (AsIII, MMAIII, and DMAIII) once the native GSH concentration of 
the cells is diluted during sample preparation prior to speciation analysis. These non-GSH 
conjugated trivalent species (especially DMAIII) then are easily oxidized to their less 
toxic pentavalent counterparts. 
Consequently, great care must be taken with sample storage and preparation to 
conserve species identities to enable us to obtain the true speciation profile of arsenic 
metabolites in human cells. Colder temperature (especially freezing) was shown to retard 
the oxidation of the trivalent species.118, 172 pH was shown to help conserve species 
identities as well. The highly toxic and oxidation prone DMAIII was shown to have a 
much higher stability at pH 6.0 than at pH 3.2.151 Dimethyldithioarsinic acid (DMDTAV) 
displays higher stability at the physiological pH of 7.4 but then its stability significantly 
drops below pH 6.0.135 The newly found human arsenic metabolite dimethylarsinothioyl 
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glutathione (DMMTAV(GS)) was found to be more stable at pH 6.0 than at 7.4 or at 
lower pH values upon extraction.34 On the other hand, trivalent GSH complexes, 
AsIII(GS)3, MMAIII(GS)2, and DMAIII(GS)) displayed the opposite trend; namely, at 
lower pH (such as pH 2.0) these complexes had a much longer half-life than at pH 7.4.115 
In summary, arsenicals display significantly different stabilities at different pH values, 
thus when a mixture of these compounds is potentially present in biological samples, pH 
cannot be used alone to preserve species identities. It was shown that maintaining GSH 
concentrations helps preserve the identities of trivalent GSH complexes. The native GSH 
concentration of the cells is between 1-10 mM providing a reducing environment 
necessary for the life of the cell. During sample preparation, the extraction solvent 
significantly dilutes the GSH concentration of the sample thus promotes the 
hydrolyzation of GSH complexes and changes the redox environment of these oxidation 
prone species to favor oxidation. 
In order to conserve species identities during storage, sample preparation, and 
extraction, I performed experiments to find a compound that can 
a) stabilize and prevent the hydrolysis and oxidation of the trivalent GSH complexes to 
their less toxic pentavalent counterparts and 
b) prevent the transformation of the other oxidation prone trivalent arsenicals to 
pentavalent arsenicals displaying much lower toxicities and 
c) conserve trivalent species without the reduction of the pentavalent species to their 
more toxic trivalent counterparts.  
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6.2 Experimental Procedures and Results 
As mentioned above, on the basis of prior studies pH control alone was determined 
not to be suitable for the stabilization of all possible human As metabolites as a 
consequence of their varying stability as a function of pH. Thus, I examined if it was 
possible to chemically stabilize these species without altering species identities. 
Numerous compounds were evaluated for this purpose. They were selected on the basis 
of their potential ability to stabilize trivalent arsenicals either by complexing them thus 
preventing their oxidation or by acting as oxygen scavengers to retard the oxidation of 
trivalent species. A summary of some of the agents explored for the stabilization of 
trivalent species is displayed in Table 6.1. These agents were added to solutions of 
trivalent arsenicals at different pH values (between 2.0-7.4) and different As:chemical 
mol ratios. The samples were monitored over time to determine if the oxidation states of 
all species were maintained.  
6.3 Discussion 
6.3.1  Oxygen Scavengers 
Oxygen scavengers such as ascorbic acid, to a small degree were able to slow 
down the oxidation of trivalent arsenicals without the reduction of pentavalent arsenicals. 
Unfortunately, not only they were unable to significantly retard the oxidation of trivalent 
species, but when these chemicals were added to biological samples, they altered the 
original pH of the sample and diluted the native GSH concentration, thus had a negative 
effect on the stability of GSH complexes and potentially other species. Oxygen 
scavengers were found to be unable to conserve As species identities and maintain their 
stabilities as a result. 
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Table 6.1 Agents explored for the stabilization of labile arsenicals 
Name Structure On the basis of Results 
NH2OH•HCl 
(hydroxylamine 
hydrochloride) 
 
Can provide a mild 
reducing environment 
and act as a sacrificial 
oxidant. Previously 
shown to help preserve 
AsIII in soil and 
sediments. 173, 174 
Did not retard the oxidation 
of DMAIII. 
Ascorbic acid 
As an antioxidant was 
previously reported to 
help the stabilization of 
some arsenicals.175 
Did not retard the oxidation 
of DMAIII. 
DMSA 
(meso-2,3-
dimercaptosuccinic 
acid) 
 
Complexing agent. Fast and effective reducer of pentavalent species. 
DMPS  
(2,3-Dimercapto-1-
propanesulfonic acid) 
  
Complexing agent. Was found to reduce pentavalent species. 
APDC  
(pyrrolidine 
dithiocarbamate 
ammonium salt)  
Complexing agent for 
the extraction of 
arsenicals.176, 177 
Was found to reduce 
pentavalens species. 
NaDDC 
(Sodium 
diethyldithiocarbamate) 
 
Complexing agent that 
was shown to stabilize 
AsIII in soil.173 
Reduction of some 
pentavalent arsenical was 
observed in addition to the 
appearance of complexation 
products. It was found to 
destroy DMA(GS). 
TGA or MAA 
(thioglycolic acid, 
mercaptoacetic acid) 
 
Monothiol, complexes 
with metals.  
Was found to reduce 
pentavalens species. 
DTPA (diethylene 
triamine pentaacetic 
acid) 
 
 
Used for intracellular 
chelation. 
 
Resulted in very complex 
ESI spectrum and did not 
prevent the oxidation of 
DMAIII. 
Glycine 
Was shown to help 
preserve the oxidation 
state of GSAO, a 
trivalent arsenical at pH 
7 over time88 
Was found not to retard the 
oxidation of trivalent species 
over time 
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6.3.2 Non-thiol-containing Chelators 
Non-thiol-containing chelators such as EDTA and DTPE were unable to 
prevent the oxidation of trivalent arsenicals. Additionally, during the addition of 
chelators, the native GSH concentration was diluted as well negatively affecting the 
stability of GSH complexes.   
6.3.3 Glycine 
Glycine was shown not to help retard the oxidation of the trivalent species. 
6.3.4 Thiol-containing Agents  
Thiol-containing chemicals are routinely used to complex arsenicals.62, 178 
Unfortunately, while they provide a reducing environment to maintain the oxidation state 
of the trivalent species, they reduce pentavalent arsenicals to their more toxic trivalent 
counterparts with various extents. Moreover, as AsV, MMAV, and DMAV have different 
affinities for reduction by the same species, the extent of reduction is also arsenic species 
dependent. These agents have also shown the ability to replace GSH on the trivalent GSH 
complexes making it impossible to evaluate the amounts of trivalent non-GSH 
conjugated arsenicals (AsIII, MMAIII, and DMAIII) and their GSH complexes (AsIII(GS)3, 
MMAIII(GS)2, and DMAIII(GS)) that were present in the original sample. 
As an example, when NaDDC was evaluated for the stabilization of trivalent 
species, it was found to destroy the glutathione complex of DMAIII (Fig. 6.1), thus 
DMAIII and DMAIII(GS) both appeared on the chromatogram as a mix of DMAIII and 
DMAV. As previous experiments have shown, GSH was found to be the only species 
capable of maintaining the identity of DMAIII(GS) over extended periods of time (Fig. 
6.1). 
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Figure 6.1 Stability of DMAIII(GS) in the presence of NaDDC and/or GSH. The mol ratio 
of As:NaDDC was 1:2 and the samples were kept at -4C° in the freezer and were 
periodically reanalyzed to monitor DMAIII(GS) stability. 
 
6.4 Conclusions 
On the basis of my results and an extensive review of the literature, it is my opinion, 
that there is no single compound that can preserve the species identities of all possible 
arsenic metabolites in biological samples. It is my recommendation, that in order to 
maintain true species distribution, the following procedures should be observed for 
sample storage and preparation prior to analysis: 
1)  The sample should be kept frozen until analysis. 
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2) If possible, the sample should be processed in an oxygen free environment, such as a 
glove box filled with an inert gas, to avoid the oxidation of highly labile and toxic 
species such as DMAIII and dimethylmonothioarsinous acid (DMMTAIII). 
3)  Extraction solvent: The pH and the redox environment of the cells should be 
maintained throughout sample processing. The usage of buffer mimicking 
physiological pH or double deionized water is recommended for sample preparation. 
The native GSH concentration of the biological sample should be measured prior to 
analysis and this GSH concentration should be maintained during sample dilution. 
4) Samples should be analyzed immediately after preparation. 
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CHAPTER 7 
 
Summary, Significance, and Future Research Directions 
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7.1 Summary 
7.1.1 Dimethylarsinothioyl Glutathione  
The formation of the newly discovered human metabolite 
dimethylarsinothioyl glutathione (DMMTAV(GS)) was confirmed in human multiple 
myeloma and identified for the first time in lymphoma cell lines employing high 
performance liquid chromatography inductively coupled mass spectrometry (HPLC-ICP-
MS) and high performance liquid chromatography electrospray ionization tandem mass 
spectrometry (HPLC-ESI-MS/MS). The pH range of formation of DMMTAV(GS) was 
evaluated. Dimethylarsinothioyl glutathione (DMMTAV(GS)) was found to form at the 
tested pH range of 3.0 to 7.4. Its formation was the most favorable at low pH and at 
higher GSH concentrations. Dimethylarsinothioyl glutathione was also found to form 
non-enzymatically at pH 7.4 in the presence of 2.5 and 5.0 mM GSH to a very small 
extent. At pH 7.4 in the presence of cells, significant amounts of DMMTAV(GS) formed 
in a short period of time indicating that it is probably mostly forms via an enzymatically 
catalyzed reaction under physiological conditions. Attempts to find the enzyme that may 
catalyze its formation in human cells were carried out.  I examined if human microsomal 
and cytosolic GSTs may catalyze the formation of DMMTAV(GS), and in particular 
human cytosolic class pi GST. The enzymes studied did not catalyze the formation of 
DMMTAV(GS) from DMMTAV. While the enzyme(s) responsible for the formation of 
DMMTAV(GS) remained elusive, I provided further proof that it is mostly enzymatically 
catalyzed in human cells. Moreover, it is also plausible that DMMTAV(GS) forms in 
acidic organelles in intact cells. 
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In order to understand the toxicological importance of the formation of 
DMMTAV(GS), its toxicity and uptake by cancer cells was evaluated along with the 
toxicities and uptakes of Darinaparsin (dimethylarsinous glutathione, DMAIII(GS)) and 
dimethylmonothioarsinic acid (DMMTAV). When assessing the toxicity by exposing 
multiple myeloma cells to arsenicals externally, DMMTAV(GS) was much less toxic than 
DMAIII(GS) and DMMTAV, probably as a result of its very limited uptake (less than 10% 
and 16% of DMAIII(GS) and DMMTAV respectively). However, the toxicity of this 
compound was evaluated by exposing the cells to DMMTAV(GS) externally, hence the 
observed low toxicity attributable to very limited uptake, might not be able to reflect the 
actual toxicity of this compound intracellularly. During the metabolism of Darinaparsin, 
this species forms inside the cells along with other metabolites, and could exhibit a higher 
toxicity. Bearing in mind that glutathione conjugation is generally a detoxification 
process and it flags the molecule for elimination from cells, the formation of this 
metabolite should be considered a detoxification process. 
7.1.2 Analytical Method Development 
During the metabolism of different arsenic-containing compounds in human, a 
variety of metabolites are produced with significantly varying toxicities. Currently 
available analytical methods could only detect a limited number of human metabolites in 
biological samples during one run as a result of their diverse characteristics. In addition, 
with most detection techniques co-elution of species is unnoticeable leading to inaccurate 
metabolic profiles and assessment of toxicity. I successfully developed a high 
performance liquid identify fourteen common arsenic metabolites possibly present in 
human in one run to ensure that no co-elution of these species occur. The 14 species 
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separated by the method are arsenite (AsIII), arsino-glutathione (As(GS)3), arsenate (AsV), 
monomethylarsonous acid (MMAIII), monomethylarsino-glutathione (MMAIII(GS)2), 
monomethylarsonic acid (MMAV), dimethylarsinous acid (DMAIII (from DMAIIII)), S-
(dimethylarsinic)cysteine (DMAIII(Cys)), dimethylarsino-glutathione (DMAIII(GS)), 
dimethylarsinic acid (DMAV), dimethylmonothioarsinic acid (DMMTAV), 
dimethyldithioarsinic acid (DMDTAV), dimethylarsinothioyl glutathione 
(DMMTAV(GS)), and the later added dimethylmonothioarsinous acid (DMMTAIII). A 
potential method to synthesize dimethylmonothioarsinous acid (DMMTAIII) was also 
offered for the first time. 
An extensive study was carried out to examine the effects of ICP nebulizer 
flow rate and composition on ICP-MS signal intensity and its importance to minimalize 
baseline disturbance that was present as a result of high acetonitrile concentration in the 
mobile phase. Moreover, the effect of composition of nebulizer flow on carbon deposits 
inside the ICP-MS was evaluated. An inexpensive method, employing a T connector, was 
introduced to augment the nebulizer flow with oxygen to protect the instrument and 
stabilize the ICP plasma during analysis. The developed method was also found to be 
compatible with the high performance liquid chromatograph electrospray ionization 
tandem mass spectrometer (HPLC-ESI-MS/MS) providing an additional tool to identify 
unknown peaks. 
I applied this method to the analysis of cancer cells that were incubated with 
Darinaparsin to demonstrate the ability of the method for the analysis of arsenic 
metabolites in human cells. Moreover, I employed this method to try to decipher the 
mechanisms and the conditions of formation of thiolated arsenic metabolites. 
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7.1.3 Mechanistic Study of Thiolated Arsenical Formation 
In the course of my research I investigated the possible mechanisms and 
conditions of formation of dimethylmonothioarsinic acid (DMMTAV), 
dimethyldithioarsinic acid (DMDTAV), dimethylarsinous glutathione (DMAIII(GS)), and 
dimethylarsinothioyl glutathione (DMMTAV(GS)) from dimethylarsinic acid (DMAV) 
and Darinaparsin (DMAIII(GS)) and the form (H2S, HS-, or S2-) and the source of sulfur 
involved in the generation of thioarsenicals (sulfane sulfur (protein persulfides in 
particular) or H2S produced during metabolism). In this study, I successfully synthesized 
and used a recently reported slow H2S releaser GYY4137 (morpholin-4-ium 4 
methoxphenyl (morpholino) phosphinodithionate), which has been shown to slowly 
release H2S both in vitro and in vivo to produce H2S creating a reaction environment 
milder and more closely relevant to physiological conditions. I provided additional 
information to enable others to unequivocally identify GYY4137. I found that DMMTAV 
can form from DMAV utilizing both H2S and HS- via different pathways, while 
DMDTAV can only form utilizing HS-. Additionally, it was shown that the reduction of 
DMAV to DMAIII is not necessary for the formation of DMMTAV. My research also 
showed that DMMTAV can form from DMAIII(GS) in the presence of HS- without the 
need for the oxidation of DMAIII(GS) to DMAV. It was proposed, for the first time, that 
the formation of DMMTAV from DMAIII(GS) is via the formation of DMMTAIII and 
highly unstable dimers. While the exact mechanism of the proposed dimerization 
pathway could not be elucidated, proof to support it was provided. 
In order to investigate the ability of arsenic to react with protein persulfides to 
form thiolated arsenicals, I employed glutathione persulfide (GSSH) as a simple model 
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molecule for protein persulfides. GSSH when reacted with DMAV formed very small 
amounts of DMMTAV. Once GSH was added to the reaction media, it liberated HS- from 
GSSH, and the very fast formation of thiolated arsenicals was observed. The experiment 
showed that protein persulfides may provide the sulfide needed for the formation of 
sulfur-containing arsenicals in the reducing environment of the cells. It was suggested in 
this work for the first time, that utilizing the sulfur of protein persulfides for the 
formation of thiolated arsenicals, may be an important contributor to arsenic induced 
toxicity (directly) as the loss of persulfide from proteins alters their enzymatic abilities. It 
was also proposed for the first time, that some of the (indirect) toxicity of arsenicals may 
be attributable to their interference with protein persulfide synthesis (an important post 
translational modification of proteins to increase their activity) by utilizing the H2S 
generated in enzymatic reactions that is used for the synthesis of protein persulfides. 
 
7.2 Significance and Implications of the Work Done 
7.2.1 Analytical Method Development 
In order to understand the metabolic pathways of As, the mode of action of As 
toxicity, and the mechanisms underlying As chemotherapy, scientists must have an 
analytical method that is capable of unequivocally identifying the arsenicals formed 
during the metabolism of environmental As exposure or therapeutic As administration. 
Speciation analysis of arsenic metabolites is very important, because each arsenic species 
possesses varying toxicities. This work is unique, since it is the first to report a validated 
analytical testing method that can simultaneously detect 14 human arsenic metabolites in 
one liquid chromatographic run. The development of such method was required as the 
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analytical methods available prior to this technique could only detect a limited number of 
human metabolites in biological samples during one chromatographic run. The 
previously reported methods could not meet the need of "full-spectrum" analysis of As 
metabolites. In addition, with employing inductively coupled mass spectroscopy (ICP-
MS) as the ionization and detection technique co-elution of species is unnoticeable 
leading to inaccurate metabolic profiles and assessment of toxicity, thus care had to be 
taken to separate all confirmed and potential human arsenic metabolites. 
The developed method was successfully applied to the analysis of human 
cancer cells incubated with Darinaparsin for the determination of arsenic speciation 
profile during the metabolism of this promising antineoplastic agent. Moreover, the 
method proved to be an indispensable tool for the mechanistic study of thiolated arsenic 
species formation.  
7.2.2 Thiolated Arsenicals 
Sulfur-containing pentavalent arsenic metabolites such as MMMTAV, 
DMMTAV, DMDTAV, and DMMTAV(GS) are important mammalian arsenic 
metabolites, though rarely detected in humans up until now.10, 11, 14, 25, 35, 36, 114, 155  The 
toxicity of most thiolated arsenicals in humans is unknown. Interestingly, while in 
general trivalent arsenic compounds are more toxic than their pentavalent counterparts, 
DMMTAV has been shown to be unusually highly toxic for a pentavalent species.10-13, 98 
Consequently, it was very important to understand and evaluate the toxicity of these 
species and to measure the ability of cells to take them up. These objectives were 
accomplished by incubating human cancer cells with DMAIII(GS)), DMMTAV, and 
DMMTAV(GS). DMMTAV(GS) was found to be much less toxic than DMAIII(GS) and 
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DMMTAV, probably as a result of its very limited uptake (less than 10% and 16% of 
DMAIII(GS) and DMMTAV respectively). However, the toxicity of this compound was 
evaluated by exposing the cells to DMMTAV(GS) externally, hence the observed low 
toxicity attributable to very limited uptake, might not be able to reflect the actual toxicity 
of this compound intracellularly.  
It was also pertinent to understand the formation and the conditions of 
formation of all thiolated arsenicals and to examine if their mechanism of formation 
contributes to arsenic toxicity in addition to the unusually high reactivity of DMMTAV 
with thiol compounds. Up until now, the form and the source of sulfur utilized for the 
formation of DMMTAV and DMDTAV in human and animal cells remained unclear. One 
possible source of sulfide was suggested to be hydrogen sulfide enzymatically generated 
in the body with the help of cystathionine beta synthase (CBS) and cystathionine gamma 
lyase (CSE) from the metabolism of cysteine and homocysteine along with other 
enzymatic processes. Another possible source of sulfur was proposed to be sulfane sulfur 
of proteins (protein persulfides). I found that under physiological conditions (pH and 
GSH concentrations) all these thiolated As species form extensively from hydrogen 
sulfide (utilizing H2S and HS-), expect for DMMTAV(GS) that was observed to form only 
to a limited degree in the absence of cellular material providing further proof that its 
formation in cells is mostly enzymatically catalyzed. For the first time evidence was 
provided to demonstrate that different pathways may be responsible for the formation of 
DMMTAV. Evidence was provided for the first time to show that the toxicity of these 
arsenical may be attributed not only to the fact that they interact with protein persulfides, 
but they are indeed capable of utilizing the HS- of protein persulfides for their formation 
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in the reducing environment of the cells. This was accomplished by employing 
glutathione persulfide as a model for protein persulfides. Moreover, it was proposed for 
the first time, that a contributing factor to the toxicity of the thiolated arsenicals may be a 
result of them utilizing the H2S generated during enzymatic processes. As hydrogen 
sulfide is an important messenger in cells affecting various physiological functions, the 
processes requiring signaling by H2S, cannot take place or to a lesser extent. Moreover, 
H2S is thought to be important in the synthesis of protein persulfides, a crucial post 
translational modification of proteins to increase their activities,   and by the arsenic 
metabolism incorporating the H2S produced by enzymatic reactions to form thiolated 
arsenicals, the formation of these species may result in the decrease or complete halt of 
the production of protein persulfides.  
7.2.3 Summary 
In summary, this study is of great analytical, biological, and medical 
importance and provides significant results to help us further understand the toxicity and 
uptake of some human arsenic metabolites and the mechanism of their formation. 
Moreover, this work provides a tool (in the form of an advanced analytical separation 
technique) that enables us to make further progress in evaluating arsenic induced toxicity 
and to speciate arsenicals in biological samples to correctly assess their toxicity and 
decipher their metabolism. 
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7.3 Future Research Directions 
7.3.1 Further Analytical Method Development 
The analytical separation method reported in this dissertation was developed 
for the speciation of most human arsenic metabolites using both ICP-MS and ESI-
MS/MS as detectors. Unfortunately, while these species are separated during the HPLC 
run, in the electrospray stage some have very low ionization efficiencies and/or they 
oxidize resulting in changes of species identities. In order to increase ionization 
efficiencies and prevent the oxidation of species, post column derivatization could 
provide an answer. Employing ESI detection, the amount of organic solvent significantly 
affects ionization efficiency. In order to achieve adequate or very high ionization, the 
presence of large amounts of organic solvents, such as methanol, is needed. 
Unfortunately, as the HPLC separation method is also used with ICP-MS detector, the 
usage of large percentage of organic solvent during separation is not possible as the 
plasma of the ICP can only tolerate small amounts of organic solvents before it 
extinguishes. When using ESI-MS as detector, organic solvent could be added to the 
HPLC effluent post column to increase ionization efficiency and thus sensitivity. The 
eluent from the HPLC column could be supplemented with the organic solvent post 
column using a T connector. Moreover, a compound containing easily ionizable group(s) 
with high affinity to arsenic could be added to the post column makeup flow to help 
complex/derivatize the easily oxidizable species without the reduction and complexation 
of the pentavalent arsenicals in order to enable us to distinguish species that may oxidize 
in the electrospray stage from their pentavalent counterparts and to increase their 
ionization efficiencies. Furthermore, pH modifiers can also be added to the post column 
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makeup flow containing the organic solvent and the derivatizing agent to further help the 
ionization of some species. The organic solvent, the derivatizing agent, and the pH 
modifier must be carefully chosen and their amounts cautiously adjusted to achieve the 
most sensitive and specific detection of all species on ESI-MS detectors. 
7.3.2 Synthesis of DMMTAIII 
During formation studies of DMMTAV, two unknown peaks were observed in 
the chromatograms where the starting material was DMAIII(GS), but not in the 
chromatograms with DMAV as the initial compound. This, along with other data, 
indicated that DMMTAV forms through distinct mechanisms from DMAV and 
DMAIII(GS).  It is important to identify these unknown species to fully decipher the 
mechanism of metabolism of Darinaparsin and to understand the possible pathways of 
DMMTAV formation. I suspected that these unknown species may be one or more of the 
proposed dimer intermediates and/or dimethylmonothioarsinous acid (DMMTAIII). As no 
information in the literature is currently available on how to synthesize DMMTAIII, I 
attempted to produce this compound by the reaction of DMAIII(GS) and Na2S in an 
oxygen free environment. Theoretically, the only product that may form in this reaction is 
DMMTAIII, as the formation of any of the dimers, DMMTAV, DMDTAV, and 
DMMTAV(GS) requires oxidation. The peak produced showed that one of the unknown 
peaks, between DMAV and the ghost peak produced by the gradient elution program, is 
probably DMMTAIII based on retention time. In order to unequivocally state that this 
unknown is indeed DMMTAIII, further experiments need to be carried out. First, the 
synthesis of relatively stable DMMTAIII needs to be resolved. This may be accomplished 
by the addition of oxygen scavengers (such as ascorbic acid) to the reaction media that do 
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not react with HS-, DMAIII(GS), and DMMTAIII, they merely retard the oxidation of 
DMMTAIII to improve stability for further characterization and verification of the 
identity of this species. Additionally, as the synthesis of stable relatively pure DMMTAV 
is resolved, a method may be developed to reduce DMMTAV to DMMTAIII employing 
reductants that do not form stable complexes with arsenic. Moreover, enzymatic 
reduction of DMMTAV to DMMTAIII may be explored.  
7.3.3 Finding the Biomolecules Responsible for Catalyzing the Formation of 
DMMTAV(GS) and DMMTAV 
The direct precursor of the formation of DMMTAV(GS) is DMMTAV. 
Theoretical calculations indicate that the conjugation of DMMTAV with GSH is probably 
exothermal, but these calculations did not take the pH effect into calculation and used 
methanethiol instead of GSH to shorten calculation time. Results obtained by Suzuki 
indicated that no DMMTAV(GS) forms from DMMTAV in the absence of cellular 
material above pH 7. Metabolic studies of Darinaparsin conducted in our lab in human 
cancer cells showed the presence of this metabolite even at pH 7.4 and its stability upon 
extraction between pH 3 to 7.4. Heat deactivation of the enzymes prevented its formation 
indicating the possibility that at physiological pH it forms in an enzymatic reaction. Later 
experiments showed that while its formation is indeed favored under acidic conditions, I 
did observed the formation of a very small amount of DMMTAV(GS) at pH 7.4 in the 
presence of 2.5 and 5.0 mM GSH and Na2S from DMAIII(GS) non-enzymatically without 
the presence of cellular material. It is possible that in the reaction media where heat-
deactivated cells were present, this small amount of DMMTAV(GS) was not detectable as 
a consequence of matrix effects. As our previous results showed the formation of 
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substantial amounts of this metabolite within ten minutes in cells, it further confirms that 
this reaction is probably mostly enzymatically catalyzed. It is also important to note, that 
it may also form in acidic organelles non-enzymatically in intact cells. The enzyme 
suspected to help its formation is glutathione S-transferase (GST). GSTs form three 
superfamilies: the cytosolic, mitochondrial, and microsomal GSTs that are further divided 
into classes on the basis of their structures. GSTs have the ability to inactivate toxic 
compounds thus play important roles in the detoxification of noxious chemicals that are 
cytotoxic and genotoxic. Moreover, glutathione conjugation flags the molecule for 
removal. While the ability of GSTs to aid in the removal of toxic chemicals is beneficial 
to the organism, in cancer therapy in the tumor cells, it is a potential problem to the host. 
Tumors may overexpress GSTs and increase their ability to conjugate GST significantly 
resulting in acquired resistance to chemotherapeutic agents. On the other hand, while 
xenobiotics may initially be detoxified by conjugation with GSH with the help of GSTs, 
the initial toxic compound can be regenerated spontaneously. I examined if human 
microsomal and cytosolic GSTs may catalyze the formation of DMMTAV(GS), but did 
not looked at mitochondrial GSTs or other enzymes or proteins at this time. Human 
cytosolic class pi GST, widely distributed in tissues, was tested individually to examine if 
it can catalyze the conjugation of GSH to DMMTAV. My results showed that these 
enzymes do not catalyze the reaction, thus further experiments are needed to identify the 
biomolecule responsible for aiding the formation of DMMTAV(GS). This could be done 
by preparing subcellular fractions and examine if in the presence of a specific fraction the 
rate of DMMTAV(GS) synthesis is increased in order to identify if microsomal, cytosolic, 
or mitochondrial enzymes (in general, not just GSTs) are responsible for the formation of 
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this species. Once the fraction responsible for the catalysis of the reaction is identified, 
further work can be done in order to identify the specific biomolecule(s) responsible for 
the catalytic activity of the formation of this metabolite.  
In order to accomplish this, tissue must be acquired (such as fragments of 
liver, hepatocytes, etc.) and then homogenized prior to use. This will break up the 
endoplasmic reticulum (ER) into small spheres called microsomes. The diluted tissue 
homogenate containing the microsomes is centrifuged to remove debris, nuclei, and 
mitochondria. The resulting supernatant containing the microsomes and cytoplasm 
contains most of the drug-metabolizing enzymes present in tissue. Using 
ultracentrifugation the supernatant can be further separated into the cytosol and the 
microsomes. Furthermore, the fraction containing the mitochondria can be further 
separated and isolated. The fractions then can be used with the necessary cofactors and 
incubated with the substrate (DMMTAV) to see if they catalyze the formation of 
DMMTAV(GS). 
It is also possible that the formation of DMMTAV is catalyzed enzymatically 
as well from DMAV or DMAIII(GS) despite of the fact that its formation can happen 
easily under non-enzymatic conditions at physiological pH in the presence of HS-. The 
amount of freely available HS- in the cells is not known and it is possible that enzymes 
donating HS- may be, to an unknown extent, responsible for its formation. The 
subcellular fractions used for studies of DMMTAV(GS) formation could also be 
employed to examine if enzymes may be involved in the catalysis of DMMTAV 
formation. 
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7.3.4 DMAIII(GS) Uptake as DMAIII(Cys) 
According to a the latest research, DMAIII(GS) may be uptaken as 
DMAIII(Cys) by cells.94 In order to provide further prove that this is indeed the case, 
human cells could be incubated with Darinaparsin, but instead of waiting at least 10-15 
minutes prior to analysis during which time DMAIII(Cys) can be further metabolized, the 
samples should be analyzed within a short period of time such as within 0.5 minute after 
treatment with Darinaparsin started to see if the presence of DMAIII(Cys) can be 
confirmed. Moreover, cells could be tested every minute after that to see how fast 
DMAIII(GS) is converted to DMAIII(Cys). Additionally, cells incubated with 
DMMTAV(GS) could also be examined via the same protocol to see if DMMTAV(Cys) 
forms enzymatically prior to uptake. For these reactions, DMMTAV(Cys) will have to be 
synthesized to establish the retention time of this compound with the newly developed 
method. The synthesis of DMMTAV(Cys) is probably easily achievable at low pH in the 
presence of excess cysteine. 
7.3.5 Assessment of the Contribution of H2S Formed in Metabolic Processes to the 
Formation of Thiolated Arsenic Metabolites  
I proposed that H2S generated from enzymatic reactions in the body with the 
help of cystathionine beta synthase (CBS) and cystathionine gamma lyase (CSE) from the 
metabolism of cysteine and homocysteine may be responsible partially for the formation 
of thiolated arsenic metabolites. While H2S may be generated in other enzymatic 
reactions, its production with the help of CBS and CSE is the most mayor source of 
endogenous hydrogen sulfide. The true concentration level of H2S in cells is highly 
debated and varies over a 105-fold concentration range in different reports, and such its 
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importance for the production of DMMTAV and other sulfur-containing compounds 
could not be accurately estimated up until now. In order to assess the contribution of H2S 
formed in metabolic processes to the formation of thiolated As-metabolites, the amounts 
of combined DMMTAV, DMDTAV, and DMMTAV(GS) present in cell lines could be 
compared in cells in which CBS and CSE (individually and combined) are inhibited 
selectively to those cells where the enzyme function of CBS and CSE is preserved. On 
the basis of the differences in the amount of total thiolated arsenic species formation, the 
contribution of H2S released in metabolic processes could be determined. Unfortunately, 
while some reported that both CSE and CBS can be selectively inhibited, most current 
research shows that only CSE can be selectively inhibited and no selective 
pharmacological inhibitor is currently available for CBS. While the selective inhibition of 
CBS is not possible, by selectively inhibiting CSE and then both of the enzymes, the 
relative contribution of CBS to thiolated arsenical formation can be estimated as well. 
7.3.6 Interactions of DMMTAV with Protein Persulfides 
My research showed that DMMTAV can form from GSSH (glutathione 
persulfide) if GSH (glutathione) is added to the reaction media to break up the disulfide 
bond in GSSH and liberate HS-. This was an important find, as protein persulfides are 
known to be prevalent in cells and thus they may supply the sulfide needed for the 
synthesis of thiolated arsenic metabolites.  It is estimated that approximately 10-25% of 
many hepatic proteins are sulfhydrated under physiological conditions and sulfhydration 
appears to be a common physiologic posttranslational modification of proteins. 
Consequently, it is very plausible that the sulfur comes from persulfides of biomolecules 
in the presence of reducing agents, such as GSH, that can liberate HS- from protein 
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persulfides. It is also a possibility that in the first step arsenic directly reacts with the 
terminal S atom of R-S-S- and forms a complex and then the disulfide gets reduced and 
the original reduced R-SH or R-S- leaves.  As sulfuration alters protein function (may 
hyperactivate or deactivate it), the permanent loss of –SH to form thiolated arsenicals 
may significantly affect protein function and in turn, the survival of the cell. If this is the 
prevalent pathway of formation of these species, it is possible that this may be one of the 
important reasons how arsenic compounds exert toxicity in addition to protein binding 
and ROS (reactive oxygen species) generation. On an important note, it was shown that 
CBS and CSE responsible for the generation of H2S in the presence of L-cysteine, are 
also partially responsible for donating the hydrogen sulfide needed for the generation of 
protein persulfides. In the liver of CSE-/- knockout mice (no working CSE present), it 
was shown that endogenous sulfhydration was abolished indicating that proteins are 
physiologically sulfhydrated through CSE activity. Thus it is reasonable that not only the 
direct destruction of these protein persulfides during thiolated arsenic metabolite 
formation may be responsible for the toxicity of arsenic (in addition to other known 
mechanisms), but by utilizing the H2S needed for the synthesis of these protein 
persulfides for thiolated arsenic species production, these important post translational 
protein modifications cannot take place and such their enzymatic capabilities diminishes 
contributing to As toxicity indirectly. 
To examine if this may be one of the contributing reasons of toxicity, a few 
(1-2) small protein-persulfides with enzymatic properties resulting from their persulfides 
present should be chosen and then reacted with DMAV and DMAIII(GS). After reaction, 
either GSH or a mild non-thiol containing disulfide bond reducing agent should be added 
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to monitor if DMMTAV or other thiolated arsenicals form and if the protein loses its 
enzymatic function as a result. The loss of or the decrease in enzymatic function can 
easily be evaluated by using a known reaction that is catalyzed by that specific protein-
persulfide. If the loss of or decrease in enzymatic function is revealed, it can be shown 
that not only ROS generation and direct bonding can deactivate enzymes (thus cause 
toxicity), but also the loss of persulfides of enzymes. On the basis of the prevalence of 
these protein persulfides, its contribution to toxicity can be estimated. 
One of the proteins that may be suitable for this experiment is glyceraldehyde-
3-phosphate dehydrogenase (GAPDH, 38 KDa). GAPDH is physiologically sulfhydrated 
uniquely at Cys150, the cysteine that is needed for its catalytic activity. At physiological 
L-cysteine concentrations in the presence of CSE approximately 50% of GAPDH can be 
sulfhydrated. The presence of sulfhydrated GAPDH can easily be confirmed using liquid 
tandem mass spectrometry (LC-MS/MS) with the addition of DTT, as the presence of this 
reducing agent will abolish the mass spectrometric signal of this compound (by breaking 
up the disulfide bond and removing the terminal HS-). Once sulfhydrated, GAPDH can 
be reacted with DMAV in the presence of GSH or other non-thiol containing disulfide 
bond reducing agent and the formation of thiolated arsenicals can be monitored to further 
confirm that it is indeed possible that these protein persulfides can donate the sulfur 
needed for the formation of thiolated arsenicals. Moreover, post reaction, the activity of 
GAPDH should be reassessed to determine if its activity has changed. A decrease in 
activity would show that the destruction of these protein thiols modifies (retards) enzyme 
activity and thus may partially be a reason for the observed toxicity of arsenicals in 
addition to other already known ways. 
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